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Abstract
Comprehensive evidence on the comparative effects of various oral antithrombotic agents
on the prevention of saphenous vein graft failure (SVGF) for patients undergoing
coronary artery bypass is lacking. A systematic review and frequentist random-effects
network meta-analysis of 18 RCTs (n=3,413 patients) comparing the effect of
antithrombotic agents on SVGF and clinical outcomes was performed. Based on
moderate quality evidence, among the six eligible interventions, dual-antiplatelet therapy
with aspirin and clopidogrel was superior to aspirin monotherapy in reducing SVGF (OR:
0.63; 95% CI: 0.41-0.97). No statistical differences were found for major bleeding,
mortality, and myocardial infarction between antithrombotic agents, owing to low
number of events for most comparisons. Though significant heterogeneity or incoherence
was not found, the quality of network evidence for these outcomes ranged from very low
to moderate. Adequately-powered multi-arm RCTs are needed to ascertain the effects of
antithrombotic therapies to help clinicians and patients achieve optimal treatment
decisions.

Keywords
Coronary artery bypass, saphenous vein graft failure, antithrombotic therapy, network
meta-analysis.
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Preface
Among antithrombotic agents, aspirin monotherapy has been recommended as the
mainstay of prevention of saphenous vein graft failure (SVGF) in patients undergoing
coronary artery bypass graft (CABG) surgery, as supported in many clinical practice
guidelines.1-7 The scientific basis for this recommendation was evidence gathered from
individual studies (randomized controlled trials (RCTs) and observational studies) and
pairwise meta-analyses. However, there remain gaps in the evidence base for the
guideline recommendation for prevention of SVGF after CABG. Although the
conventional pairwise meta-analysis of well-designed RCTs (a quantitative method of
synthesizing results from independent but similar RCTs to provide greater statistical
power) is widely considered to be the highest level of evidence, this approach does not
allow for a coherent assessment of more than two treatment strategies. This is
problematic as clinicians and patients are challenged to choose from multiple
antithrombotic drugs. Clinical-decision making is even more challenging because some
of the medications have not been compared directly in RCTs. To date, no studies have
been published that assess the comparative efficacy of all relevant antithrombotic agents
on SVGF prevention among CABG patients in a unified analysis. Therefore, we designed
a systematic review and network meta-analysis (NMA) in order to include all sources of
evidence derived from RCTs comparing antithrombotic drugs in a single analysis to
better inform clinical decision-making and guide further research in this area.
The following outline provides the overall framework for this thesis. The first chapter
describes the clinical background regarding the current information related to CABG and
oral antithrombotic agents as well as the rationale behind the present thesis work and
discusses thesis objectives. Chapter 2 provides information on the methodological
background to familiarize readers with the concepts and terminology of pairwise metaanalysis and NMA. Chapter 3 outlines the methods and statistical analyses used to answer
our objectives. The results of the systematic review, quality assessment, and NMA are
provided in Chapter 4. Finally, Chapter 5 discusses the interpretations of our findings,
strengths and limitations, directions for future research, and overall conclusions.

xvi
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Chapter 1

1

Literature Review

This chapter provides background clinical information relevant to the thesis. We provide
a brief description of cardiovascular disease and the importance of coronary artery bypass
surgery, including its inherent limitations as a treatment modality. We then summarize
current knowledge about pharmacotherapies used to prevent saphenous vein graft failure,
highlight notable gaps in the literature, and outline how the present study can expand the
existing scientific knowledge.

1.1 Cardiovascular Disease Burden
Cardiovascular disease (CVD) is an umbrella term for all acute and chronic diseases that
affect circulatory system in the heart, brain, and other parts of the body. CVD can be
broadly divided into two types: atherosclerotic CVDs and other CVDs. Atherosclerosis is
an inflammatory disease in which fatty material and cholesterol are accumulated in the
walls of blood vessels. Atherosclerotic CVDs include coronary artery disease or CAD,
which occurs when atherosclerotic plaque narrows the coronary arteries; cerebrovascular
disease, which occurs when the plaque is in the blood vessels feeding the brain; and
peripheral vascular disease, which occurs when the plaque reduces blood flow to the
peripheral arteries. Other CVDs include congenital heart disease, rheumatic heart disease,
deep vein thrombosis, and pulmonary embolism.
In 2015, CVD, the leading cause of global mortality, claimed the lives of more than 17
million (31%) individuals; of which, 80% of deaths occurred in developing countries.8
Although the mortality burden of CVD was mostly concentrated in developing countries,
the overall burden remains high in developed countries including United States (US) and
Canada. In US, nearly 37% of adults have a CVD and one of every three deaths occurs
due to CVD,9 which is similar to the CVD-specific mortality rate in Canada.10 Despite
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improved management and medical care, the number of deaths is expected to rise to more
than 23.6 million by 2030 wordwide.11
Not only does CVD take a toll on the health of individuals, it poses a substantial
economic burden. It was estimated that the 2010 global total cost attributed to CVD was
approximately US$ 863 billion. The global economic burden of CVD will continue to
increase owing to population aging and clustering of cardiovascular risk factors.12

13

Consequently, an increase in the global cost is expected with an annual total cost of US$
1,044 billion estimated by 2030 and a cumulative total cost of US$ 20,032 billion
between 2010 and 2030.14 In the US, the annual direct and indirect costs of CVD were
estimated to be $ 316 billion in 2012 and the annual total direct medical costs are
projected to double by 2030.9 A similar trend is also forecasted to occur in developing
countries such as China in which an increase from US$ 721.58 million in 2012 to US$
1.71 billion in 2030 is expected.15 To address these global health challenges, there is a
global initiative by World Health Organization to reduce premature deaths by 25% by
2025 via preventive measures, which may translate to a 34% reduction in premature
deaths attributable to CVD, and ultimately, a decrease in overall global health and health
care expenditures.16

17

The importance of reaching this goal highlights the need to

improve medical prevention strategies, in addition to primary prevention strategies.

1.2 Coronary Artery Disease
Among atherosclerotic CVDs, CAD (also known as ischemic heart disease) is the most
prevalent type of CVDs. CAD occurs when the coronary arteries, which supply blood to
heart tissues, become narrowed and stiff due to the accumulation of atherosclerotic
plaque. Left to its natural history of ischemic heart disease, these cholesterol-rich plaques
can lead to myocardial infarction (MI), blockages of the artery that lead to the death of
heart tissue, angina (chest pain), and ultimately death. Globally, CAD is the leading cause
of CVD-specific mortality.11 In the US, CAD accounts for 45% of all CVD deaths.9
Treatment strategies for CAD depend on various factors including anatomical factors
(e.g., the severity of CAD), clinical factors (e.g., presence of comorbidities such as
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diabetes), technical factors (e.g., whether revascularization is complete or incomplete),
and patient-specific factors (e.g., patient values and preferences).18 As the first line
therapy, medical management is used to control symptoms of disease in patients with
stable CAD. Stable CAD is generally characterized by episodes of chest pain that are
reversible but persist over time.19 The required pharmacological therapy, among others,
includes antiplatelet therapy and statins, which should be given to all CAD patients. In
patients with comorbidities such as chronic kidney disease, hypertension, diabetes, or
impaired left ventricular ejection fraction (LVEF), an angiotensin-converting-enzyme
inhibitor is also recommended to improve prognosis.20 However, if symptoms persist
despite medical therapy, coronary artery revascularization is required to treat the
disease.18 21 Coronary artery revascularization can be achieved via percutaneous coronary
intervention (PCI), or coronary artery bypass graft (CABG). PCI is a non-surgical
procedure where a stent is placed in the narrowed vessel via a catheter, whereas CABG is
open heart surgery that places bypass grafts by anastomosis (i.e., joining two blood
vessels) to the heart around the diseased native arteries. Due to advanced technology in
PCI and CABG, determining the optimal revascularization strategy is not always
straightforward. In general, revascularization by PCI is recommended for the following
types of patients: those with single-vessel CAD, multivessel CAD without proximal left
anterior descending (LAD) involvement that is amenable to PCI and those deemed to
have prohibitively high surgical risk.21 On the other hand, CABG is indicated for patients
with lesions that are not amenable to PCI and who have coronary anatomies suitable for
surgery. More specifically, suitable candidates for CABG are defined as patients with left
main disease with >50% diameter stenosis, three-vessel disease with left ventricular
dysfunction, or two-vessel disease with proximal LAD artery disease.21 22

1.3 Coronary Artery Bypass Graft (CABG)
CABG was first introduced in the 1950s. Now, CABG is one of the most frequent
surgical operations performed in the world. In the US in 2012, more than 200,000
patients underwent CABG with a rate of 64.6 per 100,000 population, which is similar to
that of the same year in Canada (69 per 100,000).23 24
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CABG is used to restore blood flow to the heart with the goal of relieving angina
symptoms and improving survival rates. Recent meta-analyses have observed that 84% of
CABG patients remain angina-free within the first five postoperative years and that there
is a 2.7% absolute risk reduction in mortality with CABG compared to PCI in patients
with multivessel disease.25 26 The long-term success of CABG, however, depends on the
patency of the grafts, of which there are two main types: arterial and venous conduits.
The arterial grafts include (left or right) internal mammary artery, radial artery, and rarely
gastro-epiploic artery. Among arterial grafts, left internal mammary artery (LIMA) to
LAD coronary artery anastomosis has been recognized as a method of choice followed by
right internal mammary artery and radial artery.4 21 27 28 Furthermore, compared to venous
grafts, arterial grafts are the preferred conduit given their excellent long-term patency
rates. However, total arterial revascularization is underused where <10% of CABG
patients receive total arterial grafts.29 In practice, arterial grafts are mostly used in
combination with saphenous vein grafts (SVGs).

1.3.1

Importance of assessing saphenous vein graft failure

SVGs remain the most commonly used grafts during CABG because of the benefits
afforded by the sufficient length to accommodate many anastomoses and ease of harvest.
Unfortunately, the concern regarding thrombus formation and progression of
atherosclerosis is predominantly related to SVGs. Compared to arterial grafts, SVGs are
more vulnerable to thrombotic/atherosclerotic occlusion due to their wall structure,
biochemical composition, and responses to high pressure in an arterial environment.30 Up
to 25% of SVGs occlude at one year, 15% to 35% at five years, and 29% to 68% at ≥10
years, while most (up to 95%) of LIMA grafts remain patent even after 10 years postCABG.21
Though consistent evidence is limited, some argue that the occurrence of adverse
cardiovascular events post CABG may be explained by the presence of SVG failure
(SVGF, defined as occlusion that blocks blood supply to the heart through the SVG). The
mechanism of SVGF starts with the formation of thrombus that involves the localization
of platelet adhesion and the activation of coagulation cascade system on the vein luminal
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surface.31-36 This formation is the major pathological process of SVGF within the first
month of CABG. Between one to 12 postoperative months, intimal hyperplasia is the
main reason for SVGF, which occurs when smooth muscle cells migrating from the
media to the intima of veins continue to proliferate and undergo apoptosis.34-36 Beyond 12
months, atherosclerosis takes over the process of SVGF. Compared to that in native
diseased arteries, atherosclerosis in SVGs is more likely to rupture and dislodge which
may result in life-threatening blockages of blood vessels potentially leading to MI,
angina, or even death.34 A subgroup analysis of patients who returned for catheterization
within one- and three- postoperative years showed that SVGF was associated with early
and late angina.37 In addition, another subgroup study of a clinical trial showed that
patients with SVGF were more likely to experience MI or death than those without
SVGF.38 It is important to note that these studies are subject to bias because of a high rate
of loss to follow-up and a failure to adjust for confounders. After controlling for potential
confounders, the differences in death or MI rates between those who had SVGF and those
who did not were no longer apparent at four to five years after CABG.39 Moreover,
although an observational analysis by Halabi et al40 showed that early SVGF (one to 18
months) was associated with an increased 10-year risk of major cardiovascular events,
this occurrence was mainly driven by repeat revascularization, “a faulty endpoint for
clinical trials” that is associated with referral bias as the procedure is more likely to be
performed in symptomatic patients.41

42

This significant difference can be expected

because of the high incidence of repeat revascularization relative to MI or death post
CABG providing greater statistical power to detect differences. Using separate
multivariable analyses, Lopes et al39 showed a significant association between repeat
revascularization and SVGF but not with other patient-relevant outcomes (i.e., MI or
death) at four years after CABG. Whether there is a causal relationship between SVGF
and clinical outcomes and whether repeat revascularization should be part of the
composite clinical outcomes, they remain unclear.43 Nonetheless, SVGF is still
considered an important indicator to guide the decision-making process regarding the
management of subsequent treatments. If graft failure is detected, it is recommended to
perform repeat revascularization (PCI or rarely re-do CABG) to treat restenosis.21
However, repeat revascularization is not without hazards. It is known that PCI places
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CABG patients at risk of MI, mortality, and additional repeat revascularizations, and that
re-do CABG is associated with a higher mortality rate compared to initial CABG.21 It is
therefore of clinical interest to prevent graft failure, especially SVGF given its frequent
occurrence, to avoid unnecessary invasive procedures and their inherent complications.
Importantly, emerging evidence suggests that SVG patency rates can potentially be
improved by pharmacological therapy. Since platelets and coagulation factors contribute
to the pathophysiology of SVG disease, antiplatelet therapy and anticoagulant therapy
should, in theory, prevent SVGF as these agents inhibit clotting factors of platelet and
coagulation.31-36

1.3.2

Determinants of saphenous vein graft failure

There are several factors that can affect the development of SVGF either at the patientlevel or graft-level. The well-known patient-level risk factors include traditional
cardiovascular risk factors such as diabetes, hypertension, dyslipidemia, and smoking.44
45 46 47

Although females tend to have poorer clinical outcomes following CABG, it is

unclear whether sex is predictive of SVGF.48
In addition to patient-level factors, native vessel diameter and surgical technique are the
graft-related features that predict SVG patency. It was shown that there was a 90%
patency rate for SVGs that were grafted to vessels >2.0 mm in diameter versus 52% for
vessels ≤2.0 mm.49 In terms of surgical factors, the ‘no-touch’ technique of harvesting
SVGs, whereby the vein is harvested along with its surrounding tissue to avoid creating
spasm, is found to be linked to a reduction of SVGF.50 Another graft-level predictor of
graft failure is blood flow competition between the native coronary artery and the graft, a
phenomenon that occurs when a bypass graft competes with a native vessel to supply
blood to a distal heart vessel. A high competitive flow, especially through a native
coronary artery with stenosis <70%, accelerates the process of atherosclerosis in the
grafts.51-53 However, this occurrence happens predominantly in arterial grafts, and the
association between competitive flow and SVGF remains uncertain.54
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Other factors that may be associated with the patency of SVGs include use of
cardiopulmonary bypass (CPB), time to surgery (urgent or elective), antifibrinolytic use,
and antithrombotic therapy use. A meta-analysis of 12 randomized controlled trials
(RCTs) showed a statistically significant 41% increase in risk of occlusion of SVGs in
those who underwent CABG without CPB (known as off-pump CABG or OPCAB) than
those with CPB (known as on-pump CABG or CCAB).55 Moreover, though there is little
evidence to show an association between SVGF and time to surgery, it has been
suggested that compared with elective surgery, patients undergoing urgent surgery were
likely to receive fewer internal mammary artery grafts and more SVGs.56 57 Moreover, the
relationship between antifibrinolytic therapy and SVGF remains unclear due to
conflicting results. A RCT showed that aprotinin increased 10-day occlusion of SVGs,58
whereas the use of tranexamic acid did not significantly increase the short-term rate of
SVGF.59 Lastly, the use of pharmacotherapy including lipid-lowering drugs and
antithrombotic agents was associated with improved SVG patency. 34 36 60

1.3.3

Prophylactic pharmacotherapy options for saphenous vein
graft failure

It has been established that antithrombotic therapy and lipid-lowering drugs are the
medical therapies used to inhibit the process of SVG disease.34 36

1.3.3.1

Lipid-lowering agents

The main goal of lipid-lowering drugs is to reduce blood low-density lipoprotein (LDL)
cholesterol, a fat-like substance in vein graft atherosclerosis that influences the process of
SVG disease.45 Lipid-lowering agents include statins and fibrates. Of these, statins are the
most commonly prescribed drugs.
Epidemiological studies have shown that statins slow the development of SVG disease.
In a RCT of 1,351 patients who had prior (1 to 11 years) CABG, the aggressive lovastatin
(40 to 80 mg/day) therapy was shown to reduce the incidence of SVGF and progression
of SVG atherosclerosis at four years post randomization compared to the moderate
lovastatin (2.5 to 5 mg/day) therapy.61 Moreover, a recent multivariable analysis of a
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RCT showed that among 113 CABG patients who were on statins, those who achieved
LDL levels <100 mg/dL had a lower occurrence of SVGF than those who did not. 62
Currently, preoperative statins are recommended for patients undergoing CABG and
should be restarted early after surgery.3 4 6

1.3.3.2

Antithrombotic therapy

The main goal of antithrombotic agents is to prevent the formation of thrombus, which
consists of fibrin and platelets, and the progression of thrombosis. Oral antithrombotic
therapy is identified in two main categories: oral antiplatelet therapy (aspirin, indobufen,
dipyridamole, ticlopidine, clopidogrel, ticagrelor, and prasugrel) and oral anticoagulation
therapy (warfarin, acenocoumarol, phenprocoumon, dabigatran, rivaroxaban, and
apixaban). In terms of adverse effects, all of these agents put patients at varying risk of
bleeding. Though they share the same main goal and common side effect, they have
different mechanisms of action. Antiplatelet agents prevent the activation of platelets,
reducing the aggregation of platelets on the injured vascular wall by inhibiting receptors
on platelets. By contrast, anticoagulation therapy prevents clots by interrupting the
coagulation cascade.34
Antiplatelet therapy. Aspirin prevents platelet adhesion to the vein wall by decreasing the
production of thromboxane A2, a hormone released by activated platelets that stimulates
other platelets and augments platelet aggregation, with the goal of improving graft
patency and clinical outcomes. Compared to placebo, aspirin administered early after
CABG for one year was shown to improve 60-day and one-year SVG patency.63

64

In

terms of clinical outcomes, a recent meta-analysis of RCTs showed that the beneficial
effect of preoperative aspirin was also apparent in the reduction of cardiovascular events
in CABG patients.65 Given its favourable effects, it is not surprising to have multiple
guidelines recommending the use of pre- and post- operative aspirin for the prevention of
SVG occlusion and the secondary cardiovascular prevention.1-7
Clopidogrel, ticlopidine, prasugrel, and ticagrelor selectively inhibit adenosine
diphosphate receptors, causing platelet dysfunction. Clopidogrel, ticagrelor, and prasugrel
are more potent than aspirin. The combination of these antiplatelet agents with aspirin has
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been studied in many clinical settings with the expectation of synergistic antithrombotic
effects, especially in patients with aspirin resistance i.e., patients who do not completely
respond to aspirin and continue to suffer from the clinical manifestations of thrombosis.66
For non-responders, the use of a second antiplatelet agent may therefore be justified to
maximize SVG patency as patients who had occluded vein grafts are more likely to be
non-responders than those who did not.67 However, one side effect of antiplatelet therapy
is increased bleeding risk. Using dual or poly antiplatelet agents may potentially improve
effectiveness but at the expense of a much higher risk of bleeding.
Dipyridamole and indobufen are antiplatelet drugs that inhibit the activity of platelet
cyclooxygenase and cyclic guanosine monophosphate phosphodiesterase type V enzyme,
respectively.5

68

Unlike other antiplatelet agents mentioned previously, these drugs are

often not used in current practice, especially for SVGF prevention, because of their sideeffects and the fact that they have been preferred over more effective and safer agents
such as aspirin.
Anticoagulation therapy. Warfarin, acenocoumarol, and phenprocoumon are vitamin-K
antagonists, which inhibit blood clot formation by reducing the vitamin-K dependent
coagulation factors.69 Unlike other antithrombotic agents, vitamin-K antagonists need
frequent laboratory monitoring to minimize bleeding complications associated with the
drugs. To address this problem, direct oral anticoagulant agents (DOACs) including
apixaban, rivaroxaban, and dabigatran have been developed.

1.4 Gaps in the Current Literature and Rationale of the
Thesis
Clinical practice guidelines play a role in providing current summaries of best available
evidence to health policy-makers, clinicians, researchers, patients, and other healthcare
providers with the goal of improving patient outcomes and promoting appropriate use of
optimal therapy.1-7

70

In many guidelines,1-7

70

the strength of recommendations and the

level of evidence are presented to assist healthcare providers in making informed clinical
decisions. The strength of recommendations of a specific therapy is graded based on the
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size of treatment effect ranging from Class I to Class III, where Class I indicates that the
therapy should be administered, Class II denotes that additional studies are helpful to
strengthen the recommendation, and Class III suggests that the therapy is harmful or has
no benefit. The level of evidence, on the other hand, is weighted according to the quality
of evidence (risk of bias and precision of treatment effect) ranging from Level A to Level
C, where Level A indicates that data were obtained from high quality of evidence (metaanalysis or multiple RCTs), Level B means that data were sourced from lower quality of
evidence (a single RCT or observational studies with conflicting results), and Level C
suggests that data were from poor quality of evidence (case studies or expert opinions).
Today, there are many clinical guidelines that have been developed focusing on the
prevention of SVGF after CABG. The majority of existing guidelines have strongly and
consistently emphasized the importance of aspirin (alone) administration before and early
after CABG in improving graft patency (Class of recommendation: I).1-7 However, the
scientific basis for this recommendation primarily relies on the available direct evidence
of varying quality. The majority of earlier guidelines, including American College of
Cardiology/American Heart Association (ACC/AHA)1-3 and American College of Chest
Physicians5 guidelines, developed recommendations for SVGF prevention based on
multiple observational studies and underpowered RCTs. In recent guidelines by AHA
(2015),6 recommendations were based on higher quality evidence (Level of Evidence: I).
In these guidelines, the writing group appraised and used multiple RCTs and a metaanalysis of RCTs published by Fremes et al.71 to evaluate the benefit of various oral
antithrombotic agents in SVGF prevention. However, this meta-analysis included an
intervention (i.e., dipyridamole) that is not being widely used today and rarely for the
prevention of SVGF. This is potentially problematic as the conclusions made based on
studies with irrelevant comparators may not be applicable in the current practice, where
aspirin monotherapy is the standard prophylactic treatment. Moreover, since the
publication of this meta-analysis, important evidence from RCTs with newer agents has
emerged, enriching the totality of evidence to better inform decision-making. Therefore,
revising guidelines with inclusion of more updated information and more relevant
interventions is crucial.

11

In 2016, ACC/AHA developed and published more recent guidelines for SVGF
prevention.70 Unlike many other existing guidelines that highly recommended the use of
aspirin monotherapy, these guidelines proposed a different recommendation. The 2016
guidelines suggested that the addition of clopidogrel to aspirin (known as dualantiplatelet therapy with aspirin and clopidogrel) may be reasonable for SVGF
prevention. However, this recommendation requires additional studies to strengthen the
recommendation (Class of recommendation: IIb) and is based on lower quality of
evidence (Level of evidence: Level B – Non-Randomized). Using this recommendation
poses several challenges: 1) the recommendation based on lower quality of evidence may
not be very helpful in guiding clinical decision making, especially when the intervention
involves risks to the patients. 2) Although the 2016 ACC/AHA guidelines considered
prophylactic treatments that are used in current practice, these guidelines primarily
focused on two treatments, aspirin monotherapy and dual-antiplatelet therapy with aspirin
and clopidogrel and failed to place recommendations for other relevant alternatives to
prevent SVGF. The focus on two clinical therapies may lead to uninformed clinical
decisions regarding the optimal prophylactic treatment for CABG patients. 3) In addition
to the narrow focus in the practice guidelines on aspirin monotherapy and dualantiplatelet therapy with aspirin and clopidogrel, in the absence of an appropriate
statistical analysis, objective assessments of optimal therapy are not possible.
Clinicians and patients are constantly challenged to make an optimal choice from among
the multiple antithrombotic regimens proposed for potential prevention of SVGF. Despite
the importance of providing optimal prophylactic treatments to CABG patients, most
available antithrombotic agents have not been compared directly in randomized trials,
and furthermore no studies have been published that assess the comparative effects of all
oral antithrombotic agents in the prevention of SVGF after CABG. There are a number of
ways to assess the efficacy of multiple antithrombotic agents, including designing a
multi-arm head-to-head RCT, performing a series of pairwise meta-analyses, and
conducting a network meta-analysis (NMA, also known as multiple treatment
comparison). However, well-designed RCTs comparing all relevant interventions have
not yet been performed, and conducting such RCTs can be challenging due to the high
cost and time required for studies of adequate power to detect differences between active
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comparators. Furthermore, several other pairwise meta-analyses comparing a subset of
relevant antithrombotic therapies have been recently published.72 73 Although a pairwise
meta-analysis of well-designed RCTs is widely considered to be the highest level of
evidence, this approach does not allow for a coherent assessment of more than two
antithrombotic therapies nor allow for comparison of therapies that have not been directly
compared in RCTs. Naively comparing across treatments with a series of pairwise metaanalyses is also not recommended because of a failure to appropriately handle the study
effect (i.e. the effect of patient/study characteristics that equally contribute to the
intervention and comparator). Only the treatment effect (and not the study effect) of each
RCT should be compared to obtain an unbiased estimate from an indirect comparison.74
Among the aforementioned options, NMA of RCTs may represent a better option to
determine the efficacy of all relevant antithrombotic agents as it can compare multiple
treatments simultaneously even when the treatments have not yet been compared directly,
while preserving the within-study randomization. Hence, in the present study, we used a
NMA approach, to conduct multiple treatment comparisons.

1.5 Thesis Objectives
This thesis addresses two main research objectives:
Objective 1 – Systematic Review
To systematically review the literature to identify RCTs that assessed the efficacy of
various antithrombotic therapies for the prevention of SVGF in patients undergoing
CABG.
Objective 2 –Meta-analysis
a) To conduct a pairwise meta-analysis of relevant RCTs to provide a summary of direct
estimates of the effects of antithrombotic agents (alone or in-combination with other
antithrombotic agents) versus placebo/control or other antithrombotic agents on graft
patency and clinical outcomes of interest in patients undergoing CABG.
b) To perform a NMA of relevant RCTs to evaluate the comparative efficacy of
antithrombotic agents (alone or in-combination with other antithrombotic agents)

13

versus placebo/control or other antithrombotic agents in the prevention of SVGF
among patients undergoing CABG.
c) To perform a NMA of relevant RCTs to evaluate the effect of antithrombotic agents
(alone or in-combination with other antithrombotic agents) versus placebo/control or
other antithrombotic agents on clinical outcomes in patients undergoing CABG.
d) To generate a treatment ranking for each outcome of interest.
e) To assess the quality of direct and network evidence provided by included RCTs.
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Chapter 2

2

Literature Review for Methodological Background

This chapter provides a brief background on quantitative and qualitative methodology
used in this thesis. Specifically, we introduce the concepts with a detailed review of the
underlying assumptions of pairwise meta-analysis and NMA and explain the importance
of the Grading of Recommendation, Assessment, Development, and Evaluation approach
in assessing the quality of randomized evidence for outcomes reported in evidence
synthesis.

2.1 Pairwise Meta-Analysis
2.1.1

Introduction

According to the Cochrane Collaboration,75 a systematic review is defined as “a review
of a clearly formulated question that uses systematic and explicit methods to identify,
select, and critically appraise relevant research, and to collect and analyze data from the
studies that are included in the review.” In a review, studies that address a similar
research question can be pooled together to provide a meaningful summary. When
sufficient data are available, the findings of included studies can also be quantitatively
synthesized through meta-analysis to obtain a more precise single summary estimate.76
There are a number of summary estimates that can be used to present the study findings.
The selection depends on the available data and the type of outcome of interest. When
means and standard deviations are available from the original studies, the standardized or
unstandardized mean difference or response rate are the common effect sizes. For binary
outcomes where the number of events and non-events in two study arms are reported, the
risk ratio (RR), odds ratio (OR), and risk difference (RD) are the preferred effect sizes.
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For studies that report a correlation between two continuous variables, a correlation
coefficient can be calculated and used as a summary estimate.76

2.1.2

Heterogeneity

On average, randomization balances the distributions of any prognostic factors across
study groups in a RCT. In the absence of systematic errors, the difference in event rates
(or any outcome measures) between the groups is the effect of the treatment on the
outcome of interest relative to a comparator (known as the treatment effect). Despite the
benefit of randomization, treatment effect may vary between groups of participants in a
RCT. This is expected as some people with certain characteristics that are effect
modifiers (i.e., characteristics that modify the treatment effects) may respond to
treatments differently. The true variation in treatment effects within a RCT is called
within-study heterogeneity.77 For instance, a RCT of statins may include a mixture of
participants with and without prior exposure to aspirin.
In a meta-analysis comparing two interventions, the distribution of study and patient
characteristics may not be balanced across RCTs because randomization does not occur
at study level (i.e., participants are not randomized to different studies). As a result, a
between-study variation in these characteristics is expected. If these characteristics are
effect modifiers, then this variation is called between-study heterogeneity. For example,
if some of the trials comparing treatment A with C, are not comparable in terms of
distribution of effect modifiers (e.g., severity of disease, selection of patients, or
regimens) and, hence, their observed effect sizes are not similar, then between-study
heterogeneity is present. In a pairwise meta-analysis of individual patient-level data, there
are two sources of heterogeneity: within-study heterogeneity and between-study
heterogeneity. Without individual patient-level data, we can only assess between-study
heterogeneity in an aggregate pairwise meta-analysis.77 In a meta-analysis, between-study
heterogeneity may arise from three sources: clinical, methodological, and statistical.
Clinical heterogeneity: Clinical heterogeneity is assumed to occur when studies included
in the review are not sufficiently similar in clinical characteristics, such as baseline
patient characteristics, intervention characteristics, and outcome measurements.

16

Methodological heterogeneity. Methodological heterogeneity occurs when the included
studies are not comparable in terms of risk of bias and study design (e.g., clustered RCTs
versus non-clustered RCTs. Compared with non-clustered RCTs, clustered RCTs produce
less precise estimates).
Combining studies that are clinically and methodologically diverse may increase the
generalizability of findings; however, the combination can have a negative impact on
internal validity. The more diverse a targeted population, the greater the chance of
heterogeneity.75 Furthermore, evaluating similarity among studies is based on qualitative
assessment of study and patient characteristics, which can be subjective. The involvement
of clinical experts and methodologists is therefore strongly recommended in the process
of making decisions about combining studies in order to produce a meaningful and valid
summary of estimates.78
Statistical heterogeneity: statistical heterogeneity refers to variability in treatment effect
size estimates across studies, including magnitude and/or direction of effect that is
beyond the expected play of chance. The source of this heterogeneity may arise from the
combined impact of clinical and methodological heterogeneity, biases, or random
chance.75
Statistical heterogeneity can be detected using statistical tests such as Cochran Qstatistic,79 Generalized Q-statistic, and Cochran Q-statistic adjusted for small-study
effects.80 Of these, the Cochran Q-statistic is the most commonly used test and it
performs well in controlling the type I error rate (false positive rate).81 The extent of
statistical heterogeneity can then be quantified using statistical measures such as H2
index,82 I2 statistics,83 D2 index,84 and G2 index.80 Among these measures, I2 statistic is
the most common.85 The I2 statistic describes the percentage of variation in study
estimates amongst studies that is attributable to heterogeneity and beyond what chance
alone could explain.86 An I2 of 75% indicates that 75% of the observed variance comes
from true differences across individual studies, and thus there is substantial
heterogeneity. When between-study heterogeneity is detected, it is important to explore
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its potential sources by performing subsequent analyses such as meta-regression,
subgroup analyses, and/or sensitivity analyses.
Subgroup analysis: The variation in effect sizes across different subgroups (studies of
similar characteristics) can be explored using subgroup analysis. For example, a metaanalysis comparing dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin
monotherapy included a mixture of RCTs with low and high aspirin doses (with no
variation in doses within RCTs). Subgroup analysis by dose may be performed to explore
the impact of dose on the treatment effect. These subgroups may be patient-level
variables if individual-patient level data are available or study-level variables if only
aggregate patient data are available. It is important to note that the subgroup effects are
often misleading and should be considered hypothesis-generating rather than
conclusive.87
Meta-regression: If the source of heterogeneity is a categorical or continuous variable,
then meta-regression can be used instead of subgroup analysis. Meta-regression is used to
explore the relationship between study-level variables and treatment effects. Some
examples of study-level variables used in meta-regression include treatment doses and
year of publication. There are several limitations inherent in subgroup analysis and metaregression.
First, when we perform subgroup analysis or meta-regression, randomization is broken in
cases where the original trial did not stratify randomization based on the subgroup
variable of interest. These analyses therefore are observational by nature and suffer the
limitations of any observational studies such as confounding. Second, the statistical
power by which to detect a difference among subgroups (in subgroup analysis) or to
detect a significant association between covariates and effect size (in meta-regression) is
usually low.76 Third, if study-level covariates vary between patients within a study, then
the analyses are subject to ecological bias such that an association may exist at the study
level, but may not be true at the patient-level.88 Lastly, in practice, these analyses are
often performed multiple times with a number of covariates or subgroups. Though there
is no consensus on how to handle the issue of multiple testing in meta-analysis,
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investigators should be mindful of its consequence, in particular as it relates to the
inflation of risk of type I errors (>5%).76
Sensitivity analysis: If subgroup analysis and meta-regression cannot be performed,
sensitivity analysis is particularly useful to explore the potential heterogeneity. For
example, sensitivity analyses can be done by excluding studies that had very different
baseline risks from most included studies.

2.1.3

Statistical models

The choices of statistical models in a meta-analysis are fixed-effects and random-effects
models.

2.1.3.1

Fixed-effects pairwise meta-analysis

In the fixed-effects, all included studies are assumed to share a common effect size and
any variation in observed effects is a result of sampling error.89 In other words, a fixed
effects meta-analysis is based on the assumption that there is no between-study
heterogeneity. The observed effects Yi from individual studies included in a metaanalysis are sampled from a distribution with one true effect size, μ and variance σ 2. The
observed effect Yi is:
Yi = 𝜇 + 𝜀𝑖
where 𝜀𝑖 is the within-study error of the ith study and assumed to be normally distributed,
𝜀𝑖 ~N(0, 𝑣𝑖 ). 𝑣𝑖 denotes the within-study variance of the ith study.

2.1.3.2

Random-effects pairwise meta-analysis

It may not be realistic to assume that the effect sizes are identical across studies. 82 In fact,
it is reasonable to expect slight variation between studies that we characterize as
between-study heterogeneity. The studies are required to be similar to ensure internal
validity but not identical. A random-effects model assumes that there is a common
normal distribution of true effect estimates.89 In other words, the true treatment effects
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may vary from study to study. In this model, we need to consider two levels of sampling.
First, the true effect size 𝜃𝑖 in the ith study is distributed about 𝜇, the mean of all true
effects, with a variance 𝜏 2 . The difference between 𝜃𝑖 and μ refers to between-study error
(𝑠𝑖 ). Second, the observed effect Yi in the ith study is distributed about 𝜃𝑖 , the true effect
size in the ith study, with a variance 𝜎 2 . The difference between Yi and 𝜃𝑖 refers to
variability due to sampling error, within-study error (𝜀𝑖 ). The summary estimate
represents the population mean of all true effects. In a random-effects model, the
observed effect Yi of the ith study is:
Yi = 𝜇 + 𝑠𝑖 + 𝜀𝑖
where 𝑠𝑖 ~ N(0, 𝜏 2 ) and 𝜀𝑖 ~N(0, 𝑣𝑖 ). 𝑣𝑖 denotes the within-study variance for the ith
study and 𝜏 2 denotes between-study variance. In a fixed-effects model, 𝑠𝑖 = 0.

2.2 Network meta-analysis
2.2.1

Introduction

A pairwise meta-analysis is useful when the pooled information is derived from studies
comparing two interventions. However, clinicians and patients are often challenged to
choose from multiple treatment options. Clinical decision-making becomes even more
challenging when head-to-head comparisons are not available for some of the
alternatives. NMA, also known as mixed treatment comparison (MTC), is a promising
method that overcomes these issues. NMA synthesizes evidence from direct comparisons
(between two treatments, A and B, without the need of a common comparator) and
indirect comparisons (between two treatments, A and B, via a common comparator, C)
and simultaneously combines both sources of evidence via mixed comparisons to obtain
treatment effect estimates for all relative pairwise comparisons for a particular outcome
of interest, even when the treatments have never been compared head-to-head.90
The effect of treatment A relative to treatment B can be obtained directly through a headto-head comparison. When direct evidence does not exist, indirect evidence can be
estimated by deriving direct comparisons between treatment A versus C and treatment B
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versus C, where C is a common comparator.91 The simplest way to obtain indirect
estimates in a closed loop within the network is to use Butcher’s method, the adjusted
indirect comparison.91
Figure 1. Direct and indirect comparisons.

Each node represents a treatment, solid lines represent pairwise direct comparisons,
and a dash line represents an indirect comparison.

In Figure 1, we can calculate the probability of an event if patients receive treatment A
versus treatment B using Butcher’s method. The indirect treatment effect of A versus B
can be estimated by (computations are carried out on a log scale using the odds, 𝑂𝑑𝑑𝑠 =
𝑝
1−𝑝

, as a function of probability, 𝑝)
𝑙𝑜𝑔𝑂𝑅𝐴𝐵 = 𝑙𝑜𝑔𝑂𝑅𝐴𝐶 − 𝑙𝑜𝑔𝑂𝑅𝐵𝐶

The variance:
𝑉𝑎𝑟(𝑙𝑜𝑔𝑂𝑅𝐴𝐵 ) = 𝑉𝑎𝑟(𝑙𝑜𝑔𝑂𝑅𝐴𝐶 ) + 𝑉𝑎𝑟(𝑙𝑜𝑔𝑂𝑅𝐵𝐶 )
The 95% CI for the indirect estimate can be calculated
95% 𝐶𝐼 (𝑙𝑜𝑔𝑂𝑅𝐴𝐵 ) = 𝑙𝑜𝑔𝑂𝑅𝐴𝐵 ± 1.96√𝑉𝑎𝑟(𝑙𝑜𝑔𝑂𝑅𝐴𝐵 )
For the purpose of this example, odds ratio is used, however, the method can be extended
to other outcomes. Butcher’s method is limited as it is used to estimate an indirect effect.

21

NMA is an extension of Butcher’s method and can produce direct and indirect estimates,
and combine (mix) them to gain precision.
In terms of statistical models, the same considerations for pairwise meta-analyses are
applied when choosing between a fixed-effect and a random-effects model in the NMA.
If investigators believe that the included studies are reflective of a single population and
expected to have an identical treatment effect and the generalizability of the findings are
not of interest, then the fixed-effect model may be used.92 Fixed-effect models are more
likely to be considered appropriate in cases where studies are conducted by the same
investigators under the same protocol or if studies are very similar in all important factors
clinically, methodologically, and statistically. However, this rarely happens in real
practice as it is reasonable to expect some degree of variation between studies. As a
result, the random-effects model is more commonly used as it incorporates known and
unknown heterogeneity.92
Synthesizing the totality of evidence in a NMA improves the statistical power by which
to detect effects and therefore increases the precision in the network estimates.90 This
statistical method can also produce a ranking for all treatment options, which may assist
policy makers or clinicians with decision-making.93 NMA is especially valuable when
study data are pooled from RCTs as randomization (balance in prognostic factors and
other important characteristics between treatment groups) within a RCT is maintained.94
However, NMA is not without drawbacks. Even though within-study randomization is
preserved in direct comparisons of RCTs, interventions were not randomized across
studies in NMA.94 As a result, indirect comparisons are observational by nature and may
bear some of the limitations of observational studies, such as bias due to confounding77 90
and selection bias.95 Confounding bias arises when the imbalance in the effect modifiers
between direct comparisons confound treatment effects. Additionally, selection bias
occurs when researchers selectively choose treatment comparators based on the
expectation of magnitude and direction of treatment effects, which can be minimized by
including all relevant comparators or random selection. To ensure unbiased indirect
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estimates, there are two main assumptions that need special care: homogeneity and
transitivity, with its statistical extension, known as coherence.

2.2.2

Assumptions

2.2.2.1

Homogeneity

Recall, within-study heterogeneity is observed within a study whereas between-study
heterogeneity occurs when there is substantial variation in effect modifiers across studies
of the same treatment contrast (defined as a comparison between two treatment agents).
Since a NMA can analyze multiple treatment comparisons, there is an additional source
of variation in treatment effects to be considered in a NMA, which is betweencomparison

heterogeneity.

Between-comparison

heterogeneity arises

when

the

distribution of the effect modifier is imbalanced across treatment comparisons. A
consequence of this imbalance is a biased indirect estimate.77

2.2.2.2

Transitivity

Even if studies of the same treatment comparison are comparable (or homogeneous), the
imbalance distribution of study characteristics that modify treatment effects across
treatment comparisons will lead to biased indirect estimates.77 For example, if sex is an
effect modifier and more females were included in comparisons involving newer
treatments than those in older treatments, then the indirect treatment effect is biased by
sex. This is known as a violation of the transitivity assumption. There are five possible
ways to interpret the transitivity assumption, also known as similarity or
exchangeability.94 First, treatment C is not systematically different between A-C and B-C
studies in terms of effect modifiers. Second, arms in each study are missing at random
and the choice of interventions is not associated with the treatment effects. Third,
distribution of effect modifiers is balanced across treatment comparisons within the
network irrespective of the degree of between-study heterogeneity. Fourth, subjects are
eligible to take any of the competing treatments, and could, in principle, be randomized
to any of them. Fifth, the effects of treatment A and C estimated directly and indirectly
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come from the same distribution. In other words, any (known and unknown) differences
between relative effects of A-C and B-C are attributable to heterogeneity.
The transitivity assumption cannot be evaluated using statistical tests.94 Therefore, it is
important to qualitatively identify potential violations of the transitivity assumption to aid
in interpreting NMA results by considering the five expressions. However, in the
presence of a closed loop (a path that begins and ends at the same treatment (node)),
coherence, a synonym for transitivity, can be statistically tested. Transitivity requires a
conceptual evaluation, whereas coherence is a statistical manifestation of transitivity
across a closed loop.96

2.2.2.3

Coherence

When both direct and indirect estimates are available, the combination of sources of
evidence produces a more precise estimate, known as a mixed estimate. The mixed
estimate becomes reliable when there is statistical agreement between direct and indirect
evidence. When there is a conflict between the two sources of evidence in a closed loop,
the use of mixed evidence may not be reliable; the disagreement suggests a violation of
the coherence assumption.
Incoherence can be globally investigated (in the entire network) and locally (in a specific
closed loop of evidence). Methods for assessing statistical local incoherence include:
•

Loop-specific approach: This method estimates incoherence by generating an
inconsistency factor (IF, the difference in absolute terms between indirect and direct
estimates for a specific treatment contrast in a closed loop, which is expressed in the
logarithmic scale) and its corresponding 95% confidence interval (CI).97

•

Composite test for incoherence: Unlike the loop-specific approach, this approach
incorporates information from all direct comparisons that contribute to a specific
indirect comparison. In other words, the estimated indirect summary effect is
obtained from two or more different closed loops, and not from one specific loop.98

•

Node-splitting approach: This approach assesses incoherence by comparing direct
evidence to indirect evidence via removal of a single direct pairwise comparison from
the network.99 Once the direct comparison is removed, the network is re-calculated to
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obtain an indirect effect. The direct effect estimated before the removal is then
compared with the indirect effect estimated after the removal using a Z-test.
The following are available methods for assessing incoherence globally:
•

Lu and Ades Model: This approach is an extension of the loop-specific approach,
where all IFs in the entire network are considered simultaneously. The null
hypothesis that all IFs are zero is evaluated using the χ2 test to identify the presence of
global incoherence.97

•

Design-by-Treatment interaction model: The summary estimate of A versus C from
two-arm studies of A versus C (AC design) may differ from the estimate obtained
from three-arm studies of A versus B versus C (ABC design).100 It is therefore
important to consider the study design as another potential source of incoherence.
Unlike the Lu and Ades model, the design-by-treatment interaction method can assess
incoherence globally in the presence of multi-arm studies.100

•

Q-statistic in NMA: Krahn et al provided an equation to calculate the weighted
distance between the network summary estimates and the direct summary estimates
for a particular comparison.101 The weighted distance refers to the Q-statistic for
incoherence. Hence, to statistically test incoherence, the null hypothesis that
coherence is present is evaluated using the χ2 test.

The fulfillment of transitivity and coherence assumptions results in reliable indirect
evidence.102 However, the coherence assumption should be interpreted with caution. The
number of studies contributing to a direct estimation is often small, yielding an
underpowered statistical test. Therefore, the absence of statistically significant
incoherence does not necessarily equal coherence. The likelihood of detecting
incoherence is even lower in the presence of heterogeneity because of the wider 95% CI
of an indirect estimate that overlaps with that of direct estimates, or vice versa.94 103

2.2.3

Statistical framework

Frequentist and Bayesian approaches can be used to fit data to a model in order to make
inference about the true value of a parameter of interest. The frequentist inference is a
statistical inference that evaluates parameters based on a sampling distribution, where the
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parameter of the population is assumed to be an unknown fixed constant. Consequently,
probability statements cannot be made because the parameter is not a random, but fixed,
quantity. To calculate probabilities, a random sample of observations is drawn from a
sampling distribution of all possible random samples. These probabilities therefore are
conditional on these random samples (and not actual data). Based on this sampling
distribution, frequentist statistics performs inference on the parameter.104
There are several different inference types about the parameter that frequentist
approaches consider including hypothesis testing and interval estimation. Hypothesis
testing is focused on what data from an analysis can explain by testing the null hypothesis
that there is no difference between groups, Ho: 𝜋 = 𝜋0 , against the alternative hypothesis
that there is a significant difference, Ha: 𝜋 ≠ 𝜋0 , at a level of significance, α. The
observed effect is tested under null hypothesis. The key question is, how likely is the
observed effect, if the null hypothesis is true. If we fail to reject the null hypothesis, we
would not accept the alternative hypothesis nor conclude that the null hypothesis is true.
We can say that there is insufficient evidence of difference or the observed effect can be
explained by chance alone. If we reject the null hypothesis, we would accept the
alternative hypothesis that there is a significant difference.104 Thus, analysis of study data
is conditional on the null hypothesis being true. Direct probability statements about the
true value of a parameter are not possible within the hypothesis testing framework of
frequentist statistics. Another inference type is known as interval estimation. The 95% CI
indicates that 95% of intervals calculated from repeated samples will be expected to
include the true population effect and 5% of intervals will not. Analysis of study data
using interval estimation is also conditional on the null hypothesis being true. The 95%
CI does not provide a range of values for the true parameter, although it is often
mistakenly interpreted this way. The only correct way of interpreting the 95% CI is to
indicate that 95% of intervals so constructed will contain the true parameter value,
conditional on the null hypothesis being true.
This contrasts with Bayesian statistics where parameters are assumed to be random. Since
the parameters are random, probability statements can be made. In the Bayesian
framework, the inference about parameters are updated with prior knowledge (known as
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prior). To calculate probabilities, we form a posterior distribution by combining the prior
information with the evidence from the actual data (formally, posterior ∝ prior ×
likelihood). In the Bayesian interpretation of the inference, the 95% credible intervals are
estimated which indicates that there is a 95% probability that the true population effect
lies within the interval.104
In the context of a NMA, both approaches can be used. The Bayesian approach permits
treatment rankings, i.e., the probability that a particular intervention for a particular
health condition is best, second best, and so on. In addition, Bayesian posterior
distributions can serve as inputs into probabilistic cost-effectiveness analyses.93 However,
the Bayesian approach requires appropriate prior distributions for model parameters and
careful considerations to make selections. Even though it is recommended to use the noninformative priors to minimize the subjective selection of priors, sensitivity analyses with
different priors are helpful to assess whether the results are stable and robust. With the
exception of the most simple Bayesian analysis, complex computing algorithms are
required to define the posterior distribution through sampling. The most commonly
employed algorithm is Markov Chain Monte Carlo simulation. In Bayesian statistics, we
need to ensure convergence of the Markov Chain Monte-Carlo algorithm to the posterior
distribution; otherwise, the parameter estimations are not reliable. Similar to Bayesian,
recently developed approaches within frequentist statistics allow for treatment ranking.105
However, unlike Bayesian approaches, the frequentist approach does not rely on the use
of prior information. The selection of priors can be based on subjective judgment, and it
is likely that different priors produce different results.106 For example, the between-study
variance can be varied markedly across different prior distributions when the number of
studies in a meta-analysis is small.107 Since the frequentist approach does not consider
any priors, this method provides more objective results relative to the Bayesian
method.104
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2.3 Grading of Recommendation, Assessment,
Development, and Evaluation (GRADE)
2.3.1

Introduction

Quality of evidence is highly variable as it depends on how well studies are conducted
and whether appropriate designs/analyses are used. Inadequate research methods can
produce biased study findings. Pairwise meta-analysis and NMA are quantitative
approaches that do not evaluate the quality of evidence. The estimates derived from these
approaches will reflect any biases inherent in the included studies or even increase the
risk of bias if the study selection process is not systematic. Therefore, it is crucial to
appraise the quality of each study included in a (pairwise or network) meta-analysis, in
order to better understand the strength of the resulting evidence. The Grading of
Recommendation, Assessment, Development, and Evaluation (GRADE) working group
has developed a widely used tool to rate the quality of evidence, known as the GRADE
approach.108 109

2.3.2

GRADE’s approach to rating quality of evidence

The GRADE approach is a systematic method used in health care to guide in the process
of making recommendations reflective of the certainty (confidence) in evidence. There
are five concepts that need to be considered in GRADE when assessing the quality of
evidence.110
Risk of bias: This concept focuses on the limitations of individual studies for a specific
outcome that may threaten internal validity. There are many tools that have been
developed to assess risk of bias including Cochrane Collaboration risk of bias (RoB) tool,
Jadad scale, Delphi List, Newcastle-Ottawa Scale, Downs and Black, just to mention a
few.111 Of these, the Cochrane RoB tool is a commonly used tool to assess risk of bias of
RCTs.112 This tool assesses six different bias domains:
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•

Selection bias, which produces incomparable groups and imbalanced sample sizes
leading to overrepresentation of groups of patients with certain characteristics. This
bias domain is split into two groups:
o Selection bias due to inappropriate random sequence generation, where the
process of allocating interventions to participants is not random (e.g., quasirandom allocation based on patient identification).
o Selection bias due to failure to conceal random allocation, where the
investigators randomizing the participants are aware of the study intervention
to which the next participant will be allocated (e.g., non-sequentially
numbered, non-opaque, or non-sealed envelopes; or an open random
allocation schedule).

•

Performance bias, which results in behavior change or co-interventions, which occur
differentially between treatment groups due to failure to blind participants and
personnel.

•

Detection bias, which overestimates or underestimates the treatment effect due to
failure to blind outcome assessors.

•

Attrition bias, which results in differential missing outcome data, i.e., the proportions
of missing participants and reasons for missing data are not similar across treatment
groups. This type of bias occurs when there is a high rate of loss to follow-up or a
failure to follow the intention-to-treat (ITT) analysis with substantial departure from
allocation. It is important to note that although the goal of ITT analysis is to preserve
balance in the distribution of prognosis between study groups, it does not necessarily
minimize bias introduced by large amounts of missing data.

•

Reporting bias, which results in overestimation or underestimation of meta-analytic
summary effects due to selective outcome reporting (e.g., reporting only statistically
significant results)

•

Other sources of bias that are beyond the specific domains mentioned above such as
fraud, termination of study that is related to outcome data, and considerable changes
in the protocol.
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Once the risk of bias within a study is evaluated, the quality of evidence can be rated
down or up for risk of bias treating all studies as a body of evidence. If most studies are at
low risk of bias, then the evidence is of high quality. If studies at moderate risk of bias
are a primary source of evidence, then the quality is rated down by one level. If most
studies are at high risk of bias, then the evidence is rated down by two levels.112
Inconsistency: This concept focuses on variation (heterogeneity) in treatment effects
across studies. If large statistical heterogeneity is detected, then, it is suggested to downrate the quality of evidence for inconsistency.113
Indirectness: This concept focuses on differences in population, interventions, and
outcomes between the included studies and those of interest. In other words, do patients
or treatments or outcomes of interest differ from those in the included studies? 114 In the
context of NMA, the concept of indirectness has been expanded to include the risk of bias
from indirect comparisons by assessing the coherence between indirect and direct
estimates.115
Imprecision: This concept focuses on 95% CIs around the treatment effect.116 If the 95%
CIs are wide and cross the clinical decision threshold (or line of no effect), the quality of
evidence is down-rated for imprecision. If the 95% CI does not cross the threshold but
both number of events and sample size are small or the optimal information size (OIS) is
not met, then the quality of evidence is rated down.117
Publication bias: This concept focuses on studies that are not published, especially those
that were deliberately not reported due to non-significant results.118 Egger’s test and
funnel plot are examples of methods that examine the precision and distribution of
published effect sizes to explore the potential publication bias.75
Based on these five concepts, the quality of evidence is rated separately for direct
evidence, indirect evidence, and network evidence for each treatment comparison for a
particular outcome of interest. As a first step, direct evidence is rated. Using GRADE the
quality of direct evidence is rated as high, moderate, low, and very low. High quality
evidence suggests that the degree of our confidence in effect estimates being close to the
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truth is high, whereas very low-quality evidence indicates very little confidence in the
summary estimates being close to the truth. The initial quality of randomized evidence
starts as high-quality evidence and each concept is then considered to help in rating down
or rating up the quality. The quality is rated down by one or two points for each concept
depending on how serious the problem is. The quality can be rated up if the effect size is
large or dose-response relationship is present.119 A second step involves rating the quality
of indirect evidence. The quality of the indirect estimate is rated according to the ratings
of the two direct comparisons contributing to that specific indirect estimate, where the
rating of the comparison that contributes the most will be chosen, and based on the
presence of intransitivity. Lastly, if both direct and indirect estimates are present, the
quality of the network estimate is rated based on the rating of the source of evidence with
the higher quality. Otherwise, it is rated based on the available source of evidence (i.e.,
direct or indirect estimates only).115
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Chapter 3

3

Methods

This chapter includes a description of the methods undertaken to conduct the present
thesis work. We describe the study selection process, including the eligibility criteria,
information sources, and search strategy; the data extraction and analysis; and the
assessment of study quality. The protocol of the present study was registered
(PROSPERO no.: CRD42017065678) and has been submitted for publication,120 and any
post-hoc differences between protocol and NMA are highlighted in this chapter. This
study is reported in accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) extension for NMA guidelines.121

3.1 Search Strategy
A pre-specified comprehensive and systematic literature search strategy was created
before the start of the study in collaboration with an experienced medical librarian to
identify relevant studies related to our research question. Five electronic databases
(MEDLINE, EMBASE, CINAHL, Cochrane Library, and Web of Science) were
searched for studies published as a journal article from inception until November 13,
2016, with no restriction by language or publication date placed on any searches. For
each database, we structured a search strategy into relevant search concepts according to
population, intervention/comparator, outcome, and study design (PICOS) using the
following key terms: “coronary artery bypass”, “antithrombotic”, “graft occlusion or graft
failure or repeat revascularization or percutaneous coronary intervention”, and
“randomized controlled trial”. A complete detail of the search strategy can be found in
eTables 1 to 5. Weekly auto-alerts for electronic databases during the course of this study
were also set up to receive notifications for newly relevant published reports. To ensure
all relevant studies were identified, we performed a grey literature search of trial
registries

(ClinicialTrials.gov,

International

Clinical

Trials

Registry

Platform,
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AstraZeneca, Bayer, and Bristol-Myers Squibb), USA Food and Drug Administration,
electronic theses online service, and Gray Matters (eTable 6). We also manually screened
reference lists of eligible studies and previous systematic reviews and pairwise metaanalyses to identify any additional relevant studies.

3.2 Eligibility Criteria
The study eligibility criteria were designed a priori in consultation with a team of clinical
and statistical experts (RB and JM) to assure the most pertinent studies for the NMA and
were specified in terms of PICOS. Eligible studies were selected based on the following
criteria:
Patient Population: We included adult patients (aged 18 years or older) undergoing
CABG surgery with at least one SVG who were eligible to receive any of the oral
antithrombotic agents that are used in current practice for SVGF prevention (listed
below), regardless of comorbidity, clinical setting (elective or urgent surgery), previous
antithrombotic exposure, whether perioperative heparin or antifibrinolytic was
administered, and whether CPB was used.
Interventions: The antithrombotic treatments included in this study are listed as follows:
aspirin monotherapy, clopidogrel monotherapy, dual-antiplatelet therapy with aspirin and
clopidogrel, dual-antiplatelet therapy with aspirin and ticagrelor, and vitamin-K
antagonists (warfarin, acenocoumarol, or phenprocoumon). The decision about grouping
warfarin, acenocoumarol, and phenprocoumon together was made in consultation with a
clinical expert (RB) because these agents are members of the same drug class with
similar mechanisms of action. Participants must have received at least one of these agents
as a study medication within seven days pre- and/or post-CABG, regardless of drug
regimen, timing of drug initiation (before or after CABG), and duration of treatment. A
seven-day period was chosen arbitrarily but taking into consideration the lifetime of
platelet cells (eight to nine days).122 Other antithrombotic agents were considered in the
protocol, but not included in our NMA because of a lack of data (e.g., prasugrel and
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DOACs) or because they are rarely used in current practice for the prevention of SVGF
(e.g., dipyridamole and ticlopidine).
Comparator: The comparator could be placebo/inactive control or a different oral
antithrombotic agent, regardless of drug regimen, duration of treatment, and timing of
drug initiation. Placebo/control was defined as per study author definition. The
comparator however could not be the same antithrombotic agent at a different dose as
comparing the effects of drug dosages is beyond the scope of this study. Similar to the
intervention group, participants must have received at least one of the products as a study
medication within seven days before and/or after CABG.
Outcomes: Eligible studies must have reported the incidence of SVG occlusion (defined
below) in intervention and comparator groups, as SVGF was the primary outcome of this
NMA. There were no restraints on the units of analysis, methods or time of imaging
assessment, and definitions of outcome. The lack of a universal definition for SVGF
leads to a variety of definitions being reported in the literature, which results in
inconsistencies in the reporting of events across studies and increased heterogeneity.43 If
several definitions were presented in the same study, to reduce heterogeneity in the
analysis, we extracted SVGF data according to our preferred definition. Our preferred
definition of SVGF was total occlusion in one or more SVGs detected angiographically
and expressed on a per-patient basis.
If a study did not provide data using our preferred definition, we originally planned to use
a predefined hierarchy, based on unit of patency analysis, percentage of stenosis in the
graft lumen, and need for repeat revascularization to treat restenosis. However, due to the
inadequate description of outcome measures in most included studies, we selected
outcome data in the following order of preference: a) patients with at least one occluded
SVG; b) repeat revascularization (repeat CABG or SVG-related PCI); and c) number of
occluded SVG. The new definition of occlusion was no longer based on degree of
stenosis, but rather on study author definition. We excluded studies with an unclear
definition of repeat revascularization as it would be difficult to judge, without adequate
descriptions, whether the procedure was performed to treat restenosis or different lesions.
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Our pre-specified secondary outcomes included all-cause mortality, cerebrovascular
accidents (CVA: stroke or transient ischemic attack [TIA]), MI (fatal or non-fatal), major
adverse cardiac and cerebrovascular event (MACCE), major bleeding, minor bleeding,
intracranial bleeding, heart failure, red blood cells (RBCs) transfusion, and admission to
hospital due to cardiovascular cause. These outcomes were chosen based on their clinical
importance. In our protocol, we planned to use Thrombolysis in Myocardial Infarction
(TIMI) criteria for major bleeding. However, there were several studies that were
published before the existence of TIMI criteria in the research. For fair comparisons, we
decided to use the study author’s definition. As per protocol, the remaining outcomes
were defined by the study authors. Studies were included based on the availability of
SVGF data and not on our secondary outcomes.
Study design: We included all parallel-group RCTs comparing one of the aforementioned
oral antithrombotic agents as the intervention with a different antithrombotic agent or
placebo/control as the comparator. RCTs with multiple eligible comparators (i.e. multiarm studies) were included. Non-English language studies, observational comparative
studies, non-comparative studies, editorials, secondary studies, subgroup analyses of
eligible RCTs, and RCTs without extractable outcome data were excluded from the
analysis. If duplicates were identified, we did not include them in this study because
analyzing the same information more than once in meta-analysis may lead to
overestimation of treatment effect.123 In this case, studies with the most complete reports
were selected. There were no constraints on sample size or publication date.

3.3 Screening
Once the literature search was performed, all citations were imported into Covidence
Systematic Review Software (https://www.covidence.org/) for screening. A three-level
screening procedure was used to ensure the most inclusive studies for the review. In level
one screening, two reviewers (KS and AH, a cardiology fellow) independently screened
titles and abstracts based on the pre-specified study eligibility criteria. The purpose of this
step was to include as many studies as possible that were potentially relevant to our
NMA. Prior to the screening of all titles and abstracts, screening was piloted to ensure
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consistency between reviewers in using the screening criteria. Duplicates and irrelevant
abstracts were excluded, but relevant abstracts published in non-English languages were
kept at this stage. Any discrepancies were resolved by discussion with an experienced
cardiologist (RB). In level two screening, the same reviewers independently screened the
same set of full texts of reports included in level one. In this stage, non-English citations
were excluded if the full-texts were not available in English. Again, a third reviewer (RB)
was consulted to resolve any disagreements. The first two levels of screening were done
independently and in duplicate to minimize the risk of measurement errors. Lastly, after
completing the first two levels of screening, one reviewer (KS) checked reference lists of
eligible studies and relevant reviews to find eligible studies that were not identified from
the electronic searches, and a third reviewer (RB) was asked to confirm the study’s
eligibility. Reasons for exclusion were recorded.

3.4 Data Extraction for Descriptive Statistics
After the screening, we extracted information from the eligible studies. Data were
extracted using a comprehensive data extraction form, which was pilot-tested on ten
randomly-selected eligible studies by one reviewer (TC, an interventional cardiology
fellow) and refined by another reviewer (KS) accordingly. One reviewer (KS) then
extracted data from all included studies using the final version of the data extraction form
and secondary reviewers (AH and TC) checked the extracted data for accuracy and
completeness. Any disagreements were resolved by consulting a third reviewer (RB). The
following information was collected for descriptive purposes:
Study characteristics: Inclusion and exclusion criteria, number of randomized patients
per study arm, accrual period of the study, study setting (e.g., single or multicenter),
clinical setting, CABG type (on- or off- pump), heparin or antifibrinolytic use during
CABG, antithrombotic status prior to CABG, country of conduct, Cochrane risk of bias,
and length of follow-up.
Patient characteristics: Mean age, mean number of bypass grafts per patient, mean of
LVEF, proportion of male patients, and proportion of patients with diabetes mellitus,
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hypertension, prior MI, prior CVA, or dyslipidemia. Data on chronic kidney disease, and
heart failure at baseline were collected as per protocol, however these were not reported
in this NMA due to limited or no data.
Intervention characteristics: Type, dose, and frequency of antithrombotic agents,
definition of placebo/control, duration of treatment, and timing for the start of treatment.
Outcomes: Clinical event rates (number of patients with MACCE, major bleeding, CVA,
MI, minor bleeding, intracranial bleeding, repeat revascularization, heart failure, or reexploration for bleeding; number of patients that were hospitalized due to cardiovascular
cause, number of deaths) per study arm; number of patients with at least one occluded
SVG per study arm; number of occluded SVGs, number of total SVGs, and average
number of SVGs analyzed per patient per study arm; rates of loss to follow-up (with
reasons), time and method of outcome assessment, study author definitions of outcomes,
and number of patients analyzed per study arm.
Publication details: Year of publication and first author.
Included studies had to have at least two eligible study arms. If studies had two or more
eligible intervention arms of the same product but at different doses, we included the
study arm that had the most complete follow-up data. If a study presented results from
more than one time point separately in multiple publications, we kept all publications and
treated them as a single study.
It is important to obtain data on these baseline characteristics as it allows us to visually
assess the distributions of clinical characteristics of patients and methodological
characteristics of studies both across included studies and across treatment comparisons,
to understand the baseline risk profile of patients in each study, to appreciate changes (if
any) in clinical practice over time, and to identify potential sources of heterogeneity.

37

3.5 Data Extraction for Meta-Analysis and Network MetaAnalysis
There are two different types of input data for meta-analysis and NMA: arm-level data
(the observed outcomes are reported for each study arm) and contrast-level data (the
relative effect measures are reported in a study). We extracted arm-level data from all
included studies due to the availability of arm-specific data. As a base case, we included
outcome data with the longest follow-up for studies that reported results at more than one
time point as per Cochrane guidelines.75
Our outcomes of interest were all binary. If enough studies (i.e., at least two studies per
outcome) with direct comparisons were available, we performed pairwise meta-analysis
and at least 10 studies per outcome for NMA. Outcomes included for pairwise metaanalysis were SVGF; number of deaths; number of patients with MI (fatal or non-fatal),
CVA (any stroke or TIA), re-exploration for bleeding, major bleeding, MACCE and
minor bleeding. Outcomes included for NMA were SVGF, major bleeding, all-cause
mortality, and MI. We attempted to collect data on heart failure, admission to hospital
due to cardiovascular cause, and need for RBC transfusions, but did not include them in
the meta-analysis due to limited data.
It is important to obtain information about potential effect modifiers as it allows us to
make comparisons between treatment contrasts and to evaluate whether the included
studies were sufficiently similar. A similar distribution of these variables between studies
suggests that homogeneity is likely to be present, and a similar prevalence of effect
modifiers between treatment comparisons suggests that the transitivity assumption is less
likely to be violated and that NMA is possible (details in Chapter 2.2.2). We therefore
pre-specified several potential effect modifiers in our protocol as sources of heterogeneity
and incoherence. Potential effect modifiers included antifibrinolytic use during surgery,
timing for the start of treatment, CABG type, and clinical setting. These variables were
chosen based on clinical expectations that they may influence SVG patency (see Chapter
1.3.2). Other potential effect-modifiers were SVG flow, diameter of diseased artery,
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comorbidities, and sex. However, they were not included in our list as individual patientlevel data is required.

3.6 Risk of Bias Within Individual Studies
To assess the methodological quality of eligible studies, one reviewer (KS) performed a
risk of bias assessment which was doubled checked by secondary reviewers (TC and
AH).75 There are several quality assessment tools available for randomized studies.110 124128

In this NMA, we evaluated the risk of bias of each included study using the Cochrane

Collaboration RoB tool,110 which is the standard approach for quality assessment of
randomized trials.129 Unlike other existing tools, the Cochrane Collaboration RoB tool
does not use checklists nor a numerical quality assessment scale based on the rationale
that numeric scores are not sufficiently discriminatory to identify studies with high risk of
bias beyond qualitative assessment alone.130 Instead, this standard tool uses the domainbased rating system, which incorporates six bias domains (see Chapter 2.3.2). For each
domain, we assessed the risk of bias related to trial results (i.e., internal validity) on an
outcome level and whether potential sources of bias were addressed in the included
studies.110 The judgement about risk of bias was made based on theoretical and empirical
considerations as well as the unique circumstances of each study. The answer to each
domain was assigned a score of “high risk”, “low risk”, or “unclear risk”, and as per
Cochrane guidelines,75 to ensure transparency in how assessments were made each
domain was accompanied by a concise description on the basis of judgements and quotes
supporting them.
No modifications to the Cochrane Collaboration RoB tool were made. Despite the
difficulty of blinding vitamin-K antagonists, the risks of performance bias and detection
bias were fairly assessed in all included studies regardless of the interventions. We
assessed incomplete outcome data separately for primary and secondary outcomes
because a higher rate of loss to follow-up for assessment of SVG patency was expected
during the study.
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3.7 Selection of Data for Analysis
3.7.1

Choice of interventions

Each intervention included in this NMA forms a node in the network. We clustered
different regimens (dose and frequency) of an antithrombotic agent in the same node as
comparing intervention regimens is beyond the scope of this NMA. We assumed that
there would be no systematic differences in intervention effects (beyond sampling error)
between regimens. We also kept aspirin monotherapy as a single node, regardless of
whether aspirin was started before or after CABG, since aspirin has been strongly
recommended to be administered preoperatively and restarted within six hours after
surgery,6 and regardless of whether aspirin was interrupted or continuously taken before
CABG (7 to 10 days), since an unpublished meta-analysis failed to show a significant
difference between the two groups.131

3.7.2

Choice of time points

As stated before, if studies were followed by another publication in the same population,
data from studies with the longest duration of follow-up were included as a base case.

3.7.3

Choice of units of analysis

For the primary outcome, the choices for the units of analysis were the patient and the
SVG/distal anastomosis. It is unclear whether the investigators in the included studies
chose the unit of analysis based on clinical considerations or statistical efficiency. The
patient approach may be more clinically relevant, as the interventions are naturally
applied to the patient, and not the individual graft. Although patients generally received
multiple grafts, studies that reported results expressed on a per patient basis typically
presented SVG occlusion data as a proportion of patients with at least one occluded SVG.
This outcome may have been chosen by investigators to avoid the issue of dependency
between SVGs within a patient. In other words, this outcome may have been selected to
satisfy the assumption of statistical independence, though at the expense of lower
statistical power (inflated type II error).132
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On the other hand, the per graft approach may have been preferred as it does not
compromise power.132 SVG occlusion data reported as per graft however present a
particular statistical challenge because grafts in the same patient tend to respond similarly
with respect to failure compared to grafts between different people, possibly because they
are under the same circulatory system.132
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Clustering effects must be therefore

considered in the analysis, as otherwise the assumption of statistical independence is
violated and it may result in over precision (i.e., underestimated standard errors, narrower
CIs, and inflated type I error) because the same patient is potentially counted more than
once (across multiple grafts). There are several statistical approaches used to handle
clustering effects in the context of a meta-analysis, such as the ratio-estimator approach
or the adjusted Mantel-Haenszel test.134 To use one of these approaches, information such
as the variance of the ratio estimate, intra-cluster correlation (ICC, the proportion of total
variation in the outcome being measured at the patient level), and number of SVGs per
patient are required. Due to limited individual patient-level data, we were unable to
compute variance of the ratio estimate or ICC. However, we could calculate the effective
sample size (ESS, defined as sample size after accounting for clustering effects) for each
arm in studies that provided number of SVGs per patient. We considered it appropriate to
use the ESS in the analysis rather than the original number of vein grafts provided by the
included studies, as it accounts for the lack of independence. The ESS was estimated
based on the design effect.135 The design effect was a correction factor that included ICC
and average number of SVGs per patient. The ICC was obtained from a published
study.133 Using Generalized Estimating Equation with an exchangeable correlation
structure (i.e. the outcomes of the same patient are assumed equally correlated), the
author estimated an ICC of 0.177 indicating a moderate degree of dependency. Then, the
design effect was also applied to the number of events to obtain the number of occluded
SVGs with clustering. As a result, the total number of SVGs and the number of occluded
SVGs were reduced after correlation between SVGs was considered. We planned to use
the originally reported outcome data if studies did not provide enough information.
However, all studies provided sufficient data.
Unfortunately, not all included studies reported SVGF rates on a per-patient basis. There
were studies that reported results both on a per-patient basis and a per-graft basis, but a
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few reported results only from a per-graft analysis. To address the issue of partial
reporting, the unit of analysis of this NMA depended on the consistency of effect
estimates between the per-patient (patient with at least one occluded SVGs) and per-graft
(with clustering) meta-analyses across treatment comparisons.
After conducting a separate meta-analysis for each unit of analysis, we found that the
results between per patient and per graft were consistent (i.e., similar direction and large
overlaps in the 95% CIs of effect sizes) in most comparisons. We therefore considered it
appropriate to combine data from the two units of analysis: the patient and the SVG, for
the NMA, assuming that there are no systematic differences between the units of
analysis. In other words, we combined studies that reported the per-patient data with
those that only reported the per-graft data and made an inference at the patient level (our
base case). Inference at the patient level is highly preferable as treatments will be given
on an individual basis. Unfortunately, we could not compare the consistency of results
between the two levels using NMA as some studies did not provide sufficient data, which
made it impossible to qualitatively compare results between NMAs with missing nodes.
The credibility of this data-driven approach at the NMA level is unclear and therefore,
the findings of the NMA should be interpreted with caution.

3.8 Statistical Analysis
Descriptive statistics were presented as percentages for categorical variables, and mean ±
standard deviation (SD) or median (range or interquartile range, [IQR]) for continuous
variables. We performed pairwise meta-analysis using Review Manager version 5.3
(Nordic Cochrane Center, The Cochrane Collaboration) and NMA using the network
command, a user-written command (Stata version 13.1).136 ITT was followed whenever
possible. A two-tailed p-value of less than 0.05 was considered statistically significant.

3.8.1

Direct treatment comparisons

Pairwise meta-analyses were conducted to produce direct estimates needed to supplement
the NMA results and to evaluate a potential violation against the coherence assumption of
the network. The random-effects model with an inverse-variance method was chosen
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over the fixed-effect model because we anticipated true variation in effects across
studies.137 The included studies were clinically and methodologically similar, but not
identical because they were conducted in different settings with different intervention
regimens and patient characteristics. In addition, fixed-effect models are not
recommended for common outcomes such as SVGF due to risk of over-precision.78
Empirical studies have shown that, for binary outcomes, results using relative measures
(e.g., OR and RR) are more consistent (i.e., less heterogeneous) than absolute measures
(e.g., RD) due to their insensitivity to baseline risk.138
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We therefore chose relative

measures over absolute measures to ensure more consistent effect sizes across studies
regardless of baseline risk, although absolute measures are better at communicating a
clinical impact of the intervention. Compared to RRs, ORs are more commonly used in a
NMA and preferable because of their mathematical properties (i.e., symmetric
properties), which overcome inferential fallacies.140 141 An example of this fallacy is that
a drug was suggested to both improve SVG patency and increase SVG occlusion. Given
these considerations, the causal relationship between interventions and outcomes was
estimated using OR and its corresponding 95% CI. For ease of comparison between
direct and network estimates, ORs were also selected as the appropriate effect measure
for the pairwise meta-analysis.
The extent of clinical and methodological heterogeneity was evaluated through visual
examination of important differences in patient/study characteristics (e.g., CABG type,
clinical setting) and risk of bias between studies. In addition, we assessed the extent of
statistical heterogeneity in the meta-analysis using the I2 index. An I2 of either 25%, 50%,
and 75% indicates low, moderate, and high heterogeneity, respectively.86
Whether studies with zero events in both arms should be excluded or not remains
unclear.142-144 For transparency, we included studies with zero events in both study arms
for all endpoints in the meta-analyses.144 A correction factor of 0.5 was applied when a
study contained a zero event in one of the study arms, which is a widely acceptable
approach to account for zero events.144 In each direct comparison, publication bias was
assessed if sufficient (i.e., ≥10 studies per comparison) data were available.145
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3.8.2

Indirect and mixed treatment comparisons

NMA allowed us to compare multiple treatments within a single analytic framework by
combining the direct and indirect evidence. However, before concluding that NMA was
feasible, we assessed the two important assumptions: transitivity and homogeneity.
First, we evaluated the transitivity assumption by considering the first four of its
equivalent expressions (Chapter 2.2.2.2 Transitivity).74 After checking the assumption of
transitivity and determining that transitivity was reasonable (see details in Chapter 4.6),
we performed NMA. In terms of statistical framework, there is no consensus on whether
a frequentist or Bayesian framework should be used for NMA. Despite the conceptual
benefits of Bayesian approaches (see details in Chapter 2.2.3), because they require
specification of priors, and because the study results may vary based on the chosen prior,
we opted to use the frequentist approach to NMA in this research work. We also used the
random-effects approach for the NMA to account for heterogeneity. To illustrate
information on the data structure, we produced a network plot for outcomes with
sufficient data (≥10 studies) including SVGF, mortality, and MI. In addition to these
outcomes, major bleeding was also included in the NMA, though with <10 studies,
because of its clinical relevance. We also produced the contribution matrix to summarize
the contribution (in %) of each direct estimate to the network estimates.136
Though there is no formal way to statistically test the transitivity assumption, we assessed
the statistical manifestation of this assumption, known as coherence.94 The indirect
comparison is valid when there is an agreement in treatment effects between direct and
indirect estimates. For the comparative analysis to be possible, both direct and indirect
estimates must be available together in a closed loop. We assessed the coherence
assumption in two ways (globally and locally). The design-by-treatment interaction
model was used to explore for evidence of incoherence in the entire network.100 This
approach was chosen over the other methods (e.g., Lu and Ades model) because the
presence of multi-arm studies would not influence the results.146 P-value <0.1 was
considered to be statistically significant global incoherence. We also assessed the
presence of local incoherence. The loop-specific approach was used to explore evidence
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of local incoherence within a closed loop in a network, assuming a common loop-specific
heterogeneity variance.147 This approach was chosen over the composite test because the
composite test considers multiple closed loops whereas our networks had only a single
closed loop. Moreover, though our chosen approach and the node-splitting method share
similar strengths (e.g., generally unbiased) and limitations (e.g., low power and unable to
account for correlation induced by multi-arm trials), the loop-specific approach is more
straightforward and requires less computations.148 The IF and its corresponding 95% CI
were estimated and reported. If the 95% CI excludes zero, local incoherence is detected
statistically.147
In addition to transitivity, we also assessed homogeneity. To evaluate the clinical and
methodological heterogeneity, we visually compared the distribution of clinical
characteristics and risk of bias across included studies. In terms of statistical
heterogeneity, we obtained heterogeneity variance (τ2) by squaring the standard deviation
of treatment effects estimated from the NMA model. We assumed a common
heterogeneity variance (τ2) across all comparisons, as all treatments of interest are similar
in a sense that they principally act to inhibit clotting factors.149 150 The magnitude of the
estimated τ2 was then compared with the empirical distribution of between-study
heterogeneity variances to investigate the extent of heterogeneity.151 An estimated τ2 of
either <50%, 50% to 75%, and >75% quantile of the empirical distribution was
considered low, moderate, and high heterogeneity, respectively.149
Of note, when a treatment comparison is part of a closed loop, the network estimate is the
weighted average of the two sources of evidence: direct and indirect evidence. When a
treatment comparison provides either only direct evidence or only indirect evidence, the
network estimate reflects only one of them.

3.8.2.1

Treatment ranking

We used the surface under the cumulative ranking (SUCRA) with 10,000 samples drawn
from the distribution of summary treatment effects to calculate the mean rank for each
intervention.136 We ranked the interventions for each of the four outcomes. A larger
SUCRA value indicates a more effective treatment.
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3.8.2.2

Small-study effects

For outcomes that had sufficient data (≥10 placebo-controlled studies), a comparison
adjusted funnel plot was created to explore the potential small-study effects in the
network by comparing all active treatments against placebo/control.136

3.9 GRADE
As per protocol, we assessed the quality of evidence using the GRADE approach (see
details in Chapter 2.3.2). In this NMA, the OIS for SVGF ranged between 434 and 905
patients (in one arm), based on the following assumptions: alpha of 0.05, beta of 0.20, 10
to 20% of patients with SVGF, and medically worthwhile treatment effect of 5 to 15%.
For MI, the OIS was about 2,073 patients per arm (incidence of 6.6%152 and a 2%
absolute reduction with the therapy). For mortality, the OIS was about 18,330 patients per
arm (rate of 0.5 to 14%152 and a 1% absolute reduction).

3.10 Missing Outcome Data
We tried to gather missing information by contacting the study authors. However, of 16
authors whom were contacted for further information, four responded but no one
provided data needed for the NMA. Obtaining missing outcome data from secondary
sources was also attempted.
In addition, we also used a statistical approach to handle missing data. Using empirical
data, Spineli et al153 evaluated several different imputation assumptions: missing at
random model, all missing failures model, all missing successes model, best-case model,
worst-case model, common informative missing OR, treatment-specific informative
missing OR (either on average missing at random, more missing failures, more missing
successes, more failures in placebo, or more success in placebo). Compared with the
other assumptions, the worst- and best- case models were found to increase heterogeneity
markedly and were considered extreme assumptions. Moreover, this study found that the
‘all missing failure’ model was robust to small changes in the uncertainty and the
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SUCRA values. Given this consideration, we handled missing outcome data using the ‘all
missing failure’ model, which assumes that all missing patients have a negative event.

3.11 Sensitivity Analysis for SVGF
We did not perform our preplanned sensitivity analyses because the analyses would result
in removal of nodes from the network altering the geometry of the network. Previous
studies found that changing the network pattern may substantially change the effect sizes
and/or treatment rankings and increase the likelihood of incoherence.154-156 Therefore,
comparing results between primary analyses and sensitivity analyses with different
network geometries may not be meaningful.
A series of post hoc sensitivity analyses was undertaken instead. First, we performed a
sensitivity analysis including only per-graft data to determine the impact of unit of
analysis on study findings. Another sensitivity analysis focused on duration of follow-up.
The primary analyses for SVGF endpoint included studies with the longest follow-up
data; however, this approach may lead to increased heterogeneity because the included
studies had different lengths of follow-up. To explore the potential effect of duration of
follow-up on treatment effects, a post hoc sensitivity analysis was performed by
including only angiographic data that were collected closer to one year post CABG. In
addition, we performed another post hoc sensitivity analysis excluding studies of OPCAB
(only) surgery, a type of surgery that is less commonly used (~17%), 157 to explore the
impact of outlier on study findings.
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Chapter 4

4

Results

4.1 Literature Search
Figure 2 shows the study selection process. We identified a total of 2,917 titles and
abstracts through the literature search. Of these, 125 articles were potentially eligible for
inclusion and considered for full article review. One hundred and five articles were then
excluded if they were duplicates or non-English, reported the wrong outcome (i.e., did
not assess SVG patency), wrong interventions (e.g., combine aspirin with dipyridamole
or ticlopidine), wrong patient population (e.g., randomization did not occur in proximity
[seven days] to CABG), or wrong study design (e.g., subgroup analysis of RCTs), or if
they were ongoing trials. Twenty articles describing 18 unique studies were deemed
eligible and included. Of these, two articles were longer term follow-up of the original
studies.64 158 The longest available follow-up for each of the 18 studies was used as our
base case. The list of studies deemed to be excluded and the reasons for exclusion can be
found in Supplementary Appendix eTable 7.
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Figure 2. Study selection process

Included
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Identification

Records identified through
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n = 20
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Reported in 20 papers
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Flow diagram based on PRISMA

4.2 Study and Patient Characteristics
A total of 18 parallel-group RCTs64 158-174 with 3,413 patients (range: 20 to 635 patients
per trial) and six eligible treatment arms met the inclusion criteria for our NMA. All
included studies were published between 1979 and 2017, of which, 50%161 162 165 167 169-172
174

were single-center trials. Nine (50%) studies64 159-165 167 were placebo-controlled trials

and 10 (56%)158

160 166 168-174

were head-to-head trials. Of 18 studies, one (6%)160 was

multi-arm with three eligible arms. Most trials (56%) performed CABG surgery in an
elective setting, and five (28%) trials159 160 169 173 174 combined elective and urgent cases.
Nine (50%) studies159 161-166 171 174 included patients who underwent CABG with CPB and
two (11%)168 172 without CPB, whereas three (17%) studies158 169 170 174 included a mixture
of patients with CPB and without CPB. Most studies were short-term studies, with a
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longest time of angiographic follow-up ranging from eight days to eight years (≤ threemonth follow-up from four studies,164 168 170 171 four- to 12-month follow-up from nine
studies,159 161-163 167 169 172-174 and >12-month-follow-up from five studies64 158 160 165 166). In
studies reporting duration of treatment (n=17 trials),64 158-168 170-174 the included patients
received study medications as a single-dose 12 hours before CABG164 or a regular-dose
for one to 12 months. All studies reported SVGF on a per-graft basis as an outcome
measure, but only 12 studies64 159-167 171 175 reported the outcome on a per-patient basis
and 13 studies158-161 163-166 170-174 reported at least one of major clinical endpoints (major
bleeding, mortality, CVA and/or MI). Detailed information for trial characteristics is
summarized in Table 1 and eTable 8.
In studies that reported baseline characteristics, the mean age ranged from 44 to 83 years
and 2,655 (89%) patients were male. A total of 528 (21%) patients underwent CABG
without CPB and 2,596 (95%) were elective patients. There were 409 (18%) patients with
diabetes, 824 (48%) with dyslipidemia, 1,445 (55%) with prior MI, 109 (14%) with prior
PCI, 16 (3.7%) with prior CVA, and 1,361 (47%) with hypertension. Across studies,
mean of SVGs per patient and percentage of male participants were comparable. The
proportions of patients with at least one concomitant condition were also reasonably
similar across studies. Overall, the included trials were deemed sufficiently similar in
terms of observed demographic and clinical characteristics.
Five active interventions included in this NMA were aspirin monotherapy, clopidogrel
monotherapy, vitamin-K antagonists, dual-antiplatelet therapy with aspirin and
clopidogrel, and dual-antiplatelet therapy with aspirin and ticagrelor. These agents were
compared either with inactive control/placebo or each other. Across treatment
comparisons, the percentage of males was similar. The distribution of other baseline
characteristics was generally balanced across comparisons, except for CABG type and
timing for the start of treatment. CCAB patients were more prevalent in comparisons that
included earlier studies (before 2000). In general, the timing for the start of treatment
varied across treatment comparisons ranging from seven preoperative days to four
postoperative days. Detailed information for patient characteristics is summarized in
Table 2 and eTable 9.
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Table 1. Summary of characteristics of trials included in pairwise meta-analysis and
NMA (n=18 RCTs)
RCT Characteristics
Year of publication
1979 – 1989
1990 – 2000
2001 – 2011
2012 - 2017
Study type
Single center
Multicenter
Not reported
Surgical setting
Elective
Urgent
Both
Not reported
CABG type
CCAB
OPCAB
Both
Not reported
Outcomes assessed*
Vein graft failure (Per patient)
Vein graft failure (Per graft)
Major bleeding
Mortality
Myocardial infarction
CVA
Longest time of patency assessment
≤3 months
>3 to 12 months
>12 months (up to 8 years)
Control interventions*
Placebo/control
Aspirin (usual care)
Length of treatment
<3 months
3 to 12 months
>12 months
Not reported
*RCTs can report more than one outcome or comparator.

No. of RCTs (%)
6 (33)
4 (22)
4 (22)
4 (22)
9 (50)
6 (33)
3 (17)
10 (56)
0 (0)
5 (28)
3 (17)
9 (50)
2 (11)
3 (17)
4 (22)
12 (67)
18 (100)
8 (44)
11 (61)
10 (56)
7 (39)
4 (22)
9 (50)
5 (28)
9 (50)
9 (50)
2 (11)
15 (83)
0 (0)
1 (5.6)
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4.3 Risk of Bias
Overall, the study-specific risk of bias ranged from low to high (eFigure 1 and eFigure 2).
Most studies were judged to have a low risk of bias for random sequence generation
(61%), blinding of patients (56%), blinding of outcome assessor (78%), selective
reporting (78%), and other bias (94%). In terms of allocation concealment, 78% of
studies did not report details.
Of five (28%) studies159-161 166 170 that reported failure to blind, three159 160 166 explained
that the need for International Normalized Ratio (INR) monitoring of vitamin-K
antagonists therapy prevented them from blinding patients and personnel. Eleven (61%)
studies64 158-164 166 167 171 were at high risk of bias related to incomplete patency data owing
to the high proportion of loss to follow up (16% to 49%) and/or uneven proportions
and/or reasons for loss to follow up between arms. Unlike the primary outcome, all
studies contributing to the secondary outcomes were judged to have a low risk of bias for
incomplete outcome data. A greater risk of bias for the primary outcome is not surprising,
as not all patients could return for angiographic assessment for various reasons including
refusal or development of contraindications for angiography during follow-up (e.g., renal
failure). In terms of selective reporting, three studies162 168 169 were at unclear risk of bias
as they did not report data on at least one of our secondary clinical outcomes, and one
study167 was at high risk of bias because it did not report any clinical outcome data. In
addition, only one trial162 had a high risk of bias due to other bias owing to the imbalance
in a few clinical characteristics between study groups despite randomization.
Through visual inspection, the comparison-adjusted funnel plot appears symmetric
suggesting that there was no evidence for small-study effects for placebo-controlled trials
assessing SVGF (eFigure 4).
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Table 2. Summary of baseline characteristics of patients undergoing CABG across treatment comparisons (n=18 RCTs)

DM

12

HTN

14

Dyslipidemia

8

Prior MI

12

Prior PCI

4

Aspirin vs
Control
n=8 RCTs
58±7.72
1212/1278
(95)
45/560
(8)
528/1218
(43)
27/116
(23)
703/1076
(65)
NR

Prior CVA

3

NR

NR

NR

CCAB

14

Antifibrinolytic
use
Elective surgery

2

862/862
(100)
NR

37/37
(100)
NR

616/616
(100)
NR

15

Time of drug

18

932/1006
(93)
7 preop to 5

73/145
(50)
3 to 4 postop

695/755
(92)
12 preop hours

Characteristics
Age (mean±SD)
Male

No. of
RCTs
with data
14
15

Vit K A vs
Control
n=2 RCTs
53±8
129/148
(87)
18/111
(16)
20/111
(18)
NR
74/111
(67)
NR

Vit K A vs
Aspirin
n=2 RCTs
58±8
632/722
(88)
74/722
(10)
250/722
(35)
271/616
(44)
401/722
(56)
NR

ASA/Clo vs
Aspirin
n=6 RCTs
61±8.16
599/736
(81)
168/756
(22)
417/756
(55)
426/736
(58)
253/623
(41)
77/524
(15)
16/436
(3.7)
321/776
(41)
399/399
(100)
776/776
(100)
Immediately

ASA/Clo vs
Clopidogrel
n=1 RCT
62±9.94
163/197
(83)
108/197
(55)
125/197
(64)
41/197
(21)
105/197
(53)
24/197
(12)
NR

ASA/Tic vs
Aspirin
n=1 RCT
62±8.67
61/70
(87)
21/70
(30)
54/70
(77)
59/70
(84)
12/70
(17)
8/70
(11)
NR

124/197
(63)
NR

NR

186/197
(94)
1 day

47/70
(67)
58 to 59

NR

53

initiation
(range)

postop days

days

to 4 postop
days

postop to 48
hours

postop hours

Values presented as n/N (%) unless stated otherwise. All information was obtained from first publications. ASA/Clo: Dual-antiplatelet
therapy with aspirin and clopidogrel. ASA/Tic: Dual-antiplatelet therapy with aspirin and ticagrelor. NR: Not reported. Preop:
preoperative. Postop: postoperative. Vit K A: Vitamin-K antagonists.
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4.4 Direct Estimates
4.4.1

Primary outcome

A pairwise meta-analysis of eight RCTs (n= 1,182 patients) showed that dual-antiplatelet
therapy with aspirin and clopidogrel significantly reduced SVGF compared to aspirin
monotherapy (OR: 0.60; 95% CI: 0.42-0.88). In a separate meta-analysis of six RCTs (n=
1,085 patients), aspirin monotherapy significantly decreased the odds of SVGF by 38%
(OR: 0.62; 95% CI: 0.43-0.90) relative to placebo/control. Furthermore, there was no
evidence of significant differences among other treatment comparisons. The direct
estimates were consistent in magnitude and direction between base case analyses and pergraft analyses for all comparisons (eTable 10).

4.4.2

Secondary outcomes

In a pairwise meta-analysis of four RCTs, of 506 patients assigned to aspirin
monotherapy group, 34 (6.72%) patients underwent re-exploration for bleeding, and of
485 patients assigned to placebo/control group, 9 (1.86%) patients had the event (OR:
3.59; 95% CI: 1.67-7.73; eTable 10). No significant differences between interventions in
major bleeding, mortality, MI, CVA, repeat revascularization, minor bleeding, and
MACCE were found (eTable 10).

4.5 Network Estimates, Treatment Ranking, and
Contribution of Direct Evidence
4.5.1

Primary outcome

Figure 3 shows the network of evidence for SVGF. Eighteen studies64

158-174

with six

treatment arms including 15 unique treatment comparisons were included in a NMA for
SVGF. Of the 15 comparisons, four were statistically significant with three treatments
were found to be more effective than placebo/control and one treatment was superior to
aspirin monotherapy. More specifically, when compared with placebo/control, dualantiplatelet therapy with aspirin and clopidogrel (OR: 0.40; 95% CI: 0.24-0.69), dual-
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antiplatelet therapy with aspirin and ticagrelor (OR: 0.25; 95% CI: 0.07-0.94), and aspirin
alone (OR: 0.64; 95% CI: 0.47-0.88) significantly reduced the odds of SVGF. In addition,
dual-antiplatelet therapy with aspirin and clopidogrel had a statistically significant benefit
in preventing SVGF relative to aspirin alone (OR: 0.63; 95% CI: 0.41-0.97). The network
estimates were consistent in magnitude and direction between base case analyses and pergraft analyses for all comparisons, except for the network estimate of vitamin-K
antagonists versus placebo/control (eTable 11). The difference is likely owing to a
greater statistical power with the per-graft data (i.e., larger number of occluded SVGs and
larger sample size in the two direct comparisons contributing to the network estimate)
than with the base-case data. The direct and network estimates for all treatment
comparisons can be found in Figure 4.
eTable 12 presents the SUCRA value for all interventions. According to the SUCRA,
dual-antiplatelet therapy with aspirin and ticagrelor was ranked the best in preventing
SVGF with a SUCRA of 89, followed by dual-antiplatelet therapy with aspirin and
clopidogrel (SUCRA=80), vitamin-K antagonists (SUCRA=46), aspirin monotherapy
(SUCRA=44),

clopidogrel

monotherapy

(SUCRA=33),

and

placebo/control

(SUCRA=8.4). The numerical values of SUCRA between the base-case analysis and the
per-graft analysis were similar (eTable 12).
Lastly, the direct comparison of aspirin monotherapy and dual-antiplatelet therapy with
aspirin and clopidogrel had the largest contribution to the network analyses (27.7%).
Detailed information for contributions of direct evidence in the entire network can be
found in eTable 13.
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Figure 3. Network of RCTs comparing the effect of antithrombotic agents on
saphenous vein graft failure (A), major bleeding (B), mortality (C), and myocardial
infarction (D)

The size of the nodes (circles) and edges (lines) are proportional to the number of studies
evaluating a particular treatment and the number of patients who contribute to the direct
comparison, respectively.
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Figure 4. Summary of direct and network estimates for SVGF

Control

0.77
(0.21-2.86)

--

Clopidogrel

0.62
(0.43-0.90)
0.68
(0.30-1.51)
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0.64
(0.47-0.88)
0.83
(0.23-2.96)
Aspirin

--

--

--

--

0.52
(0.17-1.60)

0.94
(0.66-1.35)
0.39
(0.12-1.32)
0.60
(0.42-0.88)

0.63
(0.37-1.06)
0.81
(0.21-3.15)
0.98
(0.61-1.57)
Vit K A

0.25
(0.07-0.94)
0.32
(0.05-1.98)
0.39
(0.11-1.42)
0.40
(0.10-1.57)

--

Aspirin & Ticagrelor

--

--

0.40
(0.24-0.69)
0.52
(0.16-1.73)
0.63
(0.41-0.97)
0.64
(0.34-1.22)
1.62
(0.41-6.31)
Aspirin & Clopidogrel

Top diagonal (network estimates): column- versus row-defining treatment
Bottom (direct estimates): row- versus column-defining treatment

Estimates are presented as OR and its corresponding 95% CI. The bolded estimates are
statistically significant.

4.5.2

Secondary outcomes

Figure 1 shows the network of treatment comparisons for secondary outcomes. Each
outcome involves five arms with an identical set of interventions. Unlike the primary
outcome, clopidogrel monotherapy was not part of the network for the secondary
outcomes as the only study169 evaluating clopidogrel monotherapy did not report data on
any of our secondary outcomes.
In the NMA, there were eight studies158 160 165 166 171-174 including 1,690 patients for major
bleeding, eleven studies158-161 163 165 166 170-173 including 2,396 patients for mortality, and
ten studies158 160 164-166 170-174 including 2,644 patients for MI. For each of these secondary
outcomes, there were 10 unique treatment comparisons in a network with no evidence of
any statistically significant differences among these comparisons (eFigure 3 and eTable
11).
According to the SUCRA, placebo/control was the best strategy in reducing major
bleeding with a SUCRA value of 83, followed by dual-antiplatelet with aspirin and
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clopidogrel (SUCRA=60), aspirin monotherapy (SUCRA=47), dual-antiplatelet with
aspirin and ticagrelor (SUCRA=46), and vitamin-K antagonists (SUCRA=14). In
addition, dual-antiplatelet therapy with aspirin and clopidogrel (SUCRA=71) was most
effective in preventing MI, but dual-antiplatelet therapy with aspirin and ticagrelor
(SUCRA=66) was best for improving survival (eTable 12).
Lastly, the direct comparison of vitamin-K antagonists and aspirin monotherapy had the
largest contribution to the network analysis for major bleeding and MI (34% and 37%,
respectively, eTable 13). Dual-antiplatelet therapy with aspirin and clopidogrel versus
aspirin monotherapy was the comparison with the most contribution to the entire network
for mortality (24%).

4.6 Assessment of Transitivity, Homogeneity, and
Coherence
We assessed the transitivity assumption using its own four expressions:
1. First, we suspected that not all treatments were sufficiently similar across trials.
While trials investigating the effect of dual-antiplatelet therapy with aspirin and
clopidogrel used similar regimens, higher aspirin doses were given to patients
who participated in earlier studies. Also, for control arms, two trials159

161

provided no study medications to patients, while the remaining studies
administered matching placebo. Therefore, the control arms in the vitamin-K
antagonists studies may not be similar to control arms in earlier studies or in the
aspirin monotherapy studies.
2. Second, we felt it is appropriate to conclude that the choice of comparator may
not be influenced by the authors’ expectations in the magnitude and/or direction
of treatment effects. In early days, placebo was used as a comparator; but after the
benefit of aspirin was established in published trials, most trials compared the
intervention of interest with aspirin monotherapy. Hence, it may be justifiable to
assume that the missing arms were missing at random.
3. Third, we visually inspected the network plot and qualitatively examined the
comparability of the distribution of potential effect modifiers, which were pre-
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specified, across treatment contrasts. We assumed that the effect modifiers were
not systematically different between treatment comparisons (Table 2). Although
the proportion of CCAB and the timing for the start of treatment varied across
comparisons, we felt these differences may not have enough strength to
substantially influence treatment effects. Due to limited data on antifibrinolytic
use, it was not possible to compare the distribution of this variable across
comparisons in this network.
4. Fourth, we felt it was appropriate to assume that the type of participants included
in these studies could conceivably have been eligible to be randomized to any of
the included interventions. Patients with a history of bleeding were excluded in all
studies, thus, equipoise between participating in a vitamin-K antagonist trial and
participating in a non-vitamin-K antagonist trial would equally apply, despite the
known bleeding risk of vitamin-K antagonists.
In summary, though we could not definitively rule out the possibility of intransitivity, we
judged that the assumption of transitivity sufficiently holds based on the current evidence
since there was no good evidence to the contrary.
In terms of the homogeneity assumption, we identified low to moderate heterogeneity (I2
of <75%) for all outcomes based on pairwise meta-analyses. In the network, the betweentrial variance (tau2) was 0.047, 5.38×10-22, 1.93×10-17, and 1.08×10-14 for SVGF, major
bleeding, mortality, and MI, respectively (see eTable 11). The estimated tau2 for SVGF
was lower than the 50% quantile of heterogeneity estimates (up to 1.10) obtained from an
empirical meta-analysis for a subjective outcome.149 Similarly, the heterogeneity variance
for all-cause mortality was lower than the corresponding 50% quantile of the empirical
tau2 (up to 0.007). Lastly, the heterogeneity variance for semi-objective outcomes (i.e.,
major bleeding and MI) was also lower than the 50% quantile of the empirical
distribution (up to 0.016). Overall, we identified low heterogeneity in our networks,
which suggests that heterogeneity is probably less likely to threaten internal validity.
With regards to the coherence assumption, there was a lack of evidence of local
incoherence for all outcomes: SVGF (IF: 0.25 (95% CI: 0.00-1.42)), major bleeding (IF:
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0.30 (95% CI: 0.00-1.12)), mortality (IF: 0.85 (95% CI: 0.00-5.22)), and MI (IF: 3.33
(95% CI: 0.00-7.06); see eTable 14). In addition, the design-by-treatment interaction
model found no evidence of incoherence in the entire network for SVGF (P= 0.834),
major bleeding (P= 0.632), mortality (P=0.476), and MI (P=0.191; see eTable 15).

4.7 Quality of Evidence
For the primary outcome, no serious risk of bias and no inconsistency was detected for all
direct comparisons, except for those involving vitamin-K antagonists, in which blinding
was a challenge. All direct comparisons were at risk of indirectness due to: 1) the use of
aspirin at doses higher than the currently recommended (75 to 100 mg/day)21; 2) the use
of a surrogate outcome (SVGF), which has not yet been validated for its relationship to
the outcomes that matter, including acute MI and death; and 3) the short duration of
treatment (e.g., one month) and follow-up (e.g., eight days) for SVGF, which are not very
applicable to the real-world situation, where long term treatment and data are of interest.
In addition, the evidence was rated down for imprecision because of the wide 95% CIs
with small number of events and sample size for most direct comparisons. The overall
quality of the direct evidence therefore ranged from very low to moderate, in which the
comparisons of aspirin monotherapy versus placebo/control and dual-antiplatelet therapy
with aspirin and clopidogrel versus aspirin monotherapy were of moderate quality. In
terms of network evidence, the overall quality of evidence was very low, ranging from
very low to moderate, primarily due to the wide 95% CIs of network estimates and the
probable intransitivity. In the network, we found eight comparisons (53% of all
comparisons) of very low quality, three (20%) of low quality, four (27%) of moderate
quality. Notably, the network evidence for most comparisons of active drugs versus
placebo/control was moderate quality because the magnitude of significant effect sizes
reached <0.5, and the only head-to-head comparison with moderate quality was dualantiplatelet therapy with aspirin and clopidogrel versus aspirin monotherapy.
For secondary outcomes, there was no serious risk of bias and inconsistency for most
direct comparisons, except for those studies using vitamin-K antagonists. Comparisons of
any drugs versus aspirin monotherapy were at risk of indirectness as aspirin was
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administered at higher doses than those that are currently used. For all direct
comparisons, evidence was rated down for imprecision because the 95% CIs crossed the
clinical decision threshold. The overall quality of direct evidence was therefore low,
ranging from very low to moderate, in which the comparison of dual-antiplatelet therapy
with aspirin and ticagrelor versus aspirin monotherapy was rated at moderate quality. In
terms of network evidence, the overall quality was very low, ranging from very low to
moderate, primarily due to the wide 95% CIs of network estimates and the possibility of
intransitivity. In each of the networks, we found six comparisons (60% of all
comparisons) of very low quality, three (30%) of low quality, one (10%) of moderate
quality. Although the evidence for dual-antiplatelet therapy with aspirin and ticagrelor
versus aspirin monotherapy was moderate quality, it is important to note that there was
only one study available for this comparison. Detailed information regarding quality of
direct and network evidence can be found in eTable 16 and eTable 17, respectively.

4.8 Post-hoc Sensitivity Analyses
To explore the potential impact of missing outcome data in the analyses, we conducted a
sensitivity analysis for SVGF. eTable 18 and eTable 19 present the results of sensitivity
analyses accounting for loss to follow-up. The results obtained from our primary analysis
were similar to those from the ‘all missing failure’ models with respect to the effect
estimates and the treatment rankings.
There were two studies with multiple follow-up data.158 160 When we included SVGF data
that were collected closer to 1-year of CABG (a shorter follow-up i.e. up to two years)
from these studies, the conclusions did not change substantially in terms of effect sizes,
treatment rankings, and coherence (eTable 20).
Lastly, we performed another sensitivity analysis excluding studies168
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that included

only patients undergoing CABG without CPB (OPCAB) and found that the results were
consistent with those obtained from the primary analyses (eTable 20), except for the
comparison of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin
monotherapy, which did not reach statistical significance. This may be owing to the
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smaller sample size (i.e., lower statistical power) because of study removal or could be
related to clinical differences in likelihood of SVGF in the context of OPCAB relative to
CABG with CPB.
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Chapter 5

5

Discussion

The aims of this chapter are to summarize the study findings, to compare them to the
existing literature, and to discuss the limitations and the conclusions of the current NMA,
including its implications for clinical practice and research.

5.1 Summary of Study Findings
A NMA was conducted to synthesize results from RCTs that assessed efficacy of
different antithrombotic therapies in the prevention of SVGF to provide evidence-based
guidance for optimal prophylactic management. In this NMA of 18 unique RCTs (n=
3,413 patients), we included six interventions for patients undergoing CABG and found
that, based on moderate-quality evidence, patients receiving dual-antiplatelet therapy
with aspirin and clopidogrel, a second-best treatment, had significantly lower odds of
developing SVGF compared to either aspirin alone or placebo/control. Furthermore,
though ranked the most effective agent, dual-antiplatelet therapy with aspirin and
ticagrelor only significantly reduced SVGF relative to placebo/control, but not in
comparison with any other interventions. Additionally, moderate-quality evidence
showed that aspirin monotherapy was protective against SVGF relative to
placebo/control. Besides the aforementioned comparisons, there were no significant
differences found in any other treatment comparisons. These results (effect sizes and
treatment rankings) were generally consistent across different units of analysis (base case
versus per graft) and different durations of follow-up (longer [up to 8 years] versus
shorter follow-up [up to 2 years]).
Our secondary objective was to conduct a NMA to assess the relative effects of
antithrombotic agents on clinical outcomes. The present NMA could not demonstrate any
significant differences in major cardiovascular adverse events (MI and mortality) and
major bleeding amongst antithrombotic therapies.
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5.2 Comparison to the Existing Literature
The current study is the first NMA to simultaneously evaluate the effect of various
antithrombotic agents on SVGF; however, a number of pairwise meta-analyses
comparing a subset of these agents had been previously published. Fremes et al and
Henderson et al published the earliest meta-analyses in the late 1980s and early 1990s
and found aspirin to be superior in reducing SVG occlusion among patients undergoing
CABG over placebo.71
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Our findings are consistent with these early meta-analyses.

Additionally, an antiplatelet meta-analysis in 1994 demonstrated that the use of
postoperative aspirin (75 to 325 mg/day) reduced the odds of any graft occlusion by 44%
relative to control, although the proportion of occluded vein grafts was not reported.177 In
terms of duration of treatment, it has been suggested that the use of aspirin for longer
than 1 year post CABG did not improve SVG patency.178 Due to insufficient data, the
current NMA could not confirm the benefits of long-term antithrombotic therapy use. In
contrast to our results, Fremes et al and Henderson et al found a reduction in SVGF with
anticoagulation. It is important to note that one of the three anticoagulation studies
included in these meta-analyses (which was excluded from our analysis) provided an
uninterrupted antiplatelet therapy with dipyridamole for seven days post CABG, an agent
that is no longer used for SVGF prevention.179 In 2013, Deo et al published a pairwise
meta-analysis of five RCTs involving 1,419 SVGs and showed that the postoperative use
of dual-antiplatelet therapy with aspirin and clopidogrel significantly reduced SVG
occlusion compared with aspirin alone,72 which was congruent with the results observed
in our NMA. In addition, the significant reduction remained when considering only
patients undergoing CABG without CPB.72 Due to the lack of data, a sensitivity analysis
including only OPCAB studies was not possible to confirm this reduction.
In terms of clinical outcomes, Fremes et al failed to demonstrate the survival benefits of
aspirin monotherapy as well as anticoagulation, which was consistent with our study.71
Furthermore, a meta-analysis of 11 RCTs and observational studies involving 25,728
CABG patients showed that dual-antiplatelet therapy with aspirin and clopidogrel was
associated with a significant reduced risk of 30-day mortality.72 Despite this association,
a causative role of antithrombotic agents in reducing mortality in this population remains
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unknown. A more recent meta-analysis examining the clinical effects of postoperative
antithrombotic therapy in five RCTs (979 patients undergoing elective CABG) reported
that there were no significant differences in mortality, MI, stroke, and major bleeding
events between monotherapy with aspirin and dual-antiplatelet therapy with aspirin and
clopidogrel.180 Similar conclusions were also observed in our study. In summary, there
have been no previously published NMAs of antithrombotic agents for SVG patency.
However, the direct comparison findings within our NMA were generally in agreement
with the previous pairwise meta-analyses in terms of SVGF and clinical outcomes.

5.2.1

Other comparisons

In this NMA, we did not observe any significant effect of vitamin-K antagonists on either
SVGF or clinical outcomes. The low sample size may be mainly responsible for the nonsignificant results. Though increasing the power of the study is one solution to this
statistical issue, warfarin has typically been used less frequently to prevent SVGF due to
its association with increased bleeding and the need for regular testing of the INR.
Our NMA was also underpowered to detect significant differences in the incidence of
SVGF or adverse events between monotherapy with clopidogrel169 or dual-antiplatelet
therapy with aspirin and ticagrelor173 and other antithrombotic agents as currently there
is only one published trial available for each comparison. It is hoped that the two trials
(DACAB

trial;

ClinicalTrials.gov

No.

NCT02201771

and

TICAB

Trial;

ClinicalTrials.gov No. NCT01755520) that are currently in progress can provide
additional data on the use of dual-antiplatelet therapy with aspirin and ticagrelor among
patients undergoing CABG.

5.3 Strengths and Limitations
The following are the main strengths of the current NMA: 1) its comprehensive
systematic search that considered all available RCTs, published or unpublished, of
antithrombotic therapies assessing the patency of SVGs as an outcome of interest. The
eligibility criteria were pre-specified and stringent, which was purposefully done to
reduce heterogeneity and risk of bias; 2) The use of a well-defined protocol. The protocol
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was prepared to provide background information to the readers, to serve as a working
outline, and most importantly, to enhance the integrity of the current study promoting
transparency in scientific research;181 3) The use of the GRADE approach to evaluate the
quality of the evidence for individual trials and in aggregate. Understanding not only the
magnitude and direction of treatment effects, but also the quality of evidence is important
to avoid the over-reliance on statistical significance and treatment ranking; 4) Lastly, the
use of NMA methodology for secondary analysis of existing studies. A NMA is useful to
estimate network estimates with greater precision while simultaneously considering all
relevant treatment options, even when some of the treatments have never been compared
previously.
Despite these strengths, the results of this study should be interpreted in light of the
following limitations. First, we encountered several challenges in evaluating the
transitivity, homogeneity, and coherence assumptions of NMA. Although we felt it was
appropriate to conclude that our networks did not transgress the transitivity assumption,
the judgment was limited by the lack of global evidence and extent of clinical
understanding of treatment-effect modification. Consequently, the choice of study-level
effect modifiers was necessarily somewhat arbitrary, based on our best knowledge of
clinical expectations rather than on empirical evidence (which does not yet exist). We
also could not confirm whether it was appropriate to treat these covariates equally across
outcomes and comparisons as potentially they could have different effects across
different outcomes and comparisons. Even if there was sufficient pre-existing evidence to
inform these relationships a priori, the assessment would still be limited if the effect
modifiers were not measured or the information was not reported by each study report.
These concerns are not unique to our NMA, and have been frequently discussed by
authors and methodologists in previous NMA publications.141
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Future research is

therefore needed to better understand treatment-effect modification. Notably, this NMA
used a qualitative approach to assess the transitivity assumption, which can be subjective.
Another method has been recently proposed by Kabali and Ghazipura to evaluate the
assumption using causal graphs and transport formulae.183 However, a detailed
description and application of this approach is beyond the scope of this NMA. Regarding
coherence, our network is sparsely populated with only one closed loop provided by
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direct comparison studies; therefore, we were not able to assess incoherence for the other
parts of network. It is also important to note that lack of evidence of statistical
incoherence does not necessarily mean evidence of coherence. There may be several
factors contributing to the absence of this evidence in our NMA, such as the low power
of tests for detecting local and global incoherence and the unexplained heterogeneity that
may further reduce the power. In terms of the homogeneity assumption, although the
statistical heterogeneity was found to be low or moderate, the power of the tests to
quantify the extent of heterogeneity was limited by the relatively few studies and small
sample size in the networks. Importantly, the inadequate data on baseline characteristics
and the lack of patient-level data also preclude carrying out a full, comprehensive
assessment of clinical and methodological heterogeneity and performing further analyses
such as subgroup analysis or meta-regression to explore potential sources of
heterogeneity or to adjust for the unbalanced distribution of effect modifiers. If factors
influencing SVGF varied markedly across comparisons, the estimated treatment effects
may be biased. While the results after we performed sensitivity analyses (to explore the
impact of missing outcome data, differing duration of follow-up, and varied units of
analysis) remained robust across different scenarios, it is important to highlight that the
sensitivity analyses were also severely limited in power to detect differences.
Second, since our inclusion criteria for eligible RCTs was restricted to a single outcome
(SVGF), the analyses of other clinically-relevant outcomes were very limited by the
amount of data reported in the SVGF study reports. As expected, several interventions
were compared in a relatively few studies and sample size. Hence, drawing definitive
conclusions regarding the clinically-relevant impact on the ultimate outcomes of interest
including MI and need for cardiac reintervention was not possible, which puts the current
study at risk of type II error (failure in finding a significant result when in truth there is
one). Most importantly, although the balance between health benefits and safety is an
important aspect that influences the choice of intervention, assessing the balance of
benefit and harms of antithrombotic therapies is not possible in this study due to limited
data. Therefore, future research is needed to expand our knowledge and depth of
understanding of the benefit:risk ratio. Third, although the chance is small, the possibility
of drawing erroneous conclusions of statistical differences between comparisons cannot
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be ruled out (type I error). Theoretically speaking, of 111 (direct, indirect, and network)
statistical tests that we performed on four different endpoints using an alpha of 0.05, a
total of six statistically significant differences (false positives) would be expected, and
therefore our significant outcomes might be explained by chance alone.
Fourth, it is unknown whether different doses lead to clinically important differences in
the patency of SVG. In this current study, we did not control for dose and our results may
be confounded by it. Fifth, our NMA included studies which were published over a 38year period, and thus, patient characteristics (i.e., risk factors and disease complexity),
surgical techniques, advances in imaging, treatment regimens used in earlier studies may
differ from those included in more recent studies (such as broad use of statins) and may
not reflect the current clinical practice. Due to the small number of trials in each
comparison, we are unable to perform a sensitivity analysis investigating the impact of
year of publication (before and after year 2000). Sixth, substantial heterogeneity in the
definition of SVGF exists in the included studies. Of those that reported clear definitions
of SVGF, one study performed angiographic assessments in surviving patients only,158
one study evaluated the patency of SVG post mortem,160 and the remaining were
unknown. Many studies also did not describe whether grafts or distal anastomoses were
being counted. In addition, studies measured SVGF at different times and it is unclear
whether these studies excluded perioperative (early) SVGF. Early SVGF is often a result
of technical factors, regardless of the antithrombotic therapy received. The inclusion of
early SVGF may underestimate the efficacy of antithrombotic agents themselves for SVG
failure after CABG. Collectively, considerable heterogeneity in definitions of SVGF may
therefore threaten internal validity. Furthermore, although the results from base case
analysis and per graft analysis were similar, combining data from two different units of
analysis may challenge the interpretation of the base case analysis. Seventh, follow-up
period and length of treatment may be potential sources of heterogeneity. Many of these
studies did not follow up patients for adequate number of years to allow for a fair
indication of whether differences in SVGF would arise, and pooling studies with different
lengths of treatment may reduce the relevance of the study findings. Eighth, women
(11%) were underrepresented in all included studies, which may limit the generalizability
of the results. Lastly, due to insufficient information, it is unclear whether studies
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presented the data based on ITT analysis, an analysis that preserves the benefits of
randomization in the presence of reasonable rate of missing data ensuring unbiased
estimates.184 The study findings therefore should be interpreted with caution due to the
potential selection bias induced by the high rate of loss to angiographic follow-up (with
patients having certain characteristics that are associated with treatment effects or side
effects of treatment forgoing further angiographic follow-up), which occurred in most of
the included studies, and by death as a competing event in SVGF analysis. The large loss
to follow up indicates that our results remain unstable. Hence, the answers remain
unknown, and demand future adequately controlled trials of sufficient duration to
measure these outcomes.

5.4 Implications for Clinical Practice
Experts have recognized the importance of rating the quality of evidence in the process of
making clinical decisions. According to the GRADE system, high quality of evidence is
considered most desirable, followed by moderate quality of evidence since the observed
treatment effect and our confidence in it are unlikely to alter as more studies emerge. 185
In this NMA, there are four comparisons with moderate quality of evidence on reducing
SVGF but no comparison with high quality of evidence. The four comparisons are dualantiplatelet therapy with aspirin and clopidogrel versus placebo/control, dual-antiplatelet
therapy with aspirin and ticagrelor versus placebo/control, monotherapy with aspirin
versus placebo/control, and dual-antiplatelet therapy with aspirin and clopidogrel versus
monotherapy with aspirin; of these, all reached statistical significance. However, the first
three comparisons included placebo/control, in which its use is not of interest. Indeed, it
is unethical to give patients placebo when a strategy known to be efficacious exists and is
recommended by clinical guidelines. Considering a placebo-controlled trial in the light
of superiority evidence may therefore raise ethical concerns.186 187 This concern leaves us
with the last comparison, which is dual-antiplatelet therapy with aspirin and clopidogrel
versus monotherapy with aspirin, to discuss.
In the context of SVG patency, aspirin monotherapy is the current standard prophylactic
treatment.6 However, there is growing evidence showing that the suboptimal performance
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of aspirin alone is not uncommon among CABG patients.188 189 As briefly discussed in
Chapter 1.3.3.2, this phenomenon is known as aspirin resistance, which affects 30 to 42%
of patients undergoing CABG.188
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Studies have shown that aspirin resistance was

associated with an increased risk of cardiovascular adverse events and was more
prevalent in patients with SVGF.67 190 191 Some argue that a higher (up to 325 mg daily)
aspirin dose should be administered to prevent aspirin resistance.6 However, aspirin
resistance is unlikely to be affected by higher doses of aspirin. Aspirin resistance is
mainly caused by decreased bioavailability of some enteric-coated formulations and drug
interactions with low-dose aspirin.192
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Alternatively, the addition of clopidogrel to

aspirin has been proposed to further reduce the risk of occlusion. Based on moderatequality evidence, our study findings supported this hypothesis and showed that the use of
dual-antiplatelet therapy with aspirin and clopidogrel reduced SVGF compared to aspirin
alone. Although providing a recommendation with lower quality of evidence (Class IIb,
Level of Evidence B-NR), the 2016 ACC/AHA guidelines on dual-antiplatelet therapy
with aspirin and clopidogrel70, also suggest that the addition of clopidogrel to aspirin (75
to 100 mg daily) for 12 postoperative months may improve the patency of SVGs. The
findings of our NMA provide further support for this recommendation.
Furthermore, the beneficial effect of dual-antiplatelet with aspirin and clopidogrel on
SVGF may have important impacts on the healthcare system as it may lead to a decrease
in the rate of SVG-related repeat revascularization, which was found to be ~5.7%
between 2004 and 2009 for SVG-related PCI and 1.3% at 10 year post initial CABG for
re-do CABG, and a reduction in costs associated with these procedures.194 195 However,
further studies are needed to ascertain whether the dual-antiplatelet therapy with aspirin
and clopidogrel will lead to cost-effectiveness.
As important as it may seem, quality of evidence alone is not sufficient in making
recommendations. There are many other aspects that should be considered including
balance between beneficial and harmful effects, values and preferences, and costeffectiveness, as they are also important factors that influence the choice of
antithrombotic agents.185 Due to insufficient information on clinical outcomes, we could
not confirm whether the benefits related to SVGF of the dual-antiplatelet therapy with
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aspirin and clopidogrel outweigh the harms or whether the beneficial effects will translate
into long-term improvements in overall health.
It is important to note that though dual-antiplatelet therapy with aspirin and ticagrelor
was the best-ranked treatment in preventing SVGF, treatment rankings derived from
NMA cannot be interpreted clinically as SUCRA is not intended as a clinical ranking
measure. Moreover, SUCRA does not account for the magnitude and uncertainty of
differences in effect estimates between interventions, the quality of the network evidence,
nor the contribution of each direct estimate to the network estimates. Consequently, it
would be difficult to decide whether being the best is clinically and statistically different
from being the second best as the difference may occur due to chance.196

5.5 Implications for Research
The following are several important evidence gaps, which should be addressed by future
research. First, SVGF is itself presumably a surrogate for more important clinical
outcomes such as acute MI and death, however, there is little research evaluating the
relationship between SVGF and these patient-important outcomes. Surrogate endpoints
are useful in clinical trials to understand the mechanism of action of a drug and often
used because trials can use smaller sample sizes and shorter follow-up periods to generate
sufficiently powered results.197 However, to appropriately use SVGF as a surrogate, the
relationship between SVGF and the hard outcomes needs to be established. As practice
patterns and patient demographics change, it is particularly important to understand its
validity and reliability as a surrogate endpoint for describing the patterns. Second, many
studies did not report data on cardiovascular adverse events as they were not designed to
demonstrate the potential cardiovascular risk with antithrombotic agents. As a result, we
were unable to adequately measure the clinical outcomes due to lack of statistical power
owing to the few studies that reported on clinical outcomes. Therefore, well-designed
studies (e.g., pragmatic RCTs) are needed to evaluate both SVGF and clinical outcomes
to ascertain the balance between potential health benefits and safety. Third, research
should focus on treatment-effect modification as identifying true effect modifiers is of
clinical and research importance; it may help clinicians focus on the specific needs of
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patients across different subgroups and may aid researchers in better evaluating the
validity of NMA findings through transitivity and homogeneity assessment.

5.6 Conclusions
A NMA of RCTs was conducted to simultaneously assess the relative effects of various
oral antithrombotic agents on SVGF and clinical outcomes among patients undergoing
CABG. Based on very low to moderate quality of evidence, no significant differences in
the incidence of major bleeding, mortality, and myocardial infarction post CABG across
antithrombotic comparisons were found, owing to low number of events and small
sample size. Compared to placebo/control, three active medications (aspirin
monotherapy, dual-antiplatelet therapy with aspirin and clopidogrel, and dual-antiplatelet
therapy with aspirin and ticagrelor) significantly reduced SVGF. Importantly, based on
moderate-quality evidence, dual-antiplatelet therapy with aspirin and clopidogrel was the
only intervention that improved the SVG patency compared to aspirin monotherapy. Our
results may, therefore, help clarify whether the current guidelines should be revisited to
more compellingly recommend the use of dual-antiplatelet therapy with aspirin and
clopidogrel in patients undergoing CABG. Certainly, optimal antithrombotic therapy
options should be individualized based on a multidisciplinary evaluation that incorporates
considerations of comorbidity burden, perception of risks, and patient values and
preferences informed by the evidence and its remaining uncertainties.
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Appendix A: eFigures

eFigure 1. Risk of bias assessments for SVGF

91

eFigure 2. The overall risk of bias graph for SVGF

92

eFigure 3. Summary of direct and network estimates for major bleeding (A),
mortality (B), and MI (C)

Estimates are presented as OR and its 95% CI.

93

eFigure 4. Comparison-adjusted funnel plot of placebo-controlled trials for SVGF

Treatment 1: Aspirin, 4: Vitamin K antagonists, 6: Control. The yellow line is the
linear regression of the comparison-specific differences (i.e., the difference between the
individual study-level effect size and the summary effect estimate for each comparison,
x-axis) on the standard error of the summary estimate of each study (y-axis)

94

Appendix B: eTables
eTable 1: Ovid MEDLINE search strategy
#
1
2
3
4
5
6
7
8
9

10

11
12

13
14
15
16
17

18

19

20

21

Searches (November 13, 2016)
exp Coronary Artery Bypass/
((aortocoronary or aorto-coronary or coronary) adj2 (bypass or by-pass or graft* or
saphenous or radial or vein or venous or internal mammar*)).mp.
(CABG or "coronary artery bypass").mp.
1 or 2 or 3
fibrinolytic agents/ or aspirin/ or ticlopidine/
platelet aggregation inhibitors/ or aspirin/ or aspirin, dipyridamole drug combination/
or dipyridamole/ or prasugrel hydrochloride/ or ticlopidine/
anticoagulants/ or acenocoumarol/ or phenprocoumon/ or warfarin/ or antithrombins/
or exp factor xa inhibitors/
(antithrombotic* or anti-thrombotic* or anticoagula* or anti-coagula* or antiplatelet*
or anti-platelet*).mp.
((platelet or thromboxane or adenosine diphosphate receptor or ADP receptor or
thienopyridine or cyclo-oxygenase or cyclooxygenase or cyclic GMP
phosphodiesterase type V enzyme or vitamin K or vitamin-K or direct thrombin or
direct factor Xa) adj1 (antagonist* or inhibitor*)).mp.
(aspirin or acetylsalicylic acid or acylpyrin or aloxiprimuma or colfarit or dispril or
easprin or ecotrin or endosprin or magnecyl or micristin or polopirin or polopiryna or
solprin or solupsan or zorprin).mp.
exp Dipyridamole/
(dipyridamole or persantine or antistenocardin or cerebrovase or cleridium or curantil
or curantyl or dipyramidole or kurantil or miosen or novo-dipiradol or persantin or
persantine).mp.
(clopidogrel or Plavix or clopilet or grepid or iscover or zopya or zylagren or
zylit).mp.
Prasugrel Hydrochloride/ or (prasugrel or effient or efient).mp.
(ticagrelor or brilinta or brilique or possia).mp.
(indobufen or ibustrin).mp.
(warfarin or adoisine or athrombin or befarin or carfin or circuvit or coumadan or
coumadin or coumadine or coumafene or coumaphene or dagonal or farin or jantoven
or aldocumar or kumatox or maforan or marevan or orgarin or panwarfarin or
panwarfin or prothromadin or sofarin or tintorane or uniwarfin or wafarin or waran or
warfarine or warfilone or warnerin or marevan or tedicumar or warfant).mp.
(acenocoumarol or acenocoumarin or acenocoumarine or acenocoumarole or
acenocoumarolum or acenocumarol or acenocumarolo or acenocumerol or
acenokumarin or acitrom or neo sintrom or neosintrom or neositron or nicoumalone or
nicumalon or nitrovarfarin or nitrowarfarin or sincoumar or sincumar or sinkumar or
sinthrom or sinthrome or sintrom or sintroma or sintron or syncoumar or syncumar or
syntrom or synthrom or trombostop or zotil or mini sintrom or mini-sintrom or
minisintrom).mp.
(phenprocoumon or falithrom or falithrome or fenprocoumon or liquamar or
marcoumar or marcumar or phenprocouman or phenprocoumalol or phenprocoumarol
or phenprocoumon or phenprocoumom or phenprocumarol or phenprogramma).mp.
(Ticlopidine or agulan or anagregal or antigreg or aplaket or cartrilet or cenpidine or
clotidone or crodin or declot or desitic or goclid or licodin or nufaclapide or panaldine
or siclot or tacron or ticard or ticdine or ticlid or ticlidil or ticlodine or ticlodix or
ticlodone or ticlomed or ticlon or ticuring or tikleen or tiklid or tiklyd or tikol or
tilodene or tiodin or tipidin or tipidine or tyklid or viladil).mp.
(Rivaroxaban or xarelto).mp.

Results
50665
68443
62608
69629
73496
72898
79011
139797
28064

65552

7772
10587

12243
1814
1480
171
7024

1674

1272

10455

3088

95

22
23
24
25
26
27
28
29
30
31
32
33
34
35

36
37

(Dabigatran or pradax or pradaxa or prazaxa or rendix).mp.
(Apixaban or eliques or eliquis).mp.
5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or
21 or 22 or 23
4 and 24
("randomized controlled trial" or "controlled clinical trial").pt.
(random* or placebo* or single-blind* or double-blind* or triple-blind* or "single
blind*" or "double blind*" or "triple blind*").ti,ab.
clinical trials as topic.sh.
26 or 27 or 28
exp animals/ not humans.sh.
29 not 30
25 and 31
("graft paten*" or "graft occlu*" or "occlu* graft*" or "graft fail*" or "fail* graft*" or
“patency rate*” or paten* or “total occlu*”).mp.
("string sign" or stenosis or Fitzgibbon or "TIMI flow").mp
("cardiac revasculari$ation" or revasculari$ation or "repeat CABG" or "repeat
coronary artery bypass" or "redo CABG" or "redo coronary artery bypass" or "re-do
CABG" or "re-do coronary artery bypass" or PCI or "percutaneous coronary
intervention").mp.
33 or 34 or 35
32 and 36

3543
1903
256464
4778
559642
1051974
189460
353315
4668056
1237283
1211
27036
175704
33226

300192
494

96

eTable 2: Ovid EMBASE search strategy
#
1
2
3
4
5
6
7

8
9

10

11

12
13
14
15
16

17

18

19

20
21
22
23
24

Searches (November 13, 2016)
exp Coronary Artery Bypass/
((aortocoronary or aorto-coronary or coronary) adj2 (bypass or by-pass or graft* or
saphenous or radial or vein or venous or internal mammar*)).mp.
(CABG or "coronary artery bypass").mp.
1 or 2 or 3
antithrombocytic agent/
acetylsalicylic acid plus clopidogrel/
exp prasugrel/ or exp antithrombocytic agent/ or exp ticlopidine/ or exp acetylsalicylic
acid/ or exp dipyridamole/ or exp ticagrelor/ or exp clopidogrel/ or exp anticoagulant
agent/
(antithrombotic* or anti-thrombotic* or anticoagula* or anti-coagula* or antiplatelet*
or anti-platelet*).mp.
((platelet or thromboxane or adenosine diphosphate receptor or ADP receptor or
thienopyridine or cyclo-oxygenase or cyclooxygenase or cyclic GMP
phosphodiesterase type V enzyme or vitamin K or vitamin-K or direct thrombin or
direct factor Xa) adj1 (antagonist* or inhibitor*)).mp.
(aspirin or acetylsalicylic acid or acylpyrin or aloxiprimuma or colfarit or dispril or
easprin or ecotrin or endosprin or magnecyl or micristin or polopirin or polopiryna or
solprin or solupsan or zorprin).mp.
(dipyridamole or persantine or antistenocardin or cerebrovase or cleridium or curantil
or curantyl or dipyramidole or kurantil or miosen or novo-dipiradol or persantin or
persantine).mp.
(clopidogrel or Plavix or clopilet or grepid or iscover or zopya or zylagren or
zylit).mp.
(prasugrel or effient or efient).mp.
(ticagrelor or brilinta or brilique or possia).mp.
(indobufen or ibustrin).mp.
(warfarin or adoisine or athrombin or befarin or carfin or circuvit or coumadan or
coumadin or coumadine or coumafene or coumaphene or dagonal or farin or jantoven
or aldocumar or kumatox or maforan or marevan or orfarin or panwarfarin or
panwarfin or prothromadin or sofarin or tintorane or uniwarfin or wafarin or waran or
warfarine or warfilone or warnerin or marevan or tedicumar or warfant).mp.
(acenocoumarol or acenocoumarin or acenocoumarine or acenocoumarole or
acenocoumarolum or acenocumarol or acenocumarolo or acenocumerol or
acenokumarin or acitrom or neo sintrom or neosintrom or neositron or nicoumalone or
nicumalon or nitrovarfarin or nitrowarfarin or sincoumar or sincumar or sinkumar or
sinthrom or sinthrome or sintrom or sintroma or sintron or syncoumar or syncumar or
syntrom or synthrom or trombostop or zotil or mini sintrom or mini-sintrom or
minisintrom).mp.
(phenprocoumon or falithrom or falithrome or fenprocoumon or liquamar or
marcoumar or marcumar or phenprocouman or phenprocoumalol or phenprocoumarol
or phenprocoumon or phenprocoumom or phenprocumarol or phenprogramma).mp.
(Ticlopidine or agulan or anagregal or antigreg or aplaket or cartrilet or cenpidine or
clotidone or crodin or declot or desitic or goclid or licodin or nufaclapide or panaldine
or siclot or tacron or ticard or ticdine or ticlid or ticlidil or ticlodine or ticlodix or
ticlodone or ticlomed or ticlon or ticuring or tikleen or tiklid or tiklyd or tikol or
tilodene or tiodin or tipidin or tipidine or tyklid or viladil).mp.
(Rivaroxaban or xarelto).mp.
(Dabigatran or pradax or pradaxa or prazaxa or rendix).mp.
(Apixaban or eliques or eliquis).mp.
5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or
21 or 22
4 and 23

Results
66277
92637
90465
98265
36964
406
605804

225540
18919

198403

24832

48978
6079
4772
492
80901

5736

13870

4922

9305
10004
5968
660898
15137

97

25
26
27
28
29
30
31

32
33

("randomized controlled trial" or "controlled clinical trial").pt.
(random* or placebo* or single-blind* or double-blind* or triple-blind* or "single
blind*" or "double blind*" or "triple blind*").ti,ab.
25 or 26
24 and 27
("graft paten*" or "graft occlu*" or "occlu* graft*" or "graft fail*" or "fail* graft*" or
"patency rate*" or paten* or "total occlu*").mp.
("string sign" or stenosis or Fitzgibbon or "TIMI flow").mp.
("cardiac revasculari$ation" or revasculari$ation or "repeat CABG" or "repeat
coronary artery bypass" or "redo CABG" or "redo coronary artery bypass" or "re-do
CABG" or "re-do coronary artery bypass" or PCI or "percutaneous coronary
intervention").mp
29 or 30 or 31
28 and 32

0
1281645
1281645
2402
171788
265679
75778

483433
1114

98

eTable 3: CINAHL search strategy
#
1
2

3
4
5
6
7
8

9
10

11

12
13
14
15
16

17

18

19
20
21
22
23
24

Searches (November 13, 2016)
(MH "Coronary Artery Bypass+")
“coronary artery bypass” or “coronary bypass” or “aortocoronary bypass” or
“aortocoronary saphenous” or “aortocoronary vein” or “saphenous vein graft*” or
CABG
S1 OR S2
(MH "Platelet Aggregation Inhibitors+")
Antiplatelet* or anti-platelet*
(MH "Anticoagulants+")
Anticoagulant* or anti-coagulant*
“platelet antagonist*” or ‘platelet inhibitor*” or “thromboxane antagonist*” or
“thromboxane inhibitor*” or “adenosine diphosphate receptor antagonist*” or
“adenosine diphosphate receptor inhibitor*” or “ADP receptor antagonist*” or “ADP
receptor inhibitor*” or “thienopyridine antagonist*” or “thienopyridine inhibitor*” or
“cyclo-oxygenase antagonist*” or “cyclo-oxygenase inhibitor*” or “cyclooxygenase
antagonist*” or ‘cyclooxygenase inhibitor*” or “cyclic GMP phosphodiesterase type V
enzyme antagonist*” or “cyclic GMP phosphodiesterase type V enzyme inhibitor*” or
“vitamin K antagonist*” or “vitamin K inhibitor*” or “vitamin-K antagonist*” or
“vitamin-K inhibitor*” or “direct thrombin antagonist*” or “direct thrombin
inhibitor*” or “direct factor Xa antagonist*” or “direct factor Xa inhibitor*”
(MH "Aspirin")
aspirin or acetylsalicylic acid or acylpyrin or aloxiprimuma or colfarit or dispril or
easprin or ecotrin or endosprin or magnecyl or micristin or polopirin or polopiryna or
solprin or solupsan or zorprin
dipyridamole or persantine or antistenocardin or cerebrovase or cleridium or curantil
or curantyl or dipyramidole or kurantil or miosen or novo-dipiradol or persantin or
persantine
clopidogrel or Plavix or clopilet or grepid or iscover or zopya or zylagren or zylit
prasugrel or effient or efient
ticagrelor or brilinta or brilique or possia
indobufen or ibustrin
warfarin or adoisine or athrombin or befarin or carfin or circuvit or coumadan or
coumadin or coumadine or coumafene or coumaphene or dagonal or farin or jantoven
or aldocumar or kumatox or maforan or marevan or orfarin or panwarfarin or
panwarfin or prothromadin or sofarin or tintorane or uniwarfin or wafarin or waran or
warfarine or warfilone or warnerin or marevan or tedicumar or warfant
acenocoumarol or acenocoumarin or acenocoumarine or acenocoumarole or
acenocoumarolum or acenocumarol or acenocumarolo or acenocumerol or
acenokumarin or acitrom or neo sintrom or neosintrom or neositron or nicoumalone or
nicumalon or nitrovarfarin or nitrowarfarin or sincoumar or sincumar or sinkumar or
sinthrom or sinthrome or sintrom or sintroma or sintron or syncoumar or syncumar or
syntrom or synthrom or trombostop or zotil or mini sintrom or mini-sintrom or
minisintrom
phenprocoumon or falithrom or falithrome or fenprocoumon or liquamar or
marcoumar or marcumar or phenprocouman or phenprocoumalol or phenprocoumarol
or phenprocoumon or phenprocoumom or phenprocumarol or phenprogramma
Rivaroxaban or xarelto
Dabigatran or pradax or pradaxa or prazaxa or rendix
Apixaban or eliques or eliquis
S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR
S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21
random* or placebo* or "single-blind*" or "double-blind*" or "triple-blind*" or
"single blind*" or "double blind*" or "triple blind*"
("graft paten*" or "graft occlu*" or "occlu* graft*" or "graft fail*" or "fail* graft*" or

Results
7115
8615

8657
10826
2779
14670
11709
779

6415
8489

544

2327
304
265
6
5257

42

29

525
722
292
28599
186004
7088

99

25
26

27
28

"patency rate*" or paten* or "total occlu*").mp.
("string sign" or stenosis or Fitzgibbon or "TIMI flow").mp.
("cardiac revasculari$ation" or revasculari$ation or "repeat CABG" or "repeat
coronary artery bypass" or "redo CABG" or "redo coronary artery bypass" or "re-do
CABG" or "re-do coronary artery bypass" or PCI or "percutaneous coronary
intervention").mp
S24 OR S25 OR S26
S3 AND S22 AND S23 AND S27

12034
4806

22912
42

100

eTable 4: Web of Science search strategy
#
1

2
3
4

5

6

7
8
9
10
11

12

13

14
15
16
17
18
19
20
21
22
23

Searches (November 13, 2016)
“coronary artery bypass” or “coronary bypass” or “aortocoronary bypass” or
“aortocoronary saphenous” or “aortocoronary vein” or “saphenous vein graft*” or
CABG
Antithrombotic* or anti-thrombotic*
Antiplatelet* or anti-platelet* or anticoagula* or anti-coagula*
“platelet antagonist*” or ‘platelet inhibitor*” or “thromboxane antagonist*” or
“thromboxane inhibitor*” or “adenosine diphosphate receptor antagonist*” or
“adenosine diphosphate receptor inhibitor*” or “ADP receptor antagonist*” or “ADP
receptor inhibitor*” or “thienopyridine antagonist*” or “thienopyridine inhibitor*” or
“cyclo-oxygenase antagonist*” or “cyclo-oxygenase inhibitor*” or “cyclooxygenase
antagonist*” or ‘cyclooxygenase inhibitor*” or “cyclic GMP phosphodiesterase type V
enzyme antagonist*” or “cyclic GMP phosphodiesterase type V enzyme inhibitor*” or
“vitamin K antagonist*” or “vitamin K inhibitor*” or “vitamin-K antagonist*” or
“vitamin-K inhibitor*” or “direct thrombin antagonist*” or “direct thrombin
inhibitor*” or “direct factor Xa antagonist*” or “direct factor Xa inhibitor*”
aspirin or acetylsalicylic acid or acylpyrin or aloxiprimuma or colfarit or dispril or
easprin or ecotrin or endosprin or magnecyl or micristin or polopirin or polopiryna or
solprin or solupsan or zorprin
dipyridamole or persantine or antistenocardin or cerebrovase or cleridium or curantil
or curantyl or dipyramidole or kurantil or miosen or novo-dipiradol or persantin or
persantine
clopidogrel or Plavix or clopilet or grepid or iscover or zopya or zylagren or zylit
prasugrel or effient or efient
ticagrelor or brilinta or brilique or possia
indobufen or ibustrin
warfarin or adoisine or athrombin or befarin or carfin or circuvit or coumadan or
coumadin or coumadine or coumafene or coumaphene or dagonal or farin or jantoven
or aldocumar or kumatox or maforan or marevan or orfarin or panwarfarin or
panwarfin or prothromadin or sofarin or tintorane or uniwarfin or wafarin or waran or
warfarine or warfilone or warnerin or marevan or tedicumar or warfant
acenocoumarol or acenocoumarin or acenocoumarine or acenocoumarole or
acenocoumarolum or acenocumarol or acenocumarolo or acenocumerol or
acenokumarin or acitrom or neo sintrom or neosintrom or neositron or nicoumalone or
nicumalon or nitrovarfarin or nitrowarfarin or sincoumar or sincumar or sinkumar or
sinthrom or sinthrome or sintrom or sintroma or sintron or syncoumar or syncumar or
syntrom or synthrom or trombostop or zotil or mini sintrom or mini-sintrom or
minisintrom
phenprocoumon or falithrom or falithrome or fenprocoumon or liquamar or
marcoumar or marcumar or phenprocouman or phenprocoumalol or phenprocoumarol
or phenprocoumon or phenprocoumom or phenprocumarol or phenprogramma
Rivaroxaban or xarelto
Dabigatran or pradax or pradaxa or prazaxa or rendix
Apixaban or eliques or eliquis
#2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
OR #14 OR #15 OR #16
#1 AND #17
controlled trial* OR clinical trial* OR comparative stud* OR OR prospective stud*
OR random* OR placebo* OR (single blind*) OR (double blind*)
#18 AND #19
"graft paten*" or "graft occlu*" or "occlu* graft*" or "graft fail*" or "fail* graft*" or
"patency rate*" or paten* or "total occlu*"
"string sign" or stenosis or Fitzgibbon or "TIMI flow"
"cardiac revasculari$ation" or revasculari$ation or "repeat CABG" or "repeat coronary

Results
45358

17850
96184
6260

56834

8316

14390
2177
1538
194
25997

1047

957

3512
4340
1887
174560
2835
2430123
1214
105834
127165
85164

101

24
25

artery bypass" or "redo CABG" or "redo coronary artery bypass" or "re-do CABG" or
"re-do coronary artery bypass" or PCI or "percutaneous coronary intervention"
#21 OR #22 OR #23
#21 AND #20

295412
705

102

eTable 5: Cochrane Library search strategy
#
1
2

3
4
5
6
7
8
9

10

11
12
13
14
15

16

17

18
19
20
21
22
23

24
25
26
27

Searches (October 31, 2016)
MeSH descriptor: [Coronary Artery Bypass] explode all trees
“coronary artery bypass” or “coronary bypass” or “aortocoronary bypass” or
“aortocoronary saphenous” or “aortocoronary vein” or “saphenous vein graft*” or
CABG:ti,ab,kw
#1 OR #2
MeSH descriptor: [Anticoagulants] explode all trees
MeSH descriptor: [Platelet Aggregation Inhibitors]
Anticoagula* or anti-coagula*:ti,ab,kw
Antiplatelet* or anti-platelet*:ti,ab,kw
MeSH descriptor: [Aspirin]
aspirin or acetylsalicylic acid or acylpyrin or aloxiprimuma or colfarit or dispril or
easprin or ecotrin or endosprin or magnecyl or micristin or polopirin or polopiryna or
solprin or solupsan or zorprin:ti,ab,kw
dipyridamole or persantine or antistenocardin or cerebrovase or cleridium or curantil
or curantyl or dipyramidole or kurantil or miosen or novo-dipiradol or persantin or
persantine:ti,ab,kw
clopidogrel or Plavix or clopilet or grepid or iscover or zopya or zylagren or
zylit:ti,ab,kw
prasugrel or effient or efient:ti,ab,kw
ticagrelor or brilinta or brilique or possia:ti,ab,kw
indobufen or ibustrin:ti,ab,kw
warfarin or adoisine or athrombin or befarin or carfin or circuvit or coumadan or
coumadin or coumadine or coumafene or coumaphene or dagonal or farin or jantoven
or aldocumar or kumatox or maforan or marevan or orfarin or panwarfarin or
panwarfin or prothromadin or sofarin or tintorane or uniwarfin or wafarin or waran or
warfarine or warfilone or warnerin or marevan or tedicumar or warfant:ti,ab,kw
acenocoumarol or acenocoumarin or acenocoumarine or acenocoumarole or
acenocoumarolum or acenocumarol or acenocumarolo or acenocumerol or
acenokumarin or acitrom or neo sintrom or neosintrom or neositron or nicoumalone or
nicumalon or nitrovarfarin or nitrowarfarin or sincoumar or sincumar or sinkumar or
sinthrom or sinthrome or sintrom or sintroma or sintron or syncoumar or syncumar or
syntrom or synthrom or trombostop or zotil or mini sintrom or mini-sintrom or
minisintrom:ti,ab,kw
phenprocoumon or falithrom or falithrome or fenprocoumon or liquamar or
marcoumar or marcumar or phenprocouman or phenprocoumalol or phenprocoumarol
or phenprocoumon or phenprocoumom or phenprocumarol or
phenprogramma:ti,ab,kw
Rivaroxaban or xarelto:ti,ab,kw
Dabigatran or pradax or pradaxa or prazaxa or rendix:ti,ab,kw
Apixaban or eliques or eliquis:ti,ab,kw
#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR
#15 OR #16 OR #17 OR #18 OR #19 OR #20
#3 AND #21
"controlled trial*" or "clinical trial*" or "comparative stud*" or "prospective stud*" or
random* or placebo* or "single blind*" or "double blind*" or “triple blind*” or
"single-blind*" or "double-blind*" or "triple-blind*":ti,ab,kw
#23 AND #22
"graft paten*" or "graft occlu*" or "occlu* graft*" or "graft fail*" or "fail* graft*" or
"patency rate" or paten* or "total occlu*":ti,ab,kw
"string sign" or stenosis or Fitzgibbon or "TIMI flow":ti,ab,kw
"cardiac revasculari$ation" or revasculari$ation or "repeat CABG" or "repeat coronary
artery bypass" or "redo CABG" or "redo coronary artery bypass" or "re-do CABG" or
"re-do coronary artery bypass" or PCI or "percutaneous coronary

Results
5397
9174

9194
4532
3505
9419
3542
4816
11585

1179

3135
480
417
85
3116

224

189

547
430
316
24362
1088
704157

952
5963
7223
6052

103

28
29

intervention":ti,ab,kw
#27 or #28 or #29
#24 AND #30

17746
432
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eTable 6: Grey literature search strategy
Sources (August 29, 2016)
ClinicalTrials.gov
International Clinical Trials Registry Platform (ICTRP): Australian (ANZCTR), India (CTRI), UK
(EU-CTR), Chinese (ChiCTR), Dutch (NTR), German (DRKS), Japanese (UMIN CTR), Korean (CRiS),
Persian (IRCT), Portuguese (ReBec), Spanish (PRCEC), Pan African (PACTR), Sri Lanka (SLCTR),
Thai (TCTR)
Other clinical trial registries: AstraZeneca, Bayer, Bristol-Myers Squibb
USA Food and Drug Administration (FDA)
Electronic Theses Online Service
Gray Matters (https://www.cadth.ca/resources/finding-evidence/grey-matters)

Key terms used for grey literature:
CABG: coronary artery bypass, coronary bypass, CABG
Antithrombotic agents: antithrombotic, antiplatelet, anticoagulation, aspirin, acetylsalicylic
acid, clopidogrel, Plavix, prasugrel, effient, ticagrelor, brilinta, indobufen, Ibustrin, dipyridamole,
persantine, warfarin, Coumadin, jantoven, acenocoumarol, sinthrome, phenprocoumon,
marcumar, ticlopidine, Ticlid, rivaroxaban, Xarelto, apixaban, eliquis, dabigatran, pradaxa.
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eTable 7: List of selected excluded studies (after full-text retrieval)
No.

Reference

1

ClinicalTrias.gov: NCT02201771; Compare the Efficacy of Different
Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft
Surgery (DACAB-1)
ClinicalTrials.gov: NCT01560780; Prasugrel for Prevention of Early
Saphenous Vein Graft Thrombosis –
ClinicalTrials.gov: NCT01598337; The Effect of Antiplatelets Therapy
on Saphenous Vein Coronary Artery Bypass Graft Patency
ClinicalTrials.gov: NCT00330772; Preoperative Aspirin and
Postoperative Antiplatelets in Coronary Artery Bypass Grafting: The
PAPA CABG Study (PAPA CABG)
ClinicalTrials.gov: NCT01268917; The Effect of Preoperative Aspirin
on Graft Patency and Cardiac Events in Off-pump Coronary Artery
Bypass
ClinicalTrials.gov: NCT02352402; The Effect of Ticagrelor on
Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery
Bypass Grafting Surgery (POPular CABG)
de Waha A, Sandner S, von Scheidt M.... A randomized, parallel group,
double-blind study of ticagrelor compared with aspirin for prevention of
vascular events in patients undergoing coronary artery bypass graft
operation: Rationale and design of the Ticagrelor in CABG (TiCAB)
trial: An Investigator-Initiated trial. Am Heart J. 2016 Sep;179:69-76.
Rafiq S, Johansson PI, Kofoed KF, Lund JT, Olsen PS, Bentsen S,
Steinbrüchel DA. Thrombelastographic hypercoagulability and
antiplatelet therapy after coronary artery bypass surgery (TEG-CABG
trial): a randomized controlled trial. Platelets. 2017 Feb 22:1-8

2
3
4

5

6

7

8

9

Kolluri R, Plessa AL, Sanders MC, Singh NK, Lucore C. A randomized
study of the safety and efficacy of fondaparinux versus placebo in the
prevention of venous thromboembolism after coronary artery bypass
graft surgery. Am Heart J. 2016 Jan;171(1):1-6.

10

El Messaoudi S, Wouters CW, van Swieten HA, …. Effect of
dipyridamole on myocardial reperfusion injury: A double-blind
randomized controlled trial in patients undergoing elective coronary
artery bypass surgery. Clin Pharmacol Ther. 2016 Apr;99(4):381-9

11

Paikin JS, Hirsh J, Ginsberg JS, Weitz JI, Chan NC, Whitlock RP, Pare
G, Johnston M, Eikelboom JW. Multiple daily doses of acetyl-salicylic
acid (ASA) overcome reduced platelet response to once-daily ASA after
coronary artery bypass graft surgery: a pilot randomized controlled trial.

12

Thopte OS, Patil SP, Deshmukh RS. A study of aspirin plus clopidogrel
versus aspirin alone on saphenous vein graft patency after coronary
artery bypass graft surgery-an angiographic follow-up after three
months. Indian Heart Journal. 2014;66:S22.
Ebrahimi R, Bakaeen FG, Uberoi A... Effect of clopidogrel use post
coronary artery bypass surgery on graft patency. Ann Thorac Surg.

13

Reason for
Exclusion
Ongoing Trial

Ongoing Trial
Ongoing Trial
Ongoing Trial

Ongoing Trial

Ongoing Trial

Ongoing Trial

Highly selected
group of patients
(patients with
hypercoagulable
states)
Wrong
intervention
(heparin and
fondapariux) and
wrong outcome
Wrong
intervention
(dipyridamole)
and Wrong
outcome
Wrong outcome
(did not assess
VGF; did not
report repeat
revascularization)
and only assess
aspirin
Results are not
reported
(published)
Wrong study
design (subgroup
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14

15

16

17

18

19

20

21

22

23

2014 Jan;97(1):15-21

analysis of RCT)

Gasparovic H, Petricevic M, Kopjar T, Djuric Z, Svetina L, Biocina B.
Impact of dual-antiplatelet therapy on outcomes among aspirin-resistant
patients following coronary artery bypass grafting. Am J Cardiol. 2014
May 15;113(10):1660-7
Wang X, Gong X, Zhu T, Zhang Q, Zhang Y, Wang X, Yang Z, Li C.
Clopidogrel improves aspirin response after off-pump coronary artery
bypass surgery. J Biomed Res. 2014 Mar;28(2):108-13
Duplication: Wang XZ, Gong XX, Zhu TT, Li CJ, Yang ZJ. [Effect of
aspirin plus clopidogrel therapy on aspirin resistance after off-pump
coronary artery bypass surgery]. Zhongguo Yi Xue Ke Xue Yuan Xue
Bao. 2013 Oct;35(5):495-502.
Suwalski G, Smoczycski R, Banach M, Gryszko L, Szaaacski P,
Krawczyk K, Hendzel P. Aspirin versus clopidogrel after off-pump
coronary artery bypass grafting: Prospective, randomized head-to-head
trial. In: 15th Annual Meeting of the International Society for
Minimally Invasive Cardiothoracic Surgery. vol. 7. Los Angeles; 2012:
138.
Deja MA, Kargul T, Domaradzki W, Stącel T, Mazur W, Wojakowski
W, Gocoł R, Gaszewska-Żurek E, Żurek P, Pytel A, Woś S. Effects of
preoperative aspirin in coronary artery bypass grafting: a double-blind,
placebo-controlled, randomized trial. J Thorac Cardiovasc Surg. 2012
Jul;144(1):204-9.

Wrong outcome
(did not assess
VGF nor repeat
revascularization)
Wrong outcome
(did not assess
VGF; did not
report repeat
revascularization)

Veeger NJ, Zijlstra F, Hillege HL, van der Meer J, CABADAS
Research Group of the Interuniversity Cardiology Institute of The
Netherlands. Fourteen-year follow-up from CABADAS: vitamin K
antagonists or dipyridamole not superior to aspirin. The Annals of
thoracic surgery. 2010 Nov 30;90(5):1515-21.
Tetik S, Ak K, Isbir S, Eksioglu-Demiralp E, Arsan S, Iqbal O,
Yardimci T. Clopidogrel provides significantly greater inhibition of
platelet activity than aspirin when combined with atorvastatin after
coronary artery bypass grafting: a prospective randomized study.
Clinical and Applied Thrombosis/Hemostasis. 2010 Apr;16(2):189-98.
Kayacioglu I, Gunay R, Saskin H…The role of clopidogrel and
acetylsalicylic acid in the prevention of early-phase graft occlusion due
to reactive thrombocytosis after coronary artery bypass operation. Heart
Surg Forum. 2008;11:E152–157.

Nielsen AB, Bochsen L, Steinbruchel DA. Hypercoagulability and
platelet inhibition after OPCAB. Randomized intervention with
clopidogrel. Scand Cardiovasc J. 2007;41:325–30.
Morawski W, Sanak M, Cisowski M, Szczeklik M, Szczeklik W,
Dropinski J, Waclawczyk T, Ulczok R, Bochenek A. Prediction of the
excessive perioperative bleeding in patients undergoing coronary artery
bypass grafting: role of aspirin and platelet glycoprotein IIIa
polymorphism. J Thorac Cardiovasc Surg. 2005 Sep;130(3):791-6
Lim E, Cornelissen J, Routledge T, Kirtland S, Charman SC, Bellm S,
Munday H, Khan O, Masood I, Large S. Clopidogrel did not inhibit
platelet function early after coronary bypass surgery: A prospective
randomized trial. J Thorac Cardiovasc Surg. 2004 Sep;128(3):432-5

Results are not
reported
(published)

Wrong outcome
(did not assess
VGF; did not
report repeat
revascularization
as an independent
endpoint)
Wrong outcome
(unclear definition
of repeat
revascularization)
Wrong outcome

Did not measured
graft patency in
all participants,
but only in those
who have positive
exercise tests
Wrong outcome

Wrong outcome

Wrong outcome
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24

25

26

27

28

29

30

31

32

Duplication: Lim E, Cornelissen J, Routledge T… Biological efficacy
of low versus medium dose aspirin after coronary surgery: results from
a randomized trial [NCT00262275]. BMC medicine. 2006 May
22;4(1):12.
Shennib H, Endo M, Benhameid O. A feasibility study of the safety and
efficacy of a combined clopidogrel and aspirin regimen following offpump coronary artery bypass grafting. Heart Surg Forum.
2003;6(5):288-91.
David JL, Limet R. Antiplatelet activity of clopidogrel in coronary
artery bypass graft surgery patients. Thromb Haemost. 1999
Nov;82(5):1417-21.
Hashimoto K, Onoguchi K, Sasaki T… Strategy for balancing
anticoagulation and hemostasis in aortocoronary bypass surgery: blood
conservation and graft patency. Jpn Circ J. 1999 Mar;63(3):165-9.
Post Coronary Artery Bypass Graft Trial Investigators. The effect of
aggressive lowering of low-density lipoprotein cholesterol levels and
low-dose anticoagulation on obstructive changes in saphenous-vein
coronary-artery bypass grafts. N Engl J Med. 1997 Jan 16;336(3):15362.
van der Meer J, Brutel de la Rivière A, van Gilst WH... Effects of low
dose aspirin (50 mg/day), low dose aspirin plus dipyridamole, and oral
anticoagulant agents after internal mammary artery bypass grafting:
patency and clinical outcome at 1 year. CABADAS Research Group of
the Interuniversity Cardiology Institute of The Netherlands. Prevention
of Coronary Artery Bypass Graft Occlusion by Aspirin, Dipyridamole
and Acenocoumarol/Phenprocoumon Study. J Am Coll Cardiol. 1994
Nov 1;24(5):1181-8.
Mulder BJ, Van der Doef RM, Van der Wall EE... Effect of various
antithrombotic regimens (aspirin, aspirin plus dipyridamole,
anticoagulants) on the functional status of patients and grafts one year
after coronary artery bypass grafting. European heart journal. 1994 Aug
1;15(8):1129-34.
Goldman S, Copeland J, Moritz T…Long-term graft patency (3 years)
after coronary artery surgery. Effects of aspirin: results of a VA
Cooperative study. Circulation. 1994 Mar 1;89(3):1138-43.
Rajah SM, Nair U, Rees M…Effects of antiplatelet therapy with
indobufen or aspirin-dipyridamole on graft patency one year after
coronary artery bypass grafting. The Journal of Thoracic and
Cardiovascular Surgery. 1994 Apr 1;107(4):1146-53.
Rohn V, Pirk J, Mach T. The effect of indobufen on aortocoronary
bypass patency after 1 week and after 1 year. Cor et vasa. 1992
Dec;35(4):162-4.

33

Yamaguchi A, Kitamura N, Miki T, Tatebayashi T, Kawashima M,
Otaki M, Tamura H. [Comparative study of anticoagulant management
after coronary artery bypass surgery--warfarin versus dipyridamole].
Nihon Kyobu Geka Gakkai Zasshi. 1992 Apr;40(4):485-9.

34

Agnew TM, French JK, Neutze JM, Whitlock RM, Brandt PW, Kerr
AR, Webber BJ, Rutherford JD. The role of dipyridamole in addition to
low dose aspirin in the prevention of occlusion of coronary artery

Wrong study
design

Wrong outcome &
Wrong
intervention
Wrong
intervention
Wrong patient
population (
randomization
occurred 1-11
years post-CABG)
Wrong outcome
(IMA patency)
and Wrong study
design (Subgroup
analysis of
CABADAS trial)

Wrong study
design (subgroup
analysis of
CABADAS trial)
Double counting

Wrong
intervention
(indobufen and
dipyridamole)
Wrong
intervention
(indobufen and
dipyridamole) and
Study not in
English
Wrong
intervention
(dipyridamole)
and Study not in
English
Wrong
intervention
(dipyridamole)
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bypass grafts. Aust N Z J Med. 1992 Dec;22(6):665-70.
35

36

37

38

39

40

41

42

Yli-Māyry S, Huikuri Hv, Korhonen Ur, Airaksinen K, Ikāheimo M,
Linnaluoto MK, Takkunen JT. Efficacy And Safety Of Anticoagulant
Therapy Started Pre-Operatively In Preventing Coronary Vein Graft
Occlusion. European Heart Journal. 1992 Sep 1;13(9):1259-64.
Rovelli F, Cataldo G, Pellegrini A, Mannucci P, Marubini E, Degaetano
G, Orzan F, Lavezzari M, Petroccione A, Pirotta N, Bertele V.
Indobufen Versus Aspirin Plus Dipyridamole After Coronary-Artery
Bypass-Surgery. Coronary Artery Disease. 1991;2(8):897-906.
Ollivier JP. [Permeability of aortocoronary bypass after 6 months. A
multicenter French study]. Arch Mal Coeur Vaiss. 1991 Apr;84(4):53742.

Ekeström SA, Gunnes S, Brodin UB. Effect of Dipyridamole
(Persantin®) on Blood Flow and Patency of Aortocoronary Vein
Bypass Grafts. Scandinavian journal of thoracic and cardiovascular
surgery. 1990 Jan 1;24(3):191-6.
Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T,
Kern KB, Sethi G, Sharma GV, Khuri S, et al. Internal mammary artery
and saphenous vein graft patency. Effects of aspirin. Circulation. 1990
Nov;82(5 Suppl):IV237-42.
Pfisterer M, Burkart F, Jockers G, Meyer B, Regenass S, Burckhardt D,
Schmitt HE, Müller-Brand J, Skarvan K, Stulz P, Hasse J. Prevention of
aortocoronary vein bypass graft occlusion: Which antithrombotic
treatment and for how long?. Thrombosis Research. 1990 Jan 1;57:1121.
First Duplication: Pfisterer M, Jockers G, Regenass S, … [How long
should antithrombotic therapy be continued following aortocoronary
bypass surgery?]. Schweiz Med Wochenschr. 1989 Oct
28;119(43):1518-20.
Second Duplication: Pfisterer 1989. Duration of thrombolytic treatment
after coronary artery bypass surgery. Schweiz Med Wochenschr
Third Duplication: Pfisterer M, Jockers G, Meier B, … [Anticoagulants
vs. low-dose aggregation inhibitors in the prevention of perioperative
occlusion of aortocoronary bypass grafts. Preliminary results of a
prospective randomized study]. Helv Chir Acta. 1987 Feb;53(4):497500.
Fourth Duplication: Pfisterer M, Burkart F, Jockers G, … Trial of lowdose aspirin plus dipyridamole versus anticoagulants for prevention of
aortocoronary vein graft occlusion. Lancet. 1989 Jul 1;2(8653):1-7.
Sanz G, Pajaron A, Alegría E, Coello I, Cardona M, Fournier JA,
Gómez-Recio M, Ruano J, Hidalgo R, Medina A. Prevention of early
aortocoronary bypass occlusion by low-dose aspirin and dipyridamole.
Grupo Espanol para el Seguimiento del Injerto Coronario (GESIC).
Circulation. 1990 Sep 1;82(3):765-73.
Duplication: Sanz G. Does low-dose aspirin prevent aortocoronary vein
bypass graft occlusion?. Thrombosis research. 1990 Jan 1;57:23-6.
Sethi GK, Copeland JG, Goldman S, Moritz T, Zadina K, Henderson
WG. Implications of preoperative administration of aspirin in patients
undergoing coronary artery bypass grafting. Journal of the American
College of Cardiology. 1990 Jan 1;15(1):15-20.

Wrong
intervention
(dipyridamole)
Wrong
intervention
(indobufen and
dipyridamole)
Wrong
intervention
(dipyridamole)
and Study not in
English
Wrong
intervention
(dipyridamole)
Wrong outcome
(IMA patency)
and Wrong study
design (subgroup
analysis of RCT)
Wrong
intervention
(OAC 12 mth vs
OAC 3 mth)

Wrong patient
population (in all
patients,
dipyridamole was
used before study
medications were
administered)
Wrong study
design (subgroup
analysis of
Goldman 1988’s
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43

44

45

46

47

48

49

50

51

52

53

54

55

Weber MA, Hasford J, Taillens C, ... Low-dose aspirin versus
anticoagulants for prevention of coronary graft occlusion. Am J Cardiol.
1990 Dec 15;66(20):1464-8
Duplication: Weber Meister. Br. J clin. Pharmac. 1984, 17, 703-11
Pirk J, Rohn V, Peregrin J. The effect of ibustrin on early aortocoronary
bypass patency. Cor Vasa. 1990;32(3):258-62.
Guiteras P, Altimiras J, Arís A, Augé JM, Bassons T, Bonal J, Caralps
JM, Castellarnau C, Crexells C, Masotti M, et al. Prevention of
aortocoronary vein-graft attrition with low-dose aspirin and triflusal,
both associated with dipyridamole: a randomized, double-blind,
placebo-controlled trial. Eur Heart J. 1989 Feb;10(2):159-67.
Gershlick AH, Lyons JP, Wright JE, …Long term clinical outcome of
coronary surgery and assessment of the benefit obtained with
postoperative aspirin and dipyridamole. Br Heart J. 1988
Aug;60(2):111-6.
Thaulow E, Frøysaker T, Dale J, Vatne K. Failure of combined
acetylsalicylic acid and dipyridamole to prevent occlusion of
aortocoronary venous bypass graft. Scand J Thorac Cardiovasc Surg.
1987;21(3):215-20.
Limet R, David JL, Magotteaux P, Larock MP, Rigo P. Prevention of
aorta-coronary bypass graft occlusion. Beneficial effect of ticlopidine
on early and late patency rates of venous coronary bypass grafts: a
double-blind study. J Thorac Cardiovasc Surg. 1987 Nov;94(5):773-83
Pirk J, Vojácek J, Kovác J. Improvement of aortocoronary bypass
patency by antiplatelet drug administration. Preliminary
communication. Cor Vasa. 1986;28(3):177-80.
Duplication: Pirk J, Vojácek J, Kovác J, .... Improved patency of the
aortocoronary bypass by antithrombotic drugs. Ann Thorac Surg. 1986
Sep;42(3):312-4.
Brooks N, Wright J, Sturridge M, Pepper J, Magee P, Walesby R,
Layton C, Honey M, Balcon R. Randomised placebo controlled trial of
aspirin and dipyridamole in the prevention of coronary vein graft
occlusion. Br Heart J. 1985 Feb;53(2):201-7.
Rothlin ME, Pfluger N, Speiser K, .... Platelet inhibitors versus
anticoagulants for prevention of aorto-coronary bypass graft occlusion.
Eur Heart J. 1985 Feb;6(2):168-75.
Rajah SM, Salter MC, Donaldson DR, … Acetylsalicylic acid and
dipyridamole improve the early patency of aorta-coronary bypass grafts.
A double-blind, placebo-controlled, randomized trial. J Thorac
Cardiovasc Surg. 1985 Sep;90(3):373-7.
Chesebro JH, Fuster V, Elveback LR, Clements IP, Smith HC, Holmes
DR Jr, Bardsley WT, Pluth JR, Wallace RB, Puga FJ, et al. Effect of
dipyridamole and aspirin on late vein-graft patency after coronary
bypass operations. N Engl J Med. 1984 Jan 26;310(4):209-14.
Chevigné M, David JL, Rigo P, Limet R. Effect of ticlopidine on
saphenous vein bypass patency rates: a double-blind study. Ann Thorac
Surg. 1984 May;37(5):371-8.
Chesebro JH, Clements IP, Fuster V…A platelet-inhibitor-drug trial in
coronary-artery bypass operations: benefit of perioperative

RCT), Wrong
intervention and
Wrong outcome
Wrong
intervention
(heparin)
Wrong
intervention
(dipyridamole)
Wrong
intervention
(dipyridamole)

Wrong
intervention
(dipyridamole)
Wrong
intervention
(dipyridamole)
Wrong
intervention
(Ticlopidine)
Wrong
intervention
(dipyridamole)

Wrong
intervention
(dipyridamole)
Wrong
intervention
(ticlopidine)
Wrong
intervention
(dipyridamole)
Wrong
intervention
(dipyridamole)
Wrong
intervention
(ticlopidine)
Wrong
intervention
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56

57
58

59

60

dipyridamole and aspirin therapy on early postoperative vein-graft
patency. N Engl J Med. 1982 Jul 8;307(2):73-8.
Mayer JE Jr, Lindsay WG, Castaneda W, Nicoloff DM. Influence of
aspirin and dipyridamole on patency of coronary artery bypass grafts.
Ann Thorac Surg. 1981 Mar;31(3):204-10.
Dale J. Prevention of closure of aorto-coronary venous bypass grafts.
Scand J Haematol Suppl. 1981;38:131-41.
Gohlke H, Gohlke-Bärwolf C, Stürzenhofecker P…Improved graft
patency with anticoagulant therapy after aortocoronary bypass surgery:
a prospective, randomized study. Circulation. 1981 Aug;64(2 Pt 2):II227
Duplication: Gohlke H, Gohlke-Bärwolf C, Stürzenhofecker P,
Görnandt L, Ritter B, Reichelt M, Buchwalsky R, Schmuziger M,
Roskamm H. [Improved flow through aortocoronary venous bypasses
after anticoagulant therapy. A prospective randomized study]. Schweiz
Med Wochenschr. 1981 Nov 7;111(45):1722-4.
Gohlke H, Gohlke C, Sturzenhofecker P…Influence Of Marcumar On
Flow Through Aortocoronary Bypass-Prospective, Randomized Study.
Inzeitschrift Fur Kardiologie 1979 Jan 1 (Vol. 68, No. 9, Pp. 651-651).
C/O Springer-Verlag, Heidelberger Platz 3, 1000 Berlin 33, Germany:
Dr Dietrich Steinkopff Verlag.
Thaneeru P.; Gamel A.E.; Harding S.; Galvin S.; Hamilton F.; Kirk M.;
Devlin G. IMPACT: Improving Coronary Graft Patency with
Postoperative Aspirin and Clopidogrel Versus Aspirin and Ticagrelor.
2017. (conference abstract)

(dipyridamole)
Wrong
intervention
(dipyridamole)
Protocol (No
results)
Wrong patient
population (in all
patients,
dipyridamole was
administered)

Study not in
English

Abstract (cannot
extract relevant
information)
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eTable 8. Characteristics of included studies in the systematic review and network meta-analysis
Patency assessment method
(unit of analysis)

Time from
random to
patency
assessment
6 mth

Location

Overall
sample
size

No. of
eligible
arms

Antithrombotic status prior
random; antifibrinolytic use;
heparin use

Pantely,
1979

US

47

2

NR; NR; NR

Angiography (per
patient+per graft)

McEnany,
1982

US

216

3

NR; NR; NR

Angiography (per
patient+per graft)

21.5 mth (range:
1 to 47 mth)

48.6%

Sharma,
1983
Lorenz,
1984

US

116

2

NR; NR; NR

12 mth

DE

60

2

NR; NR; Yes during operation

Brown,
1985
Goldman,
1988
Goldman,
1989*
Goldman,
1991
Gavaghan
1991

US

98

2

NR; NR; NR

US

307

2

US

307

2

US

489

2

AU

237

2

Van der
Meer, 1993

NL, DE,
CH

635

2

Stopped ASA ≥7 d pre-study
entry; NR; NR
Stopped ASA ≥7 d pre-study
entry; NR; NR
Stopped ASA ≥5 d pre-CABG;
NR; NR
Stopped ASA or other
antiplatelet agents ≥7 d preCABG; NR; Yes during
operation
Stopped antiplatelet ≥14 d preCABG or OAC ≥5 d preCABG; NR; Yes during

Angiography (per
patient+per graft)
Cineangiography
(per patient+per
graft)
Angiography (per
patient+per graft)
Angiography (per
patient+per graft)
Angiography (per
patient+per graft)
Angiography (per
patient+per graft)
Angiography (per
patient+per graft)

Angiography (per
patient+per graft)

Study,
Year

Overall loss
of patency
follow-up

CABG
type;
setting

21.3%

19.0%

CCAB;
Elective +
Urgent
NR;
Elective +
Urgent
CCAB; NR

4 mth

23.3%

CCAB; NR

12 mth

16.3%

9 d (range: 6 to
60 d)
367 d (range: 62
to 527 d)
8 d (range: 4 to
58 d)
363 d (range: 222
to 430 d)

20.7%

CCAB;
Elective
NR;
Elective
NR;
Elective
CCAB;
Elective
CCAB; NR

371 d

15.9%

33.5%
28.2%
7.6%

CCAB;
Elective

112

operation
Hockings,
1993

AU

140

2

Stopped aspirin or platelet
active drug ≥7 d pre-CABG;
NR; NR
All patients were on aspirin
pre-CABG; NR; Yes during
operation
Stopped antiplatelet ≥5-7 d
pre-CABG; NR

Angiography (per
patient)

6 mth

27.1%

NR;
Elective

Mujanovic,
2009

NO

20

2

Angiography (per
graft)

3 mth

0%

OPCAB;
Elective

Gao, 2009

CN

197

2

64-Multislice CT
Angiography (per
graft)

12 mth

0%

2

Aspirin was not withheld preCABG; NR; NR

Angiography (per
patient + per graft)

12 mth

18.6%

113

2

Aspirin was not withheld preCABG; NR; NR

CT Angiography
(per graft)

8y

41.6%

CN

249

2

Stopped clopidogrel or aspirin
≥7 d pre-CABG; NR; NR

3 mth

10.0%

Sun, 2010

CA

99

2

NR; Y; NR

50 d

22.0%

Mannacio,
2012

IT

300

2

12 mth

4%

OPCAB;
Elective

Saw, 2016

CA

70

2

Stopped antiplatelet ≥15 d preCABG; Yes during peri-op, but
not during first 15 d post-op;
Yes during peri-op but not
during first 15 d post-op
All patients were on aspirin
pre-CABG; NR; NR

Multislice CT
Angiography (per
graft)
Cardiac CT
angiography (per
patient)
64-slice
multidetector CT
angiography (per
graft)

CCAB +
OPCAB;
Elective +
Urgent
CCAB +
OPCAB;
Elective
CCAB +
OPCAB;
Elective
CCAB +
OPCAB;
Elective
CCAB;
Elective

Kulik, 2010

CA

113

Hage,
2017*

CA

Gao, 2010

320-detector or
128-slice dual
source CT scanner
(per graft)

12 mth

24.3%

NR;
Elective +
Urgent

113

Slim, 2016

NR

20

2

NR; NR; NR

128-slice dualsource scanner
(per graft)

12 mth

0%

CCAB +
OPCAB;
Elective

*Long-term follow-up of the originally published study. ASA: aspirin. CA: Canada. CH: Switzerland. CCAB: On-pump CABG. CN:
China. CT: computed tomography. d: day(s). DE: Germany. DK: Denmark. IT: Italy. mth: month(s). NL: Netherlands. NO: Norway.
NR: Not reported. OAC: oral anticoagulation. OD: once daily. OPCAB: Off-pump CABG. Random: randomization. Vit K A: Vitamin
K Antagonists. y: year.
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eTable 9. Demographic and clinical characteristics of patients enrolled in the included studies
Study, Year

Pantely, 1979

McEnany, 1982

Sharma, 1983

Lorenz, 1984

Brown, 1985

Goldman, 1988

Goldman, 1989*

Time of drug
initiation
post-CABG

+3 d

+3 to 4 d

+3 to 5 d

+24 h

+67 ± 27 h

-12 h

-12 h

Treatment
duration

6 mth

12 mth

Relevant study arms

Age (y)

Male
(%)

DM
(%)

HTN
(%)

Prior
MI
(%)

No. of any
graft/vein
per patient

Vit K A: warfarin (INR target:
NR)

56±8

69.2

-

-

-

2.85/2.85

Control: No study medication

52±8

83.3

-

-

-

2.54/2.54

Vit K A: warfarin (INR target:
1.5-2)

-

92.9

19.6

16.1

69.6

1.91/1.91

Aspirin: 600 mg BID

-

82.0

14.0

26.0

58.0

2.03/2.03

Control: Matching placebo

-

87.3

12.7

20.0

63.6

2.00/2.00

Aspirin: 325 mg TID

-

100

23.4

25.0

57.8

2.20/2.20

Control: No study medication

-

100

19.2

23.1

67.3

2.20/2.20

Aspirin: 100 mg OD

55±10

82.8

-

-

58.6

2.69/2.69

Control: Matching placebo

55±6

90.3

-

-

77.4

3.35/3.35

Aspirin: 325 mg TID

-

-

-

-

-

3.10/3.10

Control: Matching placebo

-

-

-

-

-

3.30/3.30

Aspirin: 325 mg OD

58±8

100

-

47.4

55.8

Control: Matching placebo

58±7

100

-

49.0

56.9

Aspirin: 325 mg OD

59±8

100

-

45.2

52.9

Control: Matching placebo

58±8

100

-

49.5

57.0

12 mth

4 mth

12 mth

<2 mth

-/3.20

12 mth

-/3.20

115

Goldman, 1991

Gavaghan 1991

Van der Meer, 1993

Hockings, 1993

Mujanovic, 2009

Gao, 2009

Kulik, 2010

Hage 2017*

Gao, 2010

-12 h

+1 h

-12 h;
24 h

-7 d

Immediately
post-op

+1 d

0d

0d
≤ +48 h

Aspirin: 325 mg OD

60±8

100

-

56.0

62.0

-/2.60

Control: Matching placebo

60±7

100

-

50.0

60.0

-/2.60

Aspirin: 324 mg OD

56±8

86.6

0.0

45.0

56.7

-/3.40

Control: Matching placebo

56±7

83.6

0.0

39.0

60.9

-/3.60

Vit K A: 4 mg Acenocoumarol or
6 mg Phenprocoumon (INR
Target: 2.8-4.8)

58±8

88.0

10.1

40.1

52.1

-/3.10

Aspirin: 50 mg OD

58±8

87.0

8.1

34.0

56.0

-/2.80

Aspirin: 100 mg OD

60±9

94.0

6.0

50.0

-

3.14/2.56

Control: Matching placebo

60±9

92.3

5.8

30.8

-

3.48/2.79

Aspirin & Clopidogrel: 100 and
75 mg OD, respectively

58±8.5

-

-

-

-

2.9±0.99/1.9

Aspirin: 100 mg OD

60±8.5

-

-

-

-

2.7±0.48/1.7

Aspirin & Clopidogrel: 100 and
75 mg OD, respectively

61±10

82.1

60.0

62.1

58.9

Clopidogrel: 75 mg OD

62±9.9

83.3

50.0

64.7

48.0

65±7.5

91.1

25.0

48.2

-

3.6±0.8/2.30

68±7.4

87.7

33.3

52.6

-

3.4±0.6/2.24

72±7.7

92.2

33.3

64.7

-

3.6±0.8/2.30ǂ

75±7.6

87.5

45.8

83.3

-

3.4±0.6/2.24ǂ

58±8.3

82.3

39.8

61.9

49.6

3.18/2.14

0h

12 mth

12 mth

6 mth

3 mth

Unclear

12 mth

12 mth

3 mth

Aspirin & Clopidogrel: 162 and
75 mg OD, respectively
Aspirin: 162 mg OD and
matching placebo
Aspirin & Clopidogrel: 162 and
75 mg OD, respectively
Aspirin: 162 mg OD and
matching placebo
Aspirin & Clopidogrel: 100 and
75 mg OD, respectively

2.66±0.75/
1.71±0.94
2.49±0.72/
1.51±0.85
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Sun, 2010

Mannacio, 2012

Saw, 2016

Slim, 2016

+6 to 7 h

+28 ± 12 h

+58 to 59 h

+6 h

1 mth

12 mth

3 mth

8 mth

Aspirin: 100 mg OD

60±7.9

83.8

40.5

56.8

44.1

3.11/2.09

Aspirin & Clopidogrel: 81 and 75
mg OD, respectively

66±9.4

93.9

36.7

69.4

46.9

4.04/2.35

Aspirin: 81 mg OD

65±9.3

86.0

34.0

70.0

32.0

3.94/2.30

Aspirin & Clopidogrel: 100 and
75 mg OD, respectively

59±7.7

73.3

0.0

47.3

38.0

3.1±0.6/1.78

Aspirin: 100 mg OD

59±8.3

75.3

0.0

45.3

34.7

3.2±0.6/1.87

62±7.5

85.7

31.4

74.3

14.3

3.49/1.14

63±9.7

88.6

28.6

80.0

20.0

3.71/1.69

-

-

41.7

100

-

3.00/2.00

-

-

62.5

87.5

-

3.38/2.38

Aspirin & Ticagrelor: 81 mg OD
and 90 mg BID, respectively
Aspirin: 81 mg OD and matching
placebo
Aspirin & Clopidogrel: 81 and 75
mg OD, respectively
Aspirin: 81 mg OD and matching
placebo

*Long-term follow-up of the originally published study. INR: International Normalized Ratio. ǂfrom a secondary source.72
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eTable 10. Pairwise meta-analyses of antithrombotic agents
Intervention,
by outcome

Comparator

SVGF (Base case analysis)
Aspirin
Control
Vit K A
Control
Vit K A
Aspirin
ASA/Clo
Aspirin
ASA/Clo
Clopidogrel
ASA/Tic
Aspirin
SVGF (Per graft analysis)
Aspirin
Control
Vit K A
Control
Vit K A
Aspirin
ASA/Clo
Aspirin
ASA/Clo
Clopidogrel
ASA/Tic
Aspirin
Major bleeding
Aspirin
Control
Vit K A
Control
Vit K A
Aspirin
ASA/Clo
Aspirin
ASA/Clo
Clopidogrel
ASA/Tic
Aspirin
Mortality
Aspirin
Control
Vit K A
Control
Vit K A
Aspirin
ASA/Clo
Aspirin
ASA/Clo
Clopidogrel
ASA/Tic
Aspirin
Myocardial infarction
Aspirin
Control
Vit K A
Control
Vit K A
Aspirin
ASA/Clo
Aspirin
ASA/Clo
Clopidogrel
ASA/Tic
Aspirin
Cerebrovascular accident
Aspirin
Control
Vit K A
Control
Vit K A
Aspirin
ASA/Clo
Aspirin
ASA/Clo
Clopidogrel
ASA/Tic
Aspirin
Repeat revascularization
Aspirin
Control
Vit K A
Control
Vit K A
Aspirin
ASA/Clo
Aspirin
ASA/Clo
Clopidogrel
ASA/Tic
Aspirin

No.
of
RCTs

No. of events/Total
OR (95% CI)

I2
(%)

Intervention

Comparator

8
2
2
6
1
1

138/599
15/47
79/291
56/546
5/145
4/39

182/583
25/61
88/310
83/539
9/141
12/53

0.62 (0.43-0.90)
0.68 (0.30-1.51)
0.94 (0.66-1.35)
0.60 (0.42-0.88)
NE
NE

41
0
0
0
NA
NA

8
2
2
6
1
1

130/1243
15/84
85/637
58/618
5/145
4/39

194/1236
26/111
100/643
81/574
9/141
12/53

0.63 (0.49-0.80)
0.72 (0.33-1.59)
0.84 (0.62-1.15)
0.61 (0.42-0.88)
NE
NE

0
17
0
0
NA
NA

2
1
2
4
0
1

1/198
4/68
29/375
6/262
NR
0/35

0/187
0/71
16/380
8/256
NR
0/35

2.62 (0.11-64.98)
NE
2.26 (0.56-9.12)
0.76 (0.25-2.31)
NR
NE

NA
NA
30
0
NA
NA

4
2
2
4
0
1

5/309
1/81
4/375
4/374
NR
0/35

3/290
0/101
8/380
6/373
NR
1/35

1.54 (0.36-6.66)
3.44 (0.14-85.97)
0.65 (0.10-4.10)
0.67 (0.20-2.30)
NR
NE

0
NA
32
0
NA
NA

3
1
2
5
0
1

4/374
1/68
25/375
6/386
NR
0/35

5/362
5/77
26/380
8/381
NR
0/35

0.97 (0.03-27)
NE
0.97 (0.55-1.71)
0.69 (0.23-2.04)
NR
NE

70
NA
0
0
NA
NA

2
0
1
3
0
1

1/223
NR
3/307
5/250
NR
0/35

1/226
NR
1/309
8/248
NR
0/35

1.09 (0.07-17.89)
NR
NE
0.60 (0.19-1.87)
NR
NE

NA
NA
NA
0
NA
NA

0
0
0
2
0
1

NR
NR
NR
7/201
NR
0/35

NR
NR
NR
9/198
NR
1/35

NR
NR
NR
0.72 (0.25-2.05)
NR
NE

NA
NA
NA
0
NA
NA
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Re-exploration for bleeding
Aspirin
Control
Vit K A
Control
Vit K A
Aspirin
ASA/Clo
Aspirin
ASA/Clo
Clopidogrel
ASA/Tic
Aspirin
Minor bleeding
Aspirin
Control
Vit K A
Control
Vit K A
Aspirin
ASA/Clo
Aspirin
ASA/Clo
Clopidogrel
ASA/Tic
Aspirin
MACCE
Aspirin
Control
Vit K A
Control
Vit K A
Aspirin
ASA/Clo
Aspirin
ASA/Clo
Clopidogrel
ASA/Tic
Aspirin

4
0
1
1
0
0

34/506
NR
18/307
0/49
NR
NR

9/485
NR
10/309
1/50
NR
NR

3.59 (1.67-7.73)
NR
NE
NE
NR
NR

0
NA
NA
NA
NA
NA

0
0
0
4
0
1

NR
NR
NR
10/262
NR
11/35

NR
NR
NR
11/256
NR
1/35

NR
NR
NR
0.89 (0.36-2.18)
NR
NE

NA
NA
NA
0
NA
NA

0
0
1
3
0
0

NR
NR
52/307
6/330
NR
NR

NR
NR
43/309
8/332
NR
NR

NR
NR
NE
0.75 (0.25-2.25)
NR
NR

NA
NA
NA
0
NA
NA

Not estimable because of zero events in both arms or insufficient data (<2 studies). ASA:
Aspirin. ASA/Clo: Dual-antiplatelet with aspirin and clopidogrel. ASA/Tic: Dualantiplatelet therapy with aspirin and ticagrelor. Control: Placebo/control. MACCE: Major
adverse cardiac and cerebrovascular event. NE: Not estimable. NR: Not reported. NA:
Not applicable. SVGF: Saphenous vein graft failure. Vit K A: Vitamin K Antagonists.
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eTable 11. Summary of direct, indirect, and network estimates for primary and
secondary outcomes
Treatment, by
Direct OR
Indirect OR
Comparator
outcome
(95% CI)
(95% CI)
SVGF (Base case analysis)
ASA/Clo
Control
0.40 (0.24-0.69)
ASA/Tic
Control
0.25 (0.07-0.94)
Vit K A
Control
0.68 (0.30-1.51)
0.58 (0.28-1.21)
Aspirin
Control
0.62 (0.43-0.90)
0.79 (0.19-3.41)
Clopidogrel
Control
0.77 (0.21-2.86)
ASA/Clo
Aspirin
0.60 (0.42-0.88)
Not estimable
ASA/Tic
Aspirin
0.39 (0.12-1.32)
Not estimable
Vit K A
Aspirin
0.94 (0.66-1.35)
1.49 (0.42-5.21)
ASA/Clo
Clopidogrel
0.52 (0.17-1.60)
Not estimable
ASA/Tic
Clopidogrel
0.32 (0.05-1.98)
Vit K A
Clopidogrel
0.81 (0.21-3.15)
Aspirin
Clopidogrel
0.83 (0.23-2.96)
ASA/Clo
Vit K A
0.64 (0.34-1.22)
ASA/Tic
Vit K A
0.40 (0.10-1.57)
ASA/Clo
ASA/Tic
1.62 (0.41-6.31)
The estimated common between-study variance (tau2) = 0.2162 = 0.047
SVGF (Per graft analysis)
ASA/Clo
Control
0.39 (0.25,0.61)
ASA/Tic
Control
0.25 (0.07-0.87)
Vit K A
Control
0.72 (0.33-1.59)
0.53 (0.35-0.81)
Aspirin
Control
0.63 (0.49-0.80)
1.04 (0.37-2.96)
Clopidogrel
Control
0.75 (0.22-2.49)
ASA/Clo
Aspirin
0.61 (0.42-0.88)
Not estimable
ASA/Tic
Aspirin
0.39 (0.12-1.32)
Not estimable
Vit K A
Aspirin
0.84 (0.62-1.15)
1.47 (0.56-3.86)
ASA/Clo
Clopidogrel
0.52 (0.17-1.60)
Not estimable
ASA/Tic
Clopidogrel
0.34 (0.06-1.84)
Vit K A
Clopidogrel
0.77 (0.23-2.59)
Aspirin
Clopidogrel
0.86 (0.27-2.81)
ASA/Clo
Vit K A
0.68 (0.42-1.11)
ASA/Tic
Vit K A
0.44 (0.13-1.54)
ASA/Clo
ASA/Tic
1.56 (0.43-5.56)
2
The estimated common between-study variance (tau ) = (3.61×10-10)2 = 1.30×10-19
Major bleeding (no Clopidogrel monotherapy)
ASA/Clo
Control
2.84 (0.25-32.26)
ASA/Tic
Control
3.75 (0.04-341.19)
Vit K A
Control
9.98 (0.53-188.92) 2.50 (0.13-48.51)
Aspirin
Control
2.62 (0.11-64.98)
Not estimable
ASA/Clo
Aspirin
0.76 (0.25-2.31)
Not estimable
ASA/Tic
Aspirin
Not estimable
Not estimable
Vit K A
Aspirin
2.26 (0.56-9.12)
Not estimable
ASA/Clo
Vit K A
0.42 (0.12-1.46)

NMA OR
(95% CI)
0.40 (0.24-0.69)
0.25 (0.07-0.94)
0.63 (0.37-1.06)
0.64 (0.47-0.88)
0.77 (0.21-2.86)
0.63 (0.41-0.97)
0.39 (0.11-1.42)
0.98 (0.61-1.57)
0.52 (0.16-1.73)
0.32 (0.05-1.98)
0.81 (0.21-3.15)
0.83 (0.23-2.96)
0.64 (0.34-1.22)
0.40 (0.10-1.57)
1.62 (0.41-6.31)

0.39 (0.25,0.61)
0.25 (0.07-0.87)
0.57 (0.40-0.82)
0.65 (0.51-0.82)
0.75 (0.22-2.49)
0.61 (0.42-0.88)
0.39 (0.12-1.32)
0.89 (0.66-1.20)
0.52 (0.17-1.60)
0.34 (0.06-1.84)
0.77 (0.23-2.59)
0.86 (0.27-2.81)
0.68 (0.42-1.11)
0.44 (0.13-1.54)
1.56 (0.43-5.56)

2.84 (0.25-32.26)
3.75 (0.04-341.19)
6.70 (0.75-59.62)
3.75 (0.42-33.28)
0.76 (0.26-2.20)
1.00 (0.02-51.80)
1.79 (0.95-3.35)
0.42 (0.12-1.46)
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ASA/Tic
Vit K A
0.56 (0.01-30.44)
ASA/Clo
ASA/Tic
0.76 (0.01-45.19)
2
The estimated common between-study variance (tau ) = (2.32×10-11)2 = 5.38×10-22
Mortality (no Clopidogrel monotherapy)
ASA/Clo
Control
1.19 (0.21-6.71)
ASA/Tic
Control
0.57 (0.02-18.18)
Vit K A
Control
3.44 (0.14-85.97)
0.53 (0.08-3.57)
Aspirin
Control
1.54 (0.36-6.66)
Not estimable
ASA/Clo
Aspirin
0.67 (0.20-2.30)
Not estimable
ASA/Tic
Aspirin
0.32 (0.01-8.23)
Not estimable
Vit K A
Aspirin
0.65 (0.10-4.10)
Not estimable
ASA/Clo
Vit K A
1.14 (0.21-6.17)
ASA/Tic
Vit K A
0.55 (0.02-17.09)
ASA/Clo
ASA/Tic
2.07 (0.07-66.02)
The estimated common between-study variance (tau2) = (4.40×10-9)2 = 1.93×10-17
Myocardial Infarction (no Clopidogrel monotherapy)
ASA/Clo
Control
0.38 (0.07-2.12)
ASA/Tic
Control
0.53 (0.01-34.71)
Vit K A
Control
0.21 (0.02-1.89)
1.74 (0.19-15.92)
Aspirin
Control
0.97 (0.03-27)
Not estimable
ASA/Clo
Aspirin
0.69 (0.23-2.04)
Not estimable
ASA/Tic
Aspirin
NA
Not estimable
Vit K A
Aspirin
0.97 (0.55-1.71)
Not estimable
ASA/Clo
Vit K A
0.77 (0.23-2.54)
ASA/Tic
Vit K A
1.09 (0.02-58.80)
ASA/Clo
ASA/Tic
0.71 (0.01-42.40)
The estimated common between-study variance (tau2) = (1.04×10-7)2 = 1.08×10-14

0.56 (0.01-30.44)
0.76 (0.01-45.19)

1.19 (0.21-6.71)
0.57 (0.02-18.18)
1.04 (0.23-4.72)
1.77 (0.52-5.99)
0.67 (0.20-2.30)
0.32 (0.01-8.23)
0.59 (0.19-1.87)
1.14 (0.21-6.17)
0.55 (0.02-17.09)
2.07 (0.07-66.02)

0.38 (0.07-2.12)
0.53 (0.01-34.71)
0.49 (0.12-2.00)
0.52 (0.13-2.10)
0.71 (0.25-2.02)
1.00 (0.02-51.80)
0.92 (0.52-1.62)
0.77 (0.23-2.54)
1.09 (0.02-58.80)
0.71 (0.01-42.40)

Not estimable because of zero events in all study arms or because a second direct
comparison needed to contribute to that specific indirect comparison is not available.
Bold estimates indicate statistically significant differences. ASA/Clo: Dual-antiplatelet
with aspirin and clopidogrel. ASA/Tic: Dual-antiplatelet therapy with aspirin and
ticagrelor. Control: Placebo/control. Vit K A: Vitamin K Antagonists.
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eTable 12. Treatment rankings according to SUCRA curves
Treatment by outcome
SUCRA
SVGF (Base case analysis)
ASA/Tic
89.3
ASA/Clo
79.9
Vit K A
45.6
Aspirin
43.5
Clopidogrel
33.3
Control
8.4
SVGF (Per graft analysis)
ASA/Tic
89.7
ASA/Clo
81.1
Vit K A
52.0
Aspirin
37.7
Clopidogrel
32.8
Control
6.7
Major Bleeding (no Clopidogrel monotherapy)
Control
83.3
ASA/Clo
59.6
Aspirin
47.3
ASA/Tic
45.9
Vit K A
13.9
Mortality (no Clopidogrel monotherapy)
ASA/Tic
66.4
Control
56.5
Vit K A
55.9
ASA/Clo
49.1
ASA
22.1
Myocardial Infarction (no Clopidogrel monotherapy)
ASA/Clo
71.4
Vit K A
57.7
ASA/Tic
50.7
Aspirin
48.9
Control
21.3
ASA/Clo: Dual-antiplatelet with aspirin and clopidogrel. ASA/Tic: Dual-antiplatelet
therapy with aspirin and ticagrelor. Control: Placebo/control. SUCRA: Surface Under the
Cumulative Ranking. Vit K A: Vitamin K Antagonists. Larger SUCRA values indicates
better interventions.
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eTable 13. Contribution percentage (%) of direct evidence to the entire network
Outcome
SVGF
(base case
analysis)
Major
bleeding
Mortality
MI

ASA/Clo
vs ASA
27.7

ASA/Tic
vs ASA
17.3

Vit K A
vs ASA
16.4

Aspirin vs
Control
16.2

ASA/Clo Vit K A vs
vs Clo
Control
17.3
5.1

31.3

NE

33.7

16.7

NA

18.3

24.0
30.9

23.9
NE

20.5
37.4

23.3
9.9

NA
NA

8.3
21.8

NE: not estimated because of zero events in all arms. NA: not applicable because
outcome data were not reported. ASA/Clo: Dual-antiplatelet with aspirin and clopidogrel.
ASA/Tic: Dual-antiplatelet therapy with aspirin and ticagrelor. Clo: Clopidogrel
monotherapy. Control: Placebo/control. Vit K A: Vitamin K Antagonists.
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eTable 14. Local inconsistency tests assuming a common loop-specific heterogeneity
estimated using the method of moments.
Closed loop of evidence
SVGF (Base case analysis)
Aspirin-Vit K A-Control
SVGF (Per graft analysis)
Aspirin-Vit K A-Control
Major Bleeding
Aspirin-Vit K A-Control
Mortality
Aspirin-Vit K A-Control
Myocardial Infarction
Aspirin-Vit K A-Control

Inconsistency factor
(IF, 95% CI)

Loop heterogeneity,
tau2

0.25 (0.00-1.42)

0.098

0.30 (0.00-1.12)

0.000

0.85 (0.00-5.25)

0.000

1.48 (0.00-5.22)

0.000

3.33 (0.00-7.06)

0.000

Control: Placebo/control. Vit K A: Vitamin-K Antagonists. If the 95% CI excludes zero,
incoherence is detected statistically.
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eTable 15. Global inconsistency using the design-by-treatment interaction model
Outcomes of interest
SVGF (Base case analysis)
SVGF (Per graft analysis)
Major bleeding
Mortality
Myocardial infarction

Chi-square
0.86 (df=3)
1.72 (df=3)
1.49 (df=2)
1.92 (df=3)
3.31 (df=2)

Global inconsistency, p-value
0.8341
0.6323
0.4759
0.5899
0.1910
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eTable 16. Quality of direct evidence assessment
Comparison

No. of RCTs

Risk of bias

Inconsistency

Indirectness

Imprecision

Publication bias

OR
(95% CI)

Quality of
evidence

Vein graft failure (Base case analysis)
Aspirin vs Control

8

Not Serious1

Not Serious2

Serious3

Not
Serious4

Unclear5

0.62 (0.43-0.90)

Moderate

Vit K A vs Control

2

Serious6

Not Serious2

Serious3

Serious7

Unclear5

0.68 (0.30-1.51)

Very Low

Vit K A vs Aspirin

2

Serious8

Not Serious2

Serious3

Serious7

Unclear5

0.94 (0.66-1.35)

Very Low

ASA/Clo vs Aspirin

6

Not Serious9

Not Serious2

Serious3

Not
Serious4

Unclear5

0.60 (0.42-0.88)

Moderate

ASA/Clo vs Clo

1

Not Serious

NA10

Serious3

Serious7

Unclear5

0.52 (0.17-1.60)

Low

ASA/Tic vs Aspirin

1

Not Serious

NA10

Serious3

Serious7

Unclear5

0.39 (0.12-1.32)

Low

Aspirin vs Control

2

Not Serious

NA10

Serious3

Serious7

NA11

2.62 (0.11-65)

Low

Vit K A vs Control

1

Serious12

NA10

Not Serious

Serious7

NA11

9.98 (0.53-189)

Low

Vit K A vs Aspirin

2

Serious12

Not Serious2

Serious3

Serious7

NA11

2.26 (0.56-9.12)

Very Low

ASA/Clo vs Aspirin

4

Not Serious

Not Serious2

Serious3

Serious7

NA11

0.76 (0.25-2.31)

Low

ASA/Tic vs Aspirin

1

Not Serious

NA10

Not Serious

Serious13

NA11

Not estimable

Moderate

Major bleeding

All-cause mortality
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Aspirin vs Control

4

Not Serious

Not Serious2

Serious3

Serious7

NA11

1.54 (0.36-6.66)

Low

Vit K A vs Control

2

Serious12

NA10

Not Serious

Serious7

NA11

3.44 (0.14-86)

Low

Vit K A vs Aspirin

2

Serious12

Not Serious2

Serious3

Serious7

NA11

0.65 (0.10-4.10)

Very Low

ASA/Clo vs Aspirin

4

Not Serious

Not Serious2

Serious3

Serious7

NA11

0.67 (0.20-2.30)

Low

ASA/Tic vs Aspirin

1

Not Serious

NA10

Not Serious

Serious7

NA11

0.32 (0.01-8.23)

Moderate

All myocardial infarction
Aspirin vs Control

3

Not Serious

Not Serious2

Serious3

Serious7

NA11

0.97 (0.03-27)

Low

Vit K A vs Control

1

Serious12

NA10

Not Serious

Serious7

NA11

0.21 (0.02-1.89)

Low

Vit K A vs Aspirin

2

Serious12

Not Serious2

Serious3

Serious7

NA11

0.97 (0.55-1.71)

Very Low

ASA/Clo vs Aspirin

5

Not Serious

Not Serious2

Serious3

Serious7

NA11

0.69 (0.23-2.04)

Low

ASA/Tic vs Aspirin

1

Not Serious

NA10

Not Serious

Serious13

NA11

Not estimable

Moderate

NA: Not applicable
1

Eight studies have incomplete patency data (range: 16% to 48.6%). Of these, three studies reported comparable missing rates and

similar reasons for missing outcome across arms. Of six studies that reported in sufficient detail, adequate generation of a randomized
sequence was performed in all of the studies and blinding was likely effective in all of them. No studies adequately described
allocation concealment.
2

Low heterogeneity (I2 <75%).

3

At least one study used aspirin at doses higher than those that are currently used (75-100 mg/day) and/or SVGF is a surrogate

outcome as well as the short duration of treatment and follow-up for SVGF are not very applicable to the real-world situation.
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4

The 95% confidence interval is narrow, does not cross the clinical decision threshold, and OIS is met.

5

As per protocol, the funnel plot or Egger’s test was not performed because of insufficient information (<10 studies).

6

No blinding in one study and incomplete blinding in another study. Both studies have incomplete patency data (range: 21% to

48.6%), and the proportion of missing data was not balanced between arms in one study.
7

The confidence interval crosses the clinical decision threshold with small number of events and sample size.

8

Both studies failed to blind patients and personnel and had incomplete patency data (range: 15.9% to 48.6%). The proportion of

missing data was not balanced between arms in one study.
9

Of six studies, one study did not blind patient and personnel and missing data (41.6%) was not balanced in another study.

10

Unable to assess because there are <2 studies available with non-zero events in both arms.

11

This NMA was designed to include studies that evaluated SVGF. Many studies reporting only clinical outcomes were excluded as a

result of the design. Therefore, it is not possible to explore the impact of publication bias for clinical outcomes.
12
13

All studies failed to blind patients and personnel completely.

Small number of events and sample size.
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eTable 17. Quality of network evidence assessment
Comparison

Direct Evidence
OR (95% CI) Quality of Evidence

SVGF (Base case analysis)
ASA/Clo vs Control
ASA/Tic vs Control
Vit K A vs Control
0.68 (0.30-1.51)
Aspirin vs Control
0.62 (0.43-0.90)
Clopidogrel vs Control
ASA/Clo vs Aspirin
0.60 (0.42-0.88)
ASA/Tic vs Aspirin
0.39 (0.12-1.32)
Vit K A vs Aspirin
0.94 (0.66-1.35)
ASA/Clo vs Clopidogrel 0.52 (0.17-1.60)
ASA/Tic vs Clopidogrel Vit K A vs Clopidogrel
Aspirin vs Clopidogrel
ASA/Clo vs Vit K A
ASA/Tic vs Vit K A
ASA/Clo vs ASA/Tic
Major Bleeding
ASA/Clo vs Control
ASA/Tic vs Control
Vit K A vs Control
9.98 (0.53-189)
Aspirin vs Control
2.62 (0.11-65)
ASA/Clo vs Aspirin
0.76 (0.25-2.31)
ASA/Tic vs Aspirin
NA
Vit K A vs Aspirin
2.26 (0.56-9.12)
ASA/Clo vs Vit K A
ASA/Tic vs Vit K A
ASA/Clo vs ASA/Tic
Mortality
ASA/Clo vs Control
ASA/Tic vs Control
-

Indirect Evidence
OR (95% CI)
Quality of Evidence

Network Meta-Analysis*
OR (95% CI) Quality of Evidence

Very Low
Moderate
Moderate
Low
Very Low
Low
-

0.40 (0.24-0.69)
0.25 (0.07-0.94)
0.58 (0.28-1.21)
0.79 (0.19-3.41)
0.77 (0.21-2.86)
Not estimable
Not estimable
1.49 (0.42-5.21)
Not estimable
0.32 (0.05-1.98)
0.81 (0.21-3.15)
0.83 (0.23-2.96)
0.64 (0.34-1.22)
0.40 (0.10-1.57)
1.62 (0.41-6.31)

Moderate1,3,5
Moderate1,3,6
Very Low2,8
Very Low2,10
Very Low1,2,5
Not estimable
Not estimable
Very Low2,4,7
Not estimable
Very Low1,2,7
Very Low1,2,7
Low2,7
Very Low1,2,5
Very Low1,2,6
Very Low2,5

0.40 (0.24-0.69)
0.25 (0.07-0.94)
0.63 (0.37-1.06)
0.64 (0.47-0.88)
0.77 (0.21-2.86)
0.63 (0.41-0.97)
0.39 (0.11-1.42)
0.98 (0.61-1.57)
0.52 (0.16-1.73)
0.32 (0.05-1.98)
0.81 (0.21-3.15)
0.83 (0.23-2.96)
0.64 (0.34-1.22)
0.40 (0.10-1.57)
1.62 (0.41-6.31)

Moderate
Moderate
Very Low
Moderate
Very Low
Moderate
Low
Very Low
Low
Very Low
Very Low
Low
Very Low
Very Low
Very Low

Low
Low
Low
Moderate
Very Low
-

2.84 (0.25-32.26)
3.75 (0.04-341.19)
2.50 (0.13-48.51)
Not estimable
Not estimable
Not estimable
Not estimable
0.42 (0.12-1.46)
0.56 (0.01-30.44)
0.76 (0.01-45.19)

Very Low1,2,6
Very Low1,2,8
Very Low1,2,8
Not estimable
Not estimable
Not estimable
Not estimable
Very Low1,2,6
Very Low1,2,9
Very Low2,4,8

2.84 (0.25-32)
3.75 (0.04-341)
6.70 (0.75-60)
3.75 (0.42-33)
0.76 (0.26-2.20)
1.00 (0.02-52)
1.79 (0.95-3.35)
0.42 (0.12-1.46)
0.56 (0.01-30)
0.76 (0.01-45)

Very Low
Very Low
Low
Low
Low
Moderate
Very Low
Very Low
Very Low
Very Low

-

1.19 (0.21-6.71)
0.57 (0.02-18.18)

Very Low1,2,6
Very Low1,2,5

1.19 (0.21-6.71)
0.57 (0.02-18)

Very Low
Very Low
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Vit K A vs Control
Aspirin vs Control
ASA/Clo vs Aspirin
ASA/Tic vs Aspirin
Vit K A vs Aspirin
ASA/Clo vs Vit K A
ASA/Tic vs Vit K A
ASA/Clo vs ASA/Tic
Myocardial Infarction
ASA/Clo vs Control
ASA/Tic vs Control
Vit K A vs Control
Aspirin vs Control
ASA/Clo vs Aspirin
ASA/Tic vs Aspirin
Vit K A vs Aspirin
ASA/Clo vs Vit K A
ASA/Tic vs Vit K A
ASA/Clo vs ASA/Tic

3.44 (0.14-86)
1.54 (0.36-6.66)
0.67 (0.20-2.30)
0.32 (0.01-8.23)
0.65 (0.10-4.10)
-

Low
Low
Low
Moderate
Very Low
-

0.53 (0.08-3.57)
Not estimable
Not estimable
Not estimable
Not estimable
1.14 (0.21-6.17)
0.55 (0.02-17.09)
2.07 (0.07-66.02)

Very Low1,2,8
Not estimable
Not estimable
Not estimable
Not estimable
Very Low1,2,8
Very Low1,2,5
Very Low2,4,8

1.04 (0.23-4.72)
1.77 (0.52-5.99)
0.67 (0.20-2.30)
0.32 (0.01-8.23)
0.59 (0.19-1.87)
1.14 (0.21-6.17)
0.55 (0.02-17)
2.07 (0.07-66)

Low
Low
Low
Moderate
Very Low
Very Low
Very Low
Very Low

0.21 (0.02-1.89)
0.97 (0.03-27)
0.69 (0.23-2.04)
NA
0.97 (0.55-1.71)
-

Low
Low
Low
Moderate
Very Low
-

0.38 (0.07-2.12)
0.53 (0.01-34.71)
1.74 (0.19-15.92)
Not estimable
Not estimable
Not estimable
Not estimable
0.77 (0.23-2.54)
1.09 (0.02-58.80)
0.71 (0.01-42.40)

Very Low1,2,6
Very Low1,2,8
Very Low1,2,8
Not estimable
Not estimable
Not estimable
Not estimable
Very Low1,2,6
Very Low1,2,9
Very Low2,4,8

0.38 (0.07-2.12)
0.53 (0.01-35)
0.49 (0.12-2.00)
0.52 (0.13-2.10)
0.71 (0.25-2.02)
1.00 (0.02-52)
0.92 (0.52-1.62)
0.77 (0.23-2.54)
1.09 (0.02-59)
0.71 (0.01-42)

Very Low
Very Low
Low
Low
Low
Moderate
Very Low
Very Low
Very Low
Very Low

ASA/Clo: Dual-antiplatelet with aspirin and clopidogrel. ASA/Tic: Dual-antiplatelet therapy with aspirin and ticagrelor. Control:
Placebo/control. Vit K A: Vitamin-K Antagonists. Not estimable because a second direct comparison needed to contribute to that
specific indirect comparison is not available. Indirect estimates were obtained using the node-splitting approach.
2
*𝜏𝑁𝑀𝐴
<50% quantiles of the empirical distribution (i.e., low heterogeneity) and lack of evidence of incoherence.
1.

Probable intransitivity (more CCAB patients and/or earlier drug administration in one of the direct comparisons).

2.

Imprecision (wide 95% CI)

3.

Effect size is <0.5 and statistically significant.

4.

Probable intransitivity (more elective patients and/or earlier drug administration in one of the direct comparisons).
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5.

The rating of the direct comparison with a stronger contribution is moderate.

6.

The rating of the direct comparison with a stronger contribution is low.

7.

Both direct comparisons have equal contributions to the indirect evidence, but the rating of the one with a larger sample size is

moderate.
8.

Both direct comparisons have equal contributions to the indirect evidence, but the rating of the one with a larger sample size is low.

9.

Both direct comparisons have equal contributions to the indirect evidence, but the rating of the one with a larger sample size is very

low.
10.

The rating of the direct comparison with a stronger contribution is very low.
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eTable 18. Imputation analysis: SVGF
Treatment
ASA/Clo
ASA/Tic
Vit K A
Aspirin
Clopidogrel
ASA/Clo
ASA/Tic
Vit K A
ASA/Clo
ASA/Tic
Vit K A
Aspirin
ASA/Clo
ASA/Tic
ASA/Clo

Comparator
Control
Control
Control
Control
Control
Aspirin
Aspirin
Aspirin
Clopidogrel
Clopidogrel
Clopidogrel
Clopidogrel
Vit K A
Vit K A
ASA/Tic

Pairwise
OR (95% CI)
0.68 (0.30-1.51)
0.62 (0.43-0.90)
0.60 (0.42-0.88)
0.39 (0.12-1.32)
0.94 (0.66-1.35)
0.52 (0.17-1.60)
-

Base Case
0.40 (0.24-0.69)
0.25 (0.07-0.94)
0.63 (0.37-1.06)
0.64 (0.47-0.88)
0.77 (0.21-2.86)
0.63 (0.41-0.97)
0.39 (0.11-1.42)
0.98 (0.61-1.57)
0.52 (0.16-1.73)
0.32 (0.05-1.98)
0.81 (0.21-3.15)
0.83 (0.23-2.96)
0.64 (0.34-1.22)
0.40 (0.10-1.57)
1.62 (0.41-6.31)

NMA
OR (95% CI)
All missing failure
0.53 (0.36-0.80)
0.28 (0.08-0.99)
0.80 (0.54-1.17)
0.71 (0.55-0.92)
1.02 (0.30-3.43)
0.75 (0.55-1.02)
0.39 (0.11-1.35)
1.12 (0.80-1.56)
0.52 (0.17-1.65)
0.27 (0.05-1.52)
0.78 (0.23-2.69)
0.70 (0.21-2.30)
0.67 (0.42-1.05)
0.35 (0.10-1.26)
1.92 (0.53-6.90)

ASA/Clo: Dual-antiplatelet with aspirin and clopidogrel. ASA/Tic: Dual-antiplatelet therapy with aspirin and ticagrelor. Control:
Placebo/control. Vit K A: Vitamin-K Antagonists.
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eTable 19. SUCRA values for SVGF after accounting for loss to follow-up
Treatment by outcome
ASA/Tic
ASA/Clo
Vit K A
Aspirin
Clopidogrel
Control

Base case

All Missing Failure

SUCRA
89.3
79.9
45.6
43.5
33.3
8.4

SUCRA
92.6
79.1
37.2
51.4
26.2
13.4

ASA/Clo: Dual-antiplatelet with aspirin and clopidogrel. ASA/Tic: Dual-antiplatelet therapy with aspirin and ticagrelor. Control:
Placebo/control. SUCRA: Surface Under the Cumulative Ranking. Vit K A: Vitamin-K Antagonists.
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eTable 20. Sensitivity analyses: SVGF
Treatment
ASA/Clo
ASA/Tic
Vit K A
Aspirin
Clopidogrel
ASA/Clo
ASA/Tic
Vit K A
ASA/Clo
ASA/Tic
Vit K A
Aspirin
ASA/Clo
ASA/Tic
ASA/Clo

Comparator
Control
Control
Control
Control
Control
Aspirin
Aspirin
Aspirin
Clopidogrel
Clopidogrel
Clopidogrel
Clopidogrel
Vit K A
Vit K A
ASA/Tic

Pairwise
OR (95% CI)
0.68 (0.30-1.51)
0.62 (0.43-0.90)
0.60 (0.42-0.88)
0.39 (0.12-1.32)
0.94 (0.66-1.35)
0.52 (0.17-1.60)
-

Base Case
0.40 (0.24-0.69)
0.25 (0.07-0.94)
0.63 (0.37-1.06)
0.64 (0.47-0.88)
0.77 (0.21-2.86)
0.63 (0.41-0.97)
0.39 (0.11-1.42)
0.98 (0.61-1.57)
0.52 (0.16-1.73)
0.32 (0.05-1.98)
0.81 (0.21-3.15)
0.83 (0.23-2.96)
0.64 (0.34-1.22)
0.40 (0.10-1.57)
1.62 (0.41-6.31)

NMA
OR (95% CI)
Closer to 1-year
follow-up
0.38 (0.22-0.66)
0.24 (0.06-0.93)
0.58 (0.32-1.04)
0.62 (0.44-0.86)
0.72 (0.19-2.75)
0.62 (0.39-0.96)
0.39 (0.11-1.44)
0.93 (0.55-1.57)
0.52 (0.16-1.76)
0.33 (0.05-2.09)
0.79 (0.20-3.21)
0.85 (0.23-3.10)
0.66 (0.33-1.32)
0.42 (0.10-1.71)
1.58 (0.40-6.26)

Without OPCAB
studies
0.50 (0.26-0.96)
0.25 (0.06-0.97)
0.63 (0.36-1.09)
0.64 (0.46-0.89)
0.95 (0.24-3.80)
0.78 (0.44-1.39)
0.39 (0.10-1.46)
0.98 (0.59-1.63)
0.52 (0.15-1.78)
0.26 (0.04-1.74)
0.66 (0.16-2.80)
0.67 (0.17-2.61)
0.79 (0.37-1.71)
0.40 (0.10-1.63)
1.99 (0.47-8.41)

ASA/Clo: Dual-antiplatelet with aspirin and clopidogrel. ASA/Tic: Dual-antiplatelet therapy with aspirin and ticagrelor. Control:
Placebo/control. OPCAB: Off-pump CABG. Vit K A: Vitamin-K Antagonists.
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eTable 21. Description of outcomes used in RCTs included in the present NMA
Study, by outcome Description of outcome
VEIN GRAFT FAILURE
Measured at six postoperative months using coronary angiography and
Pantely 1979
expressed per patient. A graft was defined as occluded if the contrast
agent failed to flow through it and into the grafted artery.
Measured at 21.5 postoperative months using coronary angiography
McEnany 1982
and expressed per graft and per patient, including post-mortem.
Measured at 12 postoperative months. Expressed per patient. Vein
Sharma 1983
grafts were “opacified by selective cannulation or aortic root
angiography.”
Measured at four postoperative months using coronary angiography
Lorenz 1984
and expressed per patient. Contrast was selectively injected into each
vein graft bypass.
Measured at 12 postoperative months. Expressed per patient. Grafts
(distal anastomoses) fully visualized to supply the distal artery during
Brown 1985
selective injection were called “patent”; otherwise they were
considered occluded.
Measured at 367 postoperative days. Expressed per patient. A single
vein graft was defined as occluded if the contrast agent failed to flow
Goldman 1989
through it and into the grafted artery. Each distal anastomotic site is
counted as a single graft
Measured at eight postoperative days. Expressed per patient. A graft
was defined as occluded if the contrast agent failed to flow through it
Goldman 1991
and into the grafted artery. Each distal anastomotic site is counted as a
single graft
Measured at 363 postoperative days using angiography with the
transfemoral Judkin's technique. Vein graft occlusion (or patency)
Gavaghan 1991
rates were expressed per patient (with one or more distal anastomoses
occluded). A graft was defined as occluded if the contrast agent failed
to flow through it and into the grafted artery.
Measured at 371 postoperative days. Expressed per patient. A graft
was defined as occluded “if the contrast agent failed to flow through
Van der Meer
the graft, or one or more distal anastomoses were occluded. A distal
1993
anastomosis was defined as occluded if contrast did not flow from the
proximal graft into the grafted native artery.”
Measured at six postoperative months using invasive angiography.
Hockings 1993
Expressed per patient.
Measured at three postoperative months using angiography.
Mujanovic 2009
Fitzgibbons method of classification was used. Expressed per graft.
Measured at 12 postoperative months using 64-Multislice Computed
Gao 2009
Tomography Angiography (MSCTA) and expressed per graft.
Measured at 12 postoperative months using angiography and
Kulik 2010
expressed per patient.
Measured at eight postoperative years using CCTA and expressed per
Hage 2017
graft in surviving patients.
Measured at three postoperative months using multislice computed
Gao 2010
tomography angiography (MSCTA) and expressed per graft. A graft
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Sun 2010

Mannacio 2012

Saw 2016

Slim 2016

was considered occluded if a conduit did not fill with contrast at all.
Measured at 50 postoperative days using cardiac CT angiography and
expressed Per patient. “Stenosed grafts without diffuse luminal
narrowing were considered to be patent”
Measured at 12 postoperative months using 64-slice multidetector CT
angiography. The quality of the anastomosis and conduits was graded
according to Fitzgibbon.
Measured at 12 postoperative months using 320-detector or 128-slice
dual source CT scanner. A graft was defined as occluded if there was
lack of contrast flow in the graft segment from the proximal
anastomosis
Measured at 12 postoperative months using a 128-slice dual-source
scanner (failure is defined as stenosis ≥50%) and expressed per graft.

MAJOR BLEEDING
McEnany 1982
No definition
Gavaghan 1991
GI bleeding
Van der Meer
If life threatening or fatal and if blood transfusion or surgery was
1993
necessary
Kulik 2010
As per CURE trial definition
A follow-up Case Report Form was designed to collect long-term
Hage 2017
clinical data and was sent to patients via mail.
Intracranial hemorrhage… bleeding causing death, or bleeding
Sun 2010
requiring transfusion of >1 unit of RBC
Mannacio 2012
Defined according to the CURE trial
Bleeding events were defined as per PLATO study. Major bleeding
was defined as “bleeding that led to clinically significant disability, or
Saw 2016
bleeding with haemoglobin drop ≥ 3.0 g/dL but <5.0 g/dL or requiring
2-3 units of transfusion”
Slim 2016
Bleeding events were defined as per TIMI study
MORTALITY
Pantely 1979
All cause mortality at 6 months
McEnany 1982
Mortality at 34 months
Sharma 1983
All cause mortality at 12 months
Brown 1985
All cause mortality at 12 months
Gavaghan 1991
All cause mortality at 12 months
Van der Meer
All cause mortality at 12 months
1993
Mujanovic
No definition at 3 months
Kulik 2010
All cause mortality at 12 months
Cardiac Mortality. A follow-up Case Report Form was designed to
Hage 2017
collect long-term clinical data and was sent to patients via mail.
Gao 2010
All cause mortality at 3 months
Sun 2010
All cause mortality at 1 month
Mannacio 2012
Cardiac death at 12 months
Cardiovascular death defined as “any death from cardiovascular or
Saw 2016
cerebrovascular cause, and any death without another known cause at
12 months”
MYOCARDIAL INFARCTION (MI)
McEnany 1982
Fatal and non-fatal MI at 24 months
Goldman 1991
Assessed during postoperative catherization (60 days)
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Gavaghan 1991
Van der Meer
1993
Kulik 2010

Peri-operative new Q wave infarction
Diagnosed according to strict ECG criteria… at 12 months

Assessed at 12 months
Collected at 8 years. A follow-up Case Report Form was designed to
Hage 2017
collect long-term clinical data and was sent to patients via mail.
30-day MI defined as “creatine kinase-MB >10 times the upper limit
of normal or >5 times the upper limit of normal with new Q waves
Sun 2010
>30 msec in 2 contiguous leads on electrocardiogram of a new wall
abnormality”
Assessed at 12 months. According to the joint ESC/ACCF/AHA/WHF
Mannacio 2012
definition
Assessed at 12 months. In accordance with the universal definition198.
Saw 2016
MI with CABG was defined as “>5 times normal reference elevation
of tropinin-I within 72 h after CABG…”
Slim 2016
Unknown. Assessed at 12 months
Cerebrovascular Accidents (CVA)
Brown 1985
CVA at 12 months
Goldman 1991
CVA during postoperative catherization (60 days)
Van der Meer
Ischemic stroke at 12 months
1993
Kulik 2010
CVA at 12 months
Ischemic stroke at 8 years. A follow-up Case Report Form was
Hage 2017
designed to collect long-term clinical data and was sent to patients via
mail.
Sun 2010
Stroke at 30 days
Mannacio 2012
Stroke at 12 months
Assessed at 12 months. Stroke defined as “focal loss of neurological
Saw 2016
function caused by an ischaemic or haemorrhagic event…lasting ≥24 h
or leading to death”
CARDIAC RE-INTERVENTION
Veeger 2010
Need for repeat revascularization at 14 years
Kulik 2010
Need for coronary intervention at 12 months
Coronary reintervention (PCI) at 8 years. A follow-up Case Report
Hage 2017
Form was designed to collect long-term clinical data and was sent to
patients via mail.
Mannacio 2012
Repeat revascularization (PCI or repeat CABG) at 12 months
Saw 2016
Repeat Revascularization (PCI or repeat CABG) at 12 months
HEART FAILURE
Van der Meer
Assessed at 12 months
1993
SURGICAL RE-EXPLORATION FOR BLEEDING
Goldman 1988
Re-operation
Goldman 1991
Re-operation
Gavaghan 1991
Re-operation
Van der Meer
Re-operation for bleeding
1993
Hockings 1993
Re-operation for bleeding
Sun 2010
Re-operation
MACCE
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Van der Meer
1993

MI, stroke, TIA, DVT, PE, major bleeding, death at 12 months

Cardiovascular death, MI, CVA, hospitalization for coronary
ischemia, need for coronary intervention at 12 months
Cardiovascular mortality, MI, and need for revascularization at 3
Gao 2010
months
Cardiac death, MI, repeat revascularization (PCI or repeat CABG),
Mannacio 2012
stroke at 12 months
ADMISSION DUE TO CARDIOVASCULAR CAUSE
Kulik 2010
Hospitalization for coronary ischemia at 12 months
MINOR BLEEDING
Kulik 2010
As per CURE trial definition
Data collected at 8 years. A follow-up Case Report Form was designed
Hage 2017
to collect long-term clinical data and was sent to patients via mail.
“Bleeding requiring modification of antithrombotic drug regimens or
Sun 2010
transfusion of 1 unit of RBC”
Mannacio 2012
Defined according to the CURE trial
“Bleeding that led to clinically significant disability, or bleeding with
Saw 2016
haemoglobin drop ≥ 3.0 g/dL but <5.0 g/dL or requiring 2-3 units of
transfusion”
Slim 2016
Defined according to the TIMI trial
Kulik 2010

DVT: deep vein thrombosis. GI: Gastrointestinal. PE: pulmonary embolism. PLATO:
Platelet Inhibition and Patient Outcomes. RBC: red blood cells. TIMI: Thrombolysis in
Myocardial Infarction. CURE: Clopidogrel in Unstable Angina to Prevent Recurrent
Events.
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eTable 22. Matrix indicating which outcomes that were and were not reported in included studies
Study ID

SVGF

Pantely, 1979
McEnany, 1982
Sharma, 1983
Lorenz, 1984
Brown, 1985
Goldman, 1988
Goldman, 1989
Goldman, 1991
Gavaghan 1991
Van der Meer,
1993
Hockings, 1993
Mujanovic, 2009
Gao, 2009
Kulik, 2010
Hage, 2017
Gao, 2010
Sun, 2010
Mannacio, 2012
Saw, 2016
Slim, 2016

√ (PP)
√ (PP)
√ (PP)
√ (PP)
√ (PP)
√ (PP)
√ (PP)
√ (PP)
√ (PP)
√ (PP)
√ (PP)
√ (PG)
√ (PG)
√ (PP)
√ (PG)
√ (PG)
√ (PP)
√ (PG)
√ (PG)
√ PG)

Major
Bleed

√

Mortality

CVA

√
√
√
√

MI

Cardiac reintervention

Heart
Failure

Surgical reexploration

Minor
bleeding

Admission
to hospital

√
√

√

√

√
√
√

√
√

√
√

√

√
√
√

√

√
√
√
√

√
√
√
√
√
√

√
√
√
√
√
√

√: Reported. PP: per patient. PG: per graft.

√
√
√
√
√

√
√
√
√
√
√
√

√
√
√
√
√

√
√
√
√
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eTable 23. Study-specific and comparison-specific risk of bias: SVGF
Comparison

No of
studies

Aspirin vs
Control

8

Vit K A vs
Control

2

Vit K A vs
Aspirin

2

ASA/Clo vs
Aspirin

ASA/Clo vs
Clo
ASA/Tic vs
Aspirin

6

1
1

Study ID

Study-specific risk
of bias

McEnany 1982,
Sharma 1983,
Lorenz 1984,
Brown 1985,
Goldman 1989,
Goldman 1991,
Gavaghan 1991,
Hockings 1993
Pantely 1979,
McEnany 1982
McEnany 1982,
Van der Meer
1993
Mujanovic 2009,
Hage 2017,
Gao 2010,
Sun 2010,
Mannacio 2012,
Slim 2016
Gao 2009

High,
High,
High,
Uncertain,
Uncertain,
Uncertain,
Low,
High
High,
High
High,
High

Saw 2016

Low

Low,
Uncertain,
Uncertain,
Uncertain,
Low,
Low
Low

Comparisonspecific risk of
bias

Moderate (not
serious)

High (serious)
High (Serious)

Low (serious)

Low (serious)
Low (serious)

Bold texts indicate studies with larger sample sizes. ASA/Clo: Dual-antiplatelet with
aspirin and clopidogrel. ASA/Tic: Dual-antiplatelet therapy with aspirin and ticagrelor.
Clo: Clopidogrel monotherapy. Control: Placebo/control. Vit K A: Vitamin-K
Antagonists.
Study-specific risk of bias assessment: low (if low risk of bias in all domains); uncertain
(if high risk of bias in 1 domain); and high (if high risk of bias in ≥2 domains).
Comparison-specific risk of bias assessment: low (if all studies with larger sample size
are at low risk of bias); moderate (if studies with larger sample size are either at low or
unclear risk of bias and no studies with high risk of bias); high (if ≥1 studies with larger
sample size are at high risk of bias).
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